Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AADAT KAT2, KATII ENSG00000109576 Aminoadipate aminotransferase 4 170060222-170091699 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037502 Supported Approved Vesicles
Plasma membrane Colorectal cancer:5.59e-4 (favourable) Expressed in all Tissue enhanced liver: 34.6 prostate: 23.3 AAK1 DKFZp686K16132, KIAA1048 ENSG00000115977 AP2 associated kinase 1 2 69457997-69674349 Enzymes, Predicted intracellular proteins Evidence at protein level HPA017931, HPA020289 Approved Supported Plasma membrane
Cytosol Ovarian cancer:3.19e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 382.6 thyroid gland: 59.1 ABCA7 ABCX ENSG00000064687 ATP-binding cassette, sub-family A (ABC1), member 7 19 1040101-1065572 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041564 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable) Expressed in all Mixed spleen: 25.8 ABCB11 ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP ENSG00000073734 ATP-binding cassette, sub-family B (MDR/TAP), member 11 2 168922938-169031322 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019035 Supported Uncertain Nucleoplasm
Plasma membrane
Cytosol Tissue enriched Tissue enriched 13 liver: 19.1 testis: 1.4 ABCB4 ABCB4, GBD1, MDR2, MDR3 , PFIC-3, PGY3 ENSG00000005471 ATP-binding cassette, sub-family B (MDR/TAP), member 4 7 87401697-87480435 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA049395, HPA053288 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments
Focal adhesion sites Tissue enriched Tissue enriched 6 liver: 69.2 adrenal gland: 10.7 ABCB6 EST45597, MTABC3, umat ENSG00000115657 ATP-binding cassette, sub-family B (MDR/TAP), member 6 (Langereis blood group) 2 219209768-219218990 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046723, HPA058011 Approved Validated Nucleoplasm
Golgi apparatus
Plasma membrane
Mitochondria
Cytosol Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable) Expressed in all Expressed in all testis: 32.5 ABCC1 GS-X, MRP, MRP1 ENSG00000103222 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 16 15949577-16143074 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002380 Uncertain Supported Plasma membrane Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.1 ABCC3 cMOAT2, EST90757, MLP2, MOAT-D, MRP3 ENSG00000108846 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 17 50634777-50692252 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037136, HPA048483 Approved Approved Plasma membrane Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable) Mixed Mixed adrenal gland: 20.8 ABCC4 EST170205, MOAT-B, MOATB, MRP4 ENSG00000125257 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 13 95019829-95301446 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002476 Supported Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable) Tissue enriched Tissue enhanced prostate: 68.5 epididymis: 23.3 ABCC5 EST277145, MOAT-C, MRP5, SMRP ENSG00000114770 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 3 183919934-184018015 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044067, HPA052295 Uncertain Supported Nucleus
Plasma membrane
Cell Junctions Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all stomach: 72.0 ABCC6 ARA, EST349056, MLP1, MRP6, PXE, URG7 ENSG00000091262 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 16 16148928-16223522 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038105 Supported Plasma membrane Liver cancer:3.82e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 15.2;liver: 19.1 duodenum: 11.6 ABCG2 ABCP, BCRP, CD338, EST157481, MXR ENSG00000118777 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) 4 88090264-88231322 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037299, HPA054719 Supported Validated Nucleus
Plasma membrane Mixed Tissue enhanced small intestine: 116.1 seminal vesicle: 55.4 ABHD3 LABH3 ENSG00000158201 Abhydrolase domain containing 3 18 21650897-21704805 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010729 Approved Approved Nucleus
Vesicles
Plasma membrane Melanoma:8.52e-4 (unfavourable) Expressed in all Expressed in all rectum: 72.4 ABI1 ABI-1, E3B1, SSH3BP1 ENSG00000136754 Abl-interactor 1 10 26746593-26861087 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008375, HPA029973, HPA068407 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all cerebral cortex: 87.6 ABLIM3 KIAA0843 ENSG00000173210 Actin binding LIM protein family, member 3 5 149141483-149260542 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003245 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions Renal cancer:1.28e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 78.1 adipose tissue: 63.4 ACIN1 ACINUS, fSAP152, KIAA0670 ENSG00000100813 Apoptotic chromatin condensation inducer 1 14 23058564-23095614 Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA000657 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:4.88e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 76.7 ACKR3 CMKOR1, CXCR7, GPR159, RDC1 ENSG00000144476 Atypical chemokine receptor 3 2 236567787-236582358 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA032003, HPA049718 Approved Supported Vesicles
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all placenta: 175.2 ACLY ACL, ATPCL, CLATP ENSG00000131473 ATP citrate lyase 17 41866908-41930542 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007783, HPA022434, HPA022953, HPA022959, HPA028758 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable) Expressed in all Expressed in all prostate: 95.8 ACOT9 ACATE2, CGI-16, MT-ACT48 ENSG00000123130 Acyl-CoA thioesterase 9 X 23702253-23766475 Predicted intracellular proteins Evidence at protein level HPA035533 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:3.23e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 46.3 ACTN1 ENSG00000072110 Actinin, alpha 1 14 68874143-68979440 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004303, HPA006035 Approved Validated Plasma membrane
Focal adhesion sites Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 744.4 ACTR6 ARP6, FLJ13433 ENSG00000075089 ARP6 actin-related protein 6 homolog (yeast) 12 100199122-100241865 Predicted intracellular proteins Evidence at protein level HPA038587, HPA038588 Uncertain Approved Plasma membrane
Cytosol Liver cancer:7.70e-9 (unfavourable) Expressed in all Mixed testis: 16.2 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM12 MCMPMltna, MLTN ENSG00000148848 ADAM metallopeptidase domain 12 10 126012381-126388455 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030866, HPA030867, HPA030868 Supported Supported Plasma membrane Renal cancer:2.39e-14 (unfavourable) Mixed Tissue enriched 8 placenta: 236.1 cervix, uterine: 29.5 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 ADAM33 C20orf153, dJ964F7.1, DKFZp434K0521 ENSG00000149451 ADAM metallopeptidase domain 33 20 3667965-3682246 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA067152, HPA071758 Approved Uncertain Nuclear speckles
Plasma membrane Mixed Mixed endometrium: 102.9 ADAMTS2 ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif, 2 5 179110851-179345430 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA028444 Uncertain Approved Vesicles
Plasma membrane Renal cancer:1.71e-8 (unfavourable) Expressed in all Mixed placenta: 27.2 ADAMTSL4 DKFZP434K1772, TSRC1 ENSG00000143382 ADAMTS-like 4 1 150549369-150560937 Disease related genes, Predicted secreted proteins Evidence at protein level HPA006279 Approved Approved Plasma membrane
Cytosol Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 89.1 lung: 32.7 ADAP1 CENTA1, GCS1L ENSG00000105963 ArfGAP with dual PH domains 1 7 897901-955407 Predicted intracellular proteins Evidence at protein level HPA007033, HPA012049 Supported Supported Plasma membrane
Cytosol Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 80.5 colon: 38.9 ADCK5 FLJ35454 ENSG00000173137 AarF domain containing kinase 5 8 144373101-144393242 Enzymes, Predicted membrane proteins Evidence at protein level HPA025692, HPA028679 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed duodenum: 9.9 ADD1 ENSG00000087274 Adducin 1 (alpha) 4 2843857-2930076 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009794, HPA035873, HPA035874 Supported Validated Nucleoplasm
Plasma membrane Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 201.7 ADD2 ADDB ENSG00000075340 Adducin 2 (beta) 2 70607618-70768225 Predicted intracellular proteins Evidence at protein level CAB009796, HPA034509, HPA034510 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Tissue enhanced Group enriched 10 bone marrow: 40.3;cerebral cortex: 44.8 testis: 4.1 ADD3 ADDL ENSG00000148700 Adducin 3 (gamma) 10 109996368-110135565 Predicted intracellular proteins Evidence at protein level CAB009797, HPA035696 Supported Supported Plasma membrane Expressed in all Expressed in all thyroid gland: 167.8 ADGRG2 EDDM6, GPR64, HE6, TM7LN2 ENSG00000173698 Adhesion G protein-coupled receptor G2 X 18989309-19122637 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001478, HPA050029 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 6 epididymis: 1469.4 parathyroid gland: 235.5 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 ADH1A ADH1 ENSG00000187758 Alcohol dehydrogenase 1A (class I), alpha polypeptide 4 99276367-99291028 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009562, HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Liver cancer:2.38e-4 (favourable) Tissue enriched Tissue enriched 134 liver: 1364.4 gallbladder: 10.2 ADH1B ADH2 ENSG00000196616 Alcohol dehydrogenase 1B (class I), beta polypeptide 4 99304964-99321401 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Renal cancer:7.87e-4 (unfavourable) Tissue enriched Group enriched 6 adipose tissue: 1534.1;liver: 2889.4 lung: 371.7 ADH1C ADH3 ENSG00000248144 Alcohol dehydrogenase 1C (class I), gamma polypeptide 4 99336492-99353027 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 522.4;liver: 886.9;stomach: 478.6 colon: 281.0 ADH7 ADH-4 ENSG00000196344 Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 4 99412261-99435737 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039695 Supported Supported Plasma membrane
Cytosol Group enriched Tissue enriched 6 esophagus: 216.3 tonsil: 35.9 ADORA1 RDC7 ENSG00000163485 Adenosine A1 receptor 1 203090654-203167405 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA044383 Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 46.5;testis: 23.4 parathyroid gland: 17.5 ADRA1B ENSG00000170214 Adrenoceptor alpha 1B 5 159916783-159972544 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074416 Supported Plasma membrane Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.8;spleen: 17.3 ovary: 4.8 ADRBK2 BARK2, GRK3 ENSG00000100077 Adrenergic, beta, receptor kinase 2 22 25564849-25729294 Enzymes, Predicted intracellular proteins Evidence at protein level HPA000804 Uncertain Approved Nucleus
Plasma membrane Urothelial cancer:1.29e-4 (favourable) Expressed in all Mixed adipose tissue: 32.7 ADRM1 ARM1, GP110, Rpn13 ENSG00000130706 Adhesion regulating molecule 1 20 62302093-62308862 Predicted intracellular proteins Evidence at protein level HPA042266 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:9.02e-6 (unfavourable) Expressed in all Expressed in all testis: 108.8 ADSS ENSG00000035687 Adenylosuccinate synthase 1 244408494-244452134 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA024400 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 116.4 AFAP1L2 Em:AC005383.4, FLJ14564, KIAA1914, XB130 ENSG00000169129 Actin filament associated protein 1-like 2 10 114294824-114404756 Predicted intracellular proteins Evidence at protein level HPA037843 Approved Supported Plasma membrane
Cytosol Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 137.4 parathyroid gland: 92.9 AGER RAGE ENSG00000204305 Advanced glycosylation end product-specific receptor 6 32180968-32184324 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB011682, HPA064436 Approved Approved Nucleoli fibrillar center
Plasma membrane
Cell Junctions Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enriched 181 lung: 891.2 thyroid gland: 4.9 AGRN AGRIN ENSG00000188157 Agrin 1 1020123-1056118 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040090 Approved Supported Plasma membrane
Cytosol Liver cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 29.4 AHNAK MGC5395 ENSG00000124942 AHNAK nucleoprotein 11 62433542-62556235 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019010, HPA019070, HPA026643 Uncertain Supported Plasma membrane
Cytosol Urothelial cancer:3.47e-6 (unfavourable), Pancreatic cancer:2.42e-4 (unfavourable) Expressed in all Expressed in all skin: 398.0 AHNAK2 C14orf78 ENSG00000185567 AHNAK nucleoprotein 2 14 104937244-104978357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000878, HPA002940, HPA004145, HPA020111 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable) Mixed Tissue enriched 8 skin: 346.3 smooth muscle: 45.9 AKAP10 D-AKAP2, MGC9414, PRKA10 ENSG00000108599 A kinase (PRKA) anchor protein 10 17 19904302-19978343 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028901 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 26.1 AKAP11 AKAP220, DKFZp781I12161, FLJ11304, KIAA0629, PPP1R44, PRKA11 ENSG00000023516 A kinase (PRKA) anchor protein 11 13 42272153-42323267 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039089 Supported Approved Nucleoli
Plasma membrane
Cytosol Cervical cancer:9.26e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 51.7 AKAP12 AKAP250, SSeCKS ENSG00000131016 A kinase (PRKA) anchor protein 12 6 151239999-151358557 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006344, CAB026379, HPA056230 Supported Supported Plasma membrane
Cytosol Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable) Expressed in all Expressed in all testis: 183.8 AKR1B10 AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI ENSG00000198074 Aldo-keto reductase family 1, member B10 (aldose reductase) 7 134527592-134541408 Predicted intracellular proteins Evidence at protein level HPA020280, CAB070163, HPA073633 Supported Supported Plasma membrane
Cytosol Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 653.4;gallbladder: 284.3;small intestine: 396.0;stomach: 417.4 esophagus: 90.2 AKR1B15 ENSG00000227471 Aldo-keto reductase family 1, member B15 7 134549136-134579875 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020280, HPA073633 Uncertain Supported Plasma membrane
Cytosol Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable) Mixed Tissue enriched 12 breast: 176.5 duodenum: 14.1 ALDH3A1 ALDH3 ENSG00000108602 Aldehyde dehydrogenase 3 family, member A1 17 19737984-19748943 Enzymes, Predicted intracellular proteins Evidence at protein level CAB045957, HPA051150, HPA063783 Supported Validated Vesicles
Plasma membrane
Cytosol Head and neck cancer:7.55e-5 (favourable) Mixed Group enriched 7 esophagus: 407.6;skin: 84.5;stomach: 210.9 tonsil: 32.2 ALK CD246 ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase 2 29192774-29921566 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010694 Approved Supported Plasma membrane Group enriched Tissue enhanced cerebral cortex: 3.5;testis: 2.3 adrenal gland: 0.9 ALOXE3 E-LOX, eLOX3 ENSG00000179148 Arachidonate lipoxygenase 3 17 8095900-8119047 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023120 Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 17 skin: 36.6 breast: 2.2 ALPI ENSG00000163295 Alkaline phosphatase, intestinal 2 232456123-232460032 Enzymes, Predicted secreted proteins Evidence at protein level HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Tissue enhanced Group enriched 31 duodenum: 208.8;small intestine: 216.4 colon: 6.8 ALPP ENSG00000163283 Alkaline phosphatase, placental 2 232378534-232382889 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026327, HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Pancreatic cancer:4.33e-4 (unfavourable) Tissue enhanced Group enriched 14 cervix, uterine: 25.2;placenta: 45.5 fallopian tube: 2.5 ALPPL2 ENSG00000163286 Alkaline phosphatase, placental-like 2 2 232406843-232410714 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB020698, HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Tissue enhanced Tissue enhanced cervix, uterine: 1.1;fallopian tube: 1.9 lung: 0.7 ALS2CR12 ENSG00000155749 Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12 2 201288271-201357398 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035793 Uncertain Approved Plasma membrane
Cytosol Not detected Group enriched 5 fallopian tube: 15.1;testis: 31.7 lung: 4.3 AMACR RACE ENSG00000242110 Alpha-methylacyl-CoA racemase 5 33986178-34008108 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB001809, HPA019527, HPA020912 Supported Supported Vesicles
Plasma membrane Colorectal cancer:7.11e-4 (favourable) Expressed in all Expressed in all kidney: 134.0 AMDHD1 MGC35366 ENSG00000139344 Amidohydrolase domain containing 1 12 95943293-95968716 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039720 Approved Approved Plasma membrane
Actin filaments
Focal adhesion sites Tissue enriched Tissue enhanced testis: 27.1 liver: 22.4 AMER1 FAM123B, FLJ39827, RP11-403E24.2, WTX ENSG00000184675 APC membrane recruitment protein 1 X 64185117-64205744 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA065214, HPA065265 Approved Supported Nuclear bodies
Vesicles
Plasma membrane Expressed in all Mixed ovary: 7.7 AMIGO2 ALI1, DEGA ENSG00000139211 Adhesion molecule with Ig-like domain 2 12 47075707-47079951 Predicted membrane proteins Evidence at protein level HPA054004, HPA059601 Uncertain Approved Golgi apparatus
Plasma membrane
Cytosol Pancreatic cancer:1.80e-4 (unfavourable) Expressed in all Mixed smooth muscle: 54.4 AMPH ENSG00000078053 Amphiphysin 7 38383704-38631567 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008559, HPA019828, HPA019829 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:9.96e-4 (favourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 84.0 cervix, uterine: 8.9 ANK3 ENSG00000151150 Ankyrin 3, node of Ranvier (ankyrin G) 10 60026298-60733490 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013249, CAB015179, HPA038455, HPA055643 Approved Approved Plasma membrane Renal cancer:8.88e-16 (favourable) Mixed Expressed in all parathyroid gland: 284.5 ANKEF1 ANKRD5, dJ839B4.6, FLJ21669 ENSG00000132623 Ankyrin repeat and EF-hand domain containing 1 20 9986126-10058303 Predicted intracellular proteins Evidence at protein level HPA041151 Approved Approved Nucleoli fibrillar center
Plasma membrane
Cytosol Thyroid cancer:1.58e-4 (unfavourable), Lung cancer:1.81e-4 (unfavourable), Renal cancer:4.44e-4 (favourable) Mixed Tissue enhanced testis: 33.7 thyroid gland: 11.3 ANKIB1 DKFZP434A0225, KIAA1386 ENSG00000001629 Ankyrin repeat and IBR domain containing 1 7 92246234-92401384 Predicted intracellular proteins Evidence at protein level HPA019358, HPA021780 Uncertain Supported Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 45.4 ANKLE2 KIAA0692, Lem4, LEMD7 ENSG00000176915 Ankyrin repeat and LEM domain containing 2 12 132725503-132761888 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003602, HPA074838 Uncertain Supported Endoplasmic reticulum
Plasma membrane Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable) Expressed in all Expressed in all testis: 80.1 ANKRA2 ENSG00000164331 Ankyrin repeat, family A (RFXANK-like), 2 5 73552335-73565686 Predicted intracellular proteins Evidence at protein level HPA065263 Approved Plasma membrane
Cell Junctions Expressed in all Expressed in all thyroid gland: 26.1 ANKRD13A ANKRD13, NY-REN-25 ENSG00000076513 Ankyrin repeat domain 13A 12 109999186-110039763 Predicted intracellular proteins Evidence at protein level HPA039488, HPA043218 Supported Supported Plasma membrane Head and neck cancer:7.70e-6 (favourable), Ovarian cancer:6.77e-4 (unfavourable) Expressed in all Expressed in all testis: 112.0 ANKRD35 FLJ25124 ENSG00000198483 Ankyrin repeat domain 35 1 145866560-145885866 Predicted intracellular proteins Evidence at protein level HPA035452, HPA035453 Approved Approved Plasma membrane Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable) Mixed Group enriched 6 cervix, uterine: 30.6;esophagus: 16.7;skin: 69.9 tonsil: 6.3 ANKRD42 FLJ37874, PPP1R79, SARP ENSG00000137494 Ankyrin repeat domain 42 11 83193739-83260694 Predicted intracellular proteins Evidence at protein level HPA039917 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Tissue enhanced testis: 71.7 epididymis: 28.4 ANKS1B AIDA-1, ANKS2, cajalin-2, EB-1 ENSG00000185046 Ankyrin repeat and sterile alpha motif domain containing 1B 12 98726457-99984654 Predicted intracellular proteins Evidence at protein level HPA044628 Approved Vesicles
Plasma membrane
Cytosol Tissue enhanced Tissue enriched 8 cerebral cortex: 112.3 testis: 14.0 ANO2 C12orf3, TMEM16B ENSG00000047617 Anoctamin 2, calcium activated chloride channel 12 5531869-5946232 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036276 Supported Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced testis: 17.7 placenta: 5.9 ANO6 DKFZp313M0720, TMEM16F ENSG00000177119 Anoctamin 6 12 45215987-45440404 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038958 Approved Approved Plasma membrane
Cytosol Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 90.8 ANPEP CD13, gp150, LAP1, p150, PEPN ENSG00000166825 Alanyl (membrane) aminopeptidase 15 89784889-89815401 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002417, HPA004625 Supported Supported Nucleus
Plasma membrane Expressed in all Group enriched 9 duodenum: 2451.4;small intestine: 2177.9 colon: 263.9 ANXA1 ANX1, LPC1 ENSG00000135046 Annexin A1 9 73151757-73170393 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA011271, HPA011272, CAB013023, CAB035987, CAB058693 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable) Expressed in all Tissue enriched 6 esophagus: 7577.8 tonsil: 1266.5 ANXA13 ANX13 ENSG00000104537 Annexin A13 8 123680794-123737407 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018535, HPA019569, HPA019650, CAB025135 Supported Supported Plasma membrane Group enriched Group enriched 5 duodenum: 304.7;fallopian tube: 91.6;gallbladder: 228.3;small intestine: 240.9 rectum: 39.8 AP2M1 AP50, CLAPM1, mu2 ENSG00000161203 Adaptor-related protein complex 2, mu 1 subunit 3 184174689-184184091 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036849, HPA069870 Uncertain Supported Plasma membrane Renal cancer:7.45e-6 (unfavourable), Liver cancer:9.12e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 559.2 APBA2 D15S1518E, HsT16821, LIN-10, MGC:14091, MINT2, X11L ENSG00000034053 Amyloid beta (A4) precursor protein-binding, family A, member 2 15 28884483-29118315 Predicted intracellular proteins Evidence at protein level CAB037065, HPA039400 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 12.2 spleen: 3.3 APBB1 Fe65, RIR ENSG00000166313 Amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) 11 6395124-6419414 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB022104, HPA038521, HPA038522 Approved Validated Plasma membrane Renal cancer:7.44e-13 (favourable), Pancreatic cancer:1.86e-5 (favourable), Liver cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 237.2 APBB1IP INAG1, RIAM ENSG00000077420 Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 10 26438203-26567803 Predicted intracellular proteins Evidence at protein level HPA017009, HPA063903 Supported Validated Plasma membrane
Cytosol Endometrial cancer:7.48e-4 (favourable) Expressed in all Mixed appendix: 63.1 APMAP BSCv, C20orf3 ENSG00000101474 Adipocyte plasma membrane associated protein 20 24962925-24992979 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012863, HPA064700 Uncertain Approved Plasma membrane Expressed in all Expressed in all thyroid gland: 322.5 AQP1 CHIP28, CO ENSG00000240583 Aquaporin 1 (Colton blood group) 7 30911855-30925516 Blood group antigen proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001707, HPA019206 Supported Supported Plasma membrane Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable) Expressed in all Expressed in all kidney: 801.2 AQP3 GIL ENSG00000165272 Aquaporin 3 (Gill blood group) 9 33441154-33447611 Blood group antigen proteins, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014924 Supported Supported Nucleus
Plasma membrane Cervical cancer:5.31e-4 (favourable) Expressed in all Expressed in all esophagus: 975.2 AQP4 MIWC ENSG00000171885 Aquaporin 4 18 26852038-26865818 Predicted membrane proteins, Transporters Evidence at protein level CAB005079, HPA014784, CAB058689 Supported Supported Supported Plasma membrane
Cell Junctions Tissue enriched Group enriched 17 cerebral cortex: 631.8;lung: 172.2 thyroid gland: 24.3 AQP5 ENSG00000161798 Aquaporin 5 12 49961870-49965681 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA065008 Supported Approved Plasma membrane Head and neck cancer:1.75e-5 (favourable) Tissue enhanced Group enriched 8 salivary gland: 257.1;stomach: 54.0;testis: 176.5 breast: 21.0 ARAP1 CENTD2 ENSG00000186635 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 11 72685069-72793599 Predicted intracellular proteins Evidence at protein level CAB020703, HPA070383 Approved Approved Nucleoplasm
Vesicles
Plasma membrane
Cytosol Pancreatic cancer:2.04e-5 (favourable), Thyroid cancer:6.41e-4 (favourable), Liver cancer:6.45e-4 (unfavourable) Expressed in all Expressed in all spleen: 92.9 ARF1 ENSG00000143761 ADP-ribosylation factor 1 1 228082660-228099212 Predicted intracellular proteins Evidence at protein level CAB007742 Uncertain Approved Plasma membrane
Cytosol Head and neck cancer:1.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 381.7 ARHGAP18 bA307O14.2, MacGAP ENSG00000146376 Rho GTPase activating protein 18 6 129576132-129710225 Predicted intracellular proteins Evidence at protein level HPA031595 Approved Approved Nuclear speckles
Plasma membrane
Cytosol Pancreatic cancer:2.54e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 48.2 ARHGAP19 FLJ00194, MGC14258 ENSG00000213390 Rho GTPase activating protein 19 10 97222173-97292673 Predicted intracellular proteins Evidence at protein level HPA035777, HPA043231 Uncertain Approved Vesicles
Plasma membrane Renal cancer:7.47e-5 (unfavourable) Expressed in all Mixed testis: 34.1 ARHGAP21 ARHGAP10, KIAA1424 ENSG00000107863 Rho GTPase activating protein 21 10 24583609-24723668 Predicted intracellular proteins Evidence at protein level HPA036610, HPA057861 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Expressed in all Expressed in all cerebral cortex: 103.8 ARHGAP22 RhoGAP2 ENSG00000128805 Rho GTPase activating protein 22 10 48446034-48656265 Predicted intracellular proteins Evidence at protein level CAB020696, HPA040391, HPA064439 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.16e-8 (unfavourable) Mixed Mixed cerebral cortex: 8.0 ARHGAP23 KIAA1501 ENSG00000275832 Rho GTPase activating protein 23 17 38419280-38512392 Predicted intracellular proteins Evidence at protein level HPA019818, HPA047291 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:5.38e-5 (unfavourable), Endometrial cancer:6.87e-5 (unfavourable), Pancreatic cancer:3.24e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 42.0 ARHGAP24 DKFZP564B1162, FilGAP, FLJ33877 ENSG00000138639 Rho GTPase activating protein 24 4 85475114-86002670 Predicted intracellular proteins Evidence at protein level HPA014288 Approved Approved Plasma membrane
Cytosol Renal cancer:1.67e-11 (favourable) Expressed in all Expressed in all kidney: 105.5 ARHGAP29 PARG1 ENSG00000137962 Rho GTPase activating protein 29 1 94148988-94275068 Predicted intracellular proteins Evidence at protein level HPA026534 Approved Approved Nucleus
Plasma membrane
Centrosome
Cytosol Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:9.63e-4 (unfavourable) Expressed in all Mixed spleen: 50.5 ARHGAP33 FLJ39019, SNX26, TCGAP ENSG00000004777 Rho GTPase activating protein 33 19 35774532-35788822 Predicted intracellular proteins Evidence at protein level HPA030117, HPA030118 Supported Approved Plasma membrane
Actin filaments
Cytosol Renal cancer:3.09e-8 (unfavourable) Expressed in all Mixed cerebral cortex: 25.9 ARHGAP36 FLJ30058 ENSG00000147256 Rho GTPase activating protein 36 X 131058242-131089883 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002064 Supported Approved Nucleus
Vesicles
Plasma membrane Tissue enriched Tissue enriched 19 adrenal gland: 138.4 cerebral cortex: 7.4 ARHGAP40 C20orf95, dJ1100H13.4 ENSG00000124143 Rho GTPase activating protein 40 20 38601934-38651035 Predicted intracellular proteins Evidence at protein level HPA042636, HPA042840 Uncertain Supported Nucleoplasm
Plasma membrane
Centrosome
Cytosol Renal cancer:2.89e-4 (unfavourable) Mixed Group enriched 7 breast: 37.4;epididymis: 43.2;esophagus: 12.7;seminal vesicle: 11.2;skin: 53.9 stomach: 4.3 ARHGEF1 LBCL2, P115-RHOGEF, SUB1.5 ENSG00000076928 Rho guanine nucleotide exchange factor (GEF) 1 19 41883161-41930150 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009502, HPA012924, HPA060784 Supported Validated Plasma membrane
Cytosol Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable) Expressed in all Expressed in all lymph node: 147.0 ARHGEF11 GTRAP48, KIAA0380, PDZ-RHOGEF ENSG00000132694 Rho guanine nucleotide exchange factor (GEF) 11 1 156934840-157045370 Predicted intracellular proteins Evidence at protein level HPA011026, HPA012037, HPA014658 Approved Approved Golgi apparatus
Plasma membrane Pancreatic cancer:1.72e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 43.6 ARHGEF12 KIAA0382, LARG ENSG00000196914 Rho guanine nucleotide exchange factor (GEF) 12 11 120336914-120489936 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA018911, CAB025581 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:5.43e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 143.2 ARHGEF15 ARGEF15, FLJ13791, KIAA0915, MGC44868, Vsm-RhoGEF ENSG00000198844 Rho guanine nucleotide exchange factor (GEF) 15 17 8310241-8322516 Predicted intracellular proteins Evidence at protein level HPA044443, HPA063495 Uncertain Supported Plasma membrane Expressed in all Tissue enhanced adipose tissue: 37.1 lung: 30.7 ARHGEF26 DKFZP434D146, SGEF ENSG00000114790 Rho guanine nucleotide exchange factor (GEF) 26 3 154121003-154257827 Predicted intracellular proteins Evidence at protein level HPA017722, HPA049195 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:9.74e-4 (favourable) Expressed in all Mixed lung: 15.6 ARHGEF28 p190RhoGEF, RGNEF, RIP2 ENSG00000214944 Rho guanine nucleotide exchange factor (GEF) 28 5 73626158-73941993 Predicted intracellular proteins Evidence at protein level HPA037602 Approved Approved Plasma membrane
Microtubules
Cytosol Renal cancer:1.91e-6 (favourable), Cervical cancer:5.31e-4 (favourable), Urothelial cancer:8.98e-4 (favourable) Mixed Mixed kidney: 33.5 ARHGEF5 GEF5, P60, TIM, TIM1 ENSG00000050327 Rho guanine nucleotide exchange factor (GEF) 5 7 144355288-144380632 Predicted intracellular proteins Evidence at protein level HPA020980, HPA029504, HPA044188, HPA045619, HPA045699 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:3.28e-7 (favourable) Mixed Mixed thyroid gland: 43.2 ARID2 BAF200, DKFZp686G052, FLJ30619, KIAA1557 ENSG00000189079 AT rich interactive domain 2 (ARID, RFX-like) 12 45729665-45908040 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063044 Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.75e-4 (favourable) Expressed in all Expressed in all testis: 47.3 ARID4A RBBP1, RBP-1, RBP1 ENSG00000032219 AT rich interactive domain 4A (RBP1-like) 14 58298385-58373887 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA048899 Supported Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:1.91e-4 (favourable), Lung cancer:7.82e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 24.1 ARID5B FLJ21150, MRF2 ENSG00000150347 AT rich interactive domain 5B (MRF1-like) 10 61901300-62096944 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015037 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all gallbladder: 62.1 ARL15 ARFRP2, FLJ20051 ENSG00000185305 ADP-ribosylation factor-like 15 5 53883945-54310582 Predicted intracellular proteins Evidence at protein level HPA044604, HPA063820 Uncertain Approved Golgi apparatus
Plasma membrane
Cell Junctions Expressed in all Expressed in all placenta: 44.4 ARL4C ARL7, LAK ENSG00000188042 ADP-ribosylation factor-like 4C 2 234493041-234497053 Predicted intracellular proteins Evidence at protein level HPA028927 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.69e-8 (unfavourable), Endometrial cancer:2.90e-7 (unfavourable), Urothelial cancer:6.99e-5 (unfavourable) Expressed in all Mixed spleen: 73.2 ARMC12 C6orf81, FLJ25390 ENSG00000157343 Armadillo repeat containing 12 6 35737032-35749079 Predicted intracellular proteins Evidence at protein level HPA030895 Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 8 testis: 62.9 epididymis: 7.4 ARPC5 ARC16, dJ127C7.3, p16-Arc ENSG00000162704 Actin related protein 2/3 complex, subunit 5, 16kDa 1 183620846-183635757 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022013, HPA031972 Approved Approved Vesicles
Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable) Expressed in all Expressed in all appendix: 207.6 ARVCF ENSG00000099889 Armadillo repeat gene deleted in velocardiofacial syndrome 22 19969896-20016808 Predicted intracellular proteins Evidence at protein level CAB016162, HPA055264, HPA063675 Approved Supported Nuclear speckles
Plasma membrane
Cell Junctions Urothelial cancer:5.76e-6 (favourable) Expressed in all Mixed spleen: 9.0 ASAP1 CENTB4, DDEF1, KIAA1249, PAP, ZG14P ENSG00000153317 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 8 130052104-130443660 Predicted intracellular proteins Evidence at protein level HPA011136, CAB037292, HPA048565 Approved Approved Plasma membrane
Centrosome
Cytosol Liver cancer:5.63e-8 (unfavourable), Renal cancer:1.50e-7 (unfavourable), Lung cancer:3.56e-5 (unfavourable), Endometrial cancer:5.81e-5 (unfavourable) Expressed in all Expressed in all testis: 56.0 ASB5 ENSG00000164122 Ankyrin repeat and SOCS box containing 5 4 176213673-176277571 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA028870 Uncertain Plasma membrane Head and neck cancer:5.67e-4 (unfavourable) Tissue enhanced Tissue enhanced skeletal muscle: 75.7 prostate: 18.1 ASGR2 CLEC4H2 ENSG00000161944 Asialoglycoprotein receptor 2 17 7101322-7115700 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014899, HPA015998 Supported Supported Endoplasmic reticulum
Plasma membrane Tissue enriched Tissue enriched 11 liver: 317.4 gallbladder: 28.1 ASH2L ASH2, ASH2L1, ASH2L2, Bre2 ENSG00000129691 Ash2 (absent, small, or homeotic)-like (Drosophila) 8 38105242-38144076 Predicted intracellular proteins Evidence at protein level HPA042289 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:4.25e-4 (favourable) Expressed in all Expressed in all testis: 74.5 ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing (proton gated) ion channel 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 57.0 parathyroid gland: 5.5 ASPM ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5 ENSG00000066279 Abnormal spindle microtubule assembly 1 197084128-197146694 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017816 Approved Approved Plasma membrane
Cytosol Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable) Mixed Tissue enhanced bone marrow: 11.0 lymph node: 9.6 ASPSCR1 ASPL, ASPS, UBXD9, UBXN9 ENSG00000169696 Alveolar soft part sarcoma chromosome region, candidate 1 17 81976807-82017406 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA026749 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable) Expressed in all Expressed in all testis: 21.3 ATG13 KIAA0652 ENSG00000175224 Autophagy related 13 11 46617527-46674818 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039350 Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:8.59e-5 (unfavourable) Expressed in all Expressed in all testis: 111.4 ATG3 APG3L, DKFZp564M1178, FLJ22125, MGC15201, PC3-96 ENSG00000144848 Autophagy related 3 3 112532509-112562046 Predicted intracellular proteins Evidence at protein level CAB037260, HPA040471 Supported Supported Plasma membrane
Cytosol Liver cancer:9.35e-6 (unfavourable), Prostate cancer:1.59e-4 (unfavourable), Cervical cancer:6.82e-4 (favourable) Expressed in all Expressed in all testis: 154.2 ATG7 APG7L, DKFZp434N0735, GSA7 ENSG00000197548 Autophagy related 7 3 11272309-11557665 Predicted intracellular proteins Evidence at protein level HPA007639, CAB018771 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.41e-4 (unfavourable), Renal cancer:9.55e-4 (favourable), Colorectal cancer:9.66e-4 (favourable) Expressed in all Expressed in all testis: 39.9 ATIC AICARFT, IMPCHASE, PURH ENSG00000138363 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 2 215311817-215349773 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013462, HPA021012 Supported Validated Plasma membrane
Cytosol Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all placenta,rectum: 44.5 ATOX1 HAH1 ENSG00000177556 Antioxidant 1 copper chaperone 5 151742316-151772532 Predicted intracellular proteins Evidence at protein level HPA055036 Approved Nucleoplasm
Plasma membrane Pancreatic cancer:9.57e-4 (favourable) Expressed in all Expressed in all thyroid gland: 151.1 ATP10D ATPVD, KIAA1487 ENSG00000145246 ATPase, class V, type 10D 4 47485288-47593486 Enzymes, Predicted membrane proteins Evidence at protein level HPA050808 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:5.00e-8 (favourable) Expressed in all Mixed parathyroid gland: 22.1 ATP13A3 AFURS1 ENSG00000133657 ATPase type 13A3 3 194402672-194498364 Predicted membrane proteins Evidence at protein level HPA029471 Approved Approved Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 146.4 ATP1B3 CD298, FLJ29027 ENSG00000069849 ATPase, Na+/K+ transporting, beta 3 polypeptide 3 141876124-141926514 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB020697, HPA048963 Supported Supported Plasma membrane Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable) Expressed in all Expressed in all skin: 310.5 ATP2B1 PMCA1 ENSG00000070961 ATPase, Ca++ transporting, plasma membrane 1 12 89588049-89709300 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB005605, HPA011166, HPA012945 Supported Supported Plasma membrane Liver cancer:7.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.0 ATP2B3 CFAP39, CLA2, PMCA3, SCAX1 ENSG00000067842 ATPase, Ca++ transporting, plasma membrane 3 X 153517676-153582939 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA001583 Supported Uncertain Golgi apparatus
Plasma membrane Not detected Group enriched 8 adrenal gland: 12.2;cerebral cortex: 19.1 fallopian tube: 2.0 ATP2B4 ATP2B2, MXRA1, PMCA4 ENSG00000058668 ATPase, Ca++ transporting, plasma membrane 4 1 203626561-203744081 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB016118, HPA040431 Supported Supported Plasma membrane Renal cancer:1.21e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 251.3 ATP2C2 KIAA0703, SPCA2 ENSG00000064270 ATPase, Ca++ transporting, type 2C, member 2 16 84368527-84464187 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA052262, HPA075812 Approved Approved Plasma membrane
Focal adhesion sites Endometrial cancer:6.20e-6 (favourable) Mixed Tissue enhanced rectum: 39.0 skin: 30.1 ATP6AP1 16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3 ENSG00000071553 ATPase, H+ transporting, lysosomal accessory protein 1 X 154428632-154436516 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015218 Uncertain Approved Plasma membrane
Microtubules
Cytosol Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 205.5 ATP6V0A2 a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1 ENSG00000185344 ATPase, H+ transporting, lysosomal V0 subunit a2 12 123712318-123761755 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044279 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all skin: 15.2 ATP8A2 ATPIB, ML-1 ENSG00000132932 ATPase, aminophospholipid transporter, class I, type 8A, member 2 13 25372071-26025851 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA039926, HPA040033 Approved Supported Nucleoplasm
Plasma membrane Mixed Group enriched 6 cerebral cortex: 26.5;testis: 10.6 adrenal gland: 2.9 ATXN10 E46L, FLJ37990, SCA10 ENSG00000130638 Ataxin 10 22 45671798-45845307 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049531 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 83.7 ATXN3 ATX3, JOS, MJD, SCA3 ENSG00000066427 Ataxin 3 14 92038652-92106621 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB021976, HPA024123, HPA069338 Uncertain Supported Nucleus
Nucleoli
Plasma membrane Mixed Mixed testis: 18.5 ATXN7L3 DKFZp761G2113 ENSG00000087152 Ataxin 7-like 3 17 44191805-44200113 Predicted intracellular proteins Evidence at protein level HPA064316 Supported Approved Nuclear speckles
Plasma membrane Renal cancer:2.87e-4 (unfavourable), Liver cancer:4.03e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 84.0 AVEN PDCD12 ENSG00000169857 Apoptosis, caspase activation inhibitor 15 33866227-34039176 Predicted intracellular proteins Evidence at protein level HPA020863 Approved Approved Plasma membrane
Actin filaments
Centrosome Renal cancer:5.29e-10 (unfavourable) Expressed in all Expressed in all smooth muscle: 19.1 AVPI1 PP5395, VIP32, VIT32 ENSG00000119986 Arginine vasopressin-induced 1 10 97677424-97687323 Predicted intracellular proteins Evidence at protein level HPA037649 Approved Approved Nucleus
Plasma membrane Expressed in all Mixed adrenal gland: 42.4 AXIN2 DKFZp781B0869, MGC126582 ENSG00000168646 Axin 2 17 65528563-65561647 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB012283, CAB017783 Approved Uncertain Nucleus
Plasma membrane
Cytosol Pancreatic cancer:6.58e-4 (favourable) Expressed in all Mixed endometrium: 31.0 B2M ENSG00000166710 Beta-2-microglobulin 15 44711477-44718877 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002572, HPA006361 Supported Validated Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all lymph node: 5182.5 B3GALT2 beta3Gal-T2 ENSG00000162630 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 1 193179045-193186654 Predicted membrane proteins Evidence at transcript level HPA078659 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 29.0;gallbladder: 26.0 heart muscle: 16.2 BACE1 BACE ENSG00000186318 Beta-site APP-cleaving enzyme 1 11 117285207-117316259 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB016358 Approved Supported Plasma membrane Urothelial cancer:6.76e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex,pancreas: 100.6 BAG3 ENSG00000151929 BCL2-associated athanogene 3 10 119651370-119677819 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018493, HPA020586 Supported Validated Plasma membrane
Cytosol Expressed in all Expressed in all skeletal muscle: 98.2 BAIAP2 BAP2 ENSG00000175866 BAI1-associated protein 2 17 81035122-81117432 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023310, HPA027421 Approved Validated Plasma membrane
Cytosol Urothelial cancer:7.58e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 125.1 BAIAP2L1 IRTKS ENSG00000006453 BAI1-associated protein 2-like 1 7 98291651-98401068 Predicted intracellular proteins Evidence at protein level HPA019484, HPA021257, HPA023874, HPA029503 Supported Validated Plasma membrane
Cytosol Mixed Mixed stomach: 55.7 BANK1 BANK, FLJ20706 ENSG00000153064 B-cell scaffold protein with ankyrin repeats 1 4 101411286-102074812 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA037002 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Group enriched 5 appendix: 47.6;lymph node: 97.9;spleen: 78.5;thyroid gland: 21.5;tonsil: 90.9 urinary bladder: 13.3 BASP1 CAP-23, CAP23, NAP-22, NAP22 ENSG00000176788 Brain abundant, membrane attached signal protein 1 5 17065598-17276843 Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA045218, HPA050333 Supported Validated Plasma membrane Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 420.3;epididymis: 364.8 prostate: 133.3 BBOF1 C14orf45, CCDC176 ENSG00000119636 Basal body orientation factor 1 14 74019353-74082863 Predicted intracellular proteins Evidence at protein level HPA003090, HPA003136 Uncertain Approved Nucleus
Plasma membrane
Microtubule organizing center Endometrial cancer:6.34e-4 (favourable) Expressed in all Tissue enhanced testis: 69.7 fallopian tube: 35.6 BCAR1 CAS, CASS1, Crkas, P130Cas ENSG00000050820 Breast cancer anti-estrogen resistance 1 16 75228187-75268053 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000443, HPA042282 Approved Supported Approved Plasma membrane
Cytosol Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable) Expressed in all Mixed spleen: 42.0 BCAR3 NSP2, SH2D3B ENSG00000137936 Breast cancer anti-estrogen resistance 3 1 93561786-93847150 Predicted intracellular proteins Evidence at protein level HPA014858 Approved Approved Plasma membrane
Centrosome
Cytosol Renal cancer:3.08e-7 (favourable), Lung cancer:8.92e-7 (unfavourable), Pancreatic cancer:4.38e-4 (unfavourable), Liver cancer:5.42e-4 (unfavourable), Head and neck cancer:8.41e-4 (unfavourable) Expressed in all Mixed adipose tissue: 32.5 BCORL1 CXorf10, FLJ11362 ENSG00000085185 BCL6 corepressor-like 1 X 129981107-130058083 Predicted intracellular proteins Evidence at protein level HPA031775, HPA031777, HPA068568 Uncertain Approved Nucleoplasm
Plasma membrane Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable) Expressed in all Expressed in all placenta: 18.2 BEND6 bA203B9.1, C6orf65, FLJ30162 ENSG00000151917 BEN domain containing 6 6 56955126-57027342 Predicted intracellular proteins Evidence at protein level HPA052973 Approved Nucleus
Plasma membrane Tissue enriched Tissue enriched 6 cerebral cortex: 39.3 cervix, uterine: 6.7 BFSP1 CP115, CP94, filensin, LIFL-H ENSG00000125864 Beaded filament structural protein 1, filensin 20 17493905-17569220 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040748, HPA042038 Supported Supported Plasma membrane
Cytosol Endometrial cancer:1.39e-4 (favourable) Mixed Mixed testis: 6.5 BFSP2 CP47, CP49, LIFL-L, phakinin ENSG00000170819 Beaded filament structural protein 2, phakinin 3 133399995-133475222 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038464, HPA062959 Supported Uncertain Plasma membrane
Cytosol Tissue enriched Not detected epididymis,lymph node: 0.4 BICD2 KIAA0699 ENSG00000185963 Bicaudal D homolog 2 (Drosophila) 9 92711363-92764812 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA023013, HPA024452 Supported Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.39e-4 (favourable) Expressed in all Expressed in all skin: 69.4 BLVRB FLR, SDR43U1 ENSG00000090013 Biliverdin reductase B 19 40447789-40465840 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041698, HPA041937 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 339.1 BMPR2 BMPR-II, BMPR3, BRK-3, PPH1, T-ALK ENSG00000204217 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 2 202376936-202567751 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017385, HPA049014 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all cerebral cortex: 36.5 BMX ETK, PSCTK3 ENSG00000102010 BMX non-receptor tyrosine kinase X 15464246-15556529 Enzymes, Predicted intracellular proteins Evidence at protein level HPA001048, CAB032495 Supported Supported Nucleoplasm
Plasma membrane Mixed Tissue enriched 18 epididymis: 122.9 placenta: 6.9 BOC CDON2 ENSG00000144857 BOC cell adhesion associated, oncogene regulated 3 113211003-113287459 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025806, HPA060778, HPA061787 Uncertain Supported Nucleoplasm
Plasma membrane Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable) Mixed Mixed fallopian tube: 56.6 BRPF1 BR140 ENSG00000156983 Bromodomain and PHD finger containing, 1 3 9731729-9748018 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003359 Supported Approved Plasma membrane
Cytosol Liver cancer:3.20e-5 (unfavourable), Prostate cancer:5.28e-4 (unfavourable) Expressed in all Expressed in all testis: 26.3 BST2 CD317, tetherin ENSG00000130303 Bone marrow stromal cell antigen 2 19 17402939-17405648 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA017060 Approved Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable) Expressed in all Expressed in all ovary: 585.6 BTN2A1 BT2.1, BTF1, BTN2.1 ENSG00000112763 Butyrophilin, subfamily 2, member A1 6 26457904-26476621 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019208 Approved Approved Plasma membrane Urothelial cancer:4.52e-5 (favourable), Renal cancer:5.90e-5 (unfavourable) Expressed in all Expressed in all placenta: 26.1 BTRC beta-TrCP1, betaTrCP, bTrCP, bTrCP1, FBXW1A, Fwd1 ENSG00000166167 Beta-transducin repeat containing E3 ubiquitin protein ligase 10 101354033-101557321 Predicted intracellular proteins Evidence at protein level HPA031156, CAB032986 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 34.1 BZW2 HSPC028, MST017, MSTP017 ENSG00000136261 Basic leucine zipper and W2 domains 2 7 16646131-16706523 Predicted intracellular proteins Evidence at protein level HPA022813, HPA026709 Approved Approved Plasma membrane
Actin filaments
Cytosol Liver cancer:7.86e-8 (unfavourable), Renal cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 167.1 C10orf90 bA422P15.2, FATS, FLJ32938 ENSG00000154493 Chromosome 10 open reading frame 90 10 126424997-126670446 Predicted intracellular proteins Evidence at protein level HPA038648, HPA057599 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Tissue enriched Group enriched 13 breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.4;testis: 12.4 adipose tissue,skin,tonsil: 0.7 C12orf73 DKFZp547P055, FLJ13975 ENSG00000204954 Chromosome 12 open reading frame 73 12 103950202-103965708 Predicted secreted proteins Evidence at protein level HPA038883 Uncertain Approved Plasma membrane
Centrosome
Mitochondria Urothelial cancer:1.61e-4 (favourable), Liver cancer:6.98e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex,thyroid gland: 17.8 C12orf76 FLJ40142 ENSG00000174456 Chromosome 12 open reading frame 76 12 110027028-110073686 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA039713, HPA042013 Uncertain Approved Plasma membrane
Actin filaments Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 106.1 C14orf37 ENSG00000139971 Chromosome 14 open reading frame 37 14 57999735-58298139 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001580, HPA001789 Approved Approved Plasma membrane Mixed Mixed kidney: 8.8 C14orf93 FLJ12154 ENSG00000100802 Chromosome 14 open reading frame 93 14 22985908-23010166 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002569 Approved Approved Nucleus
Plasma membrane Breast cancer:5.05e-4 (favourable) Expressed in all Expressed in all skin: 21.7 C16orf74 MGC17624 ENSG00000154102 Chromosome 16 open reading frame 74 16 85690084-85751129 Predicted intracellular proteins Evidence at protein level HPA049367 Uncertain Approved Plasma membrane
Centrosome Pancreatic cancer:1.54e-5 (unfavourable), Head and neck cancer:1.71e-4 (unfavourable), Melanoma:4.08e-4 (unfavourable) Mixed Mixed urinary bladder: 13.8 C17orf58 ENSG00000186665 Chromosome 17 open reading frame 58 17 67991101-67993649 Predicted intracellular proteins Evidence at transcript level HPA023036 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable) Expressed in all Expressed in all placenta: 58.5 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 C18orf21 HsT3108, PNAS-124, PNAS-131 ENSG00000141428 Chromosome 18 open reading frame 21 18 35972083-35979286 Predicted intracellular proteins Evidence at protein level HPA065505, HPA067322 Uncertain Approved Nucleoli
Plasma membrane Liver cancer:1.38e-6 (unfavourable), Ovarian cancer:1.81e-6 (favourable) Expressed in all Expressed in all testis: 59.3 C19orf33 H2RSP, IMUP, IMUP-1, IMUP-2 ENSG00000167644 Chromosome 19 open reading frame 33 19 38304161-38305009 Predicted intracellular proteins Evidence at protein level HPA054406, HPA059696 Uncertain Supported Nucleus
Plasma membrane
Cytosol Pancreatic cancer:5.05e-4 (unfavourable), Lung cancer:5.42e-4 (unfavourable) Mixed Mixed esophagus: 178.5 C19orf38 HIDE1 ENSG00000214212 Chromosome 19 open reading frame 38 19 10836575-10869790 Predicted membrane proteins Evidence at protein level HPA012150, HPA055027 Uncertain Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.75e-7 (unfavourable), Cervical cancer:2.43e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 62.9 spleen: 17.8 C19orf48 MGC13170 ENSG00000167747 Chromosome 19 open reading frame 48 19 50797704-50804929 Predicted intracellular proteins Evidence at transcript level HPA042000 Uncertain Approved Plasma membrane Liver cancer:8.80e-5 (unfavourable) Expressed in all Expressed in all prostate: 76.2 C19orf71 LOC100128569 ENSG00000183397 Chromosome 19 open reading frame 71 19 3539154-3544030 Predicted intracellular proteins Evidence at protein level HPA048654 Uncertain Approved Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:2.02e-5 (favourable), Pancreatic cancer:2.03e-5 (favourable), Head and neck cancer:2.35e-4 (favourable) Tissue enriched Mixed testis: 29.7 C1orf116 FLJ36507, MGC2742, MGC4309, SARG ENSG00000182795 Chromosome 1 open reading frame 116 1 207018521-207032756 Predicted intracellular proteins Evidence at protein level HPA011888, HPA011889 Supported Supported Plasma membrane
Cytosol Renal cancer:1.01e-5 (favourable) Mixed Tissue enhanced esophagus: 112.9;lung: 109.5;prostate: 80.5 stomach: 54.8 C1orf27 FLJ20505, odr-4, TTG1 ENSG00000157181 Chromosome 1 open reading frame 27 1 186375838-186421378 Predicted membrane proteins Evidence at protein level HPA015988, HPA031352 Uncertain Approved Nucleoplasm
Plasma membrane Ovarian cancer:9.92e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 75.0 C1orf35 MGC4174, MMTAG2 ENSG00000143793 Chromosome 1 open reading frame 35 1 228100726-228105411 Predicted intracellular proteins Evidence at protein level HPA046175 Approved Approved Nuclear speckles
Plasma membrane
Cytosol Renal cancer:1.79e-6 (unfavourable), Ovarian cancer:7.38e-4 (favourable), Colorectal cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all skin: 14.3 C1orf74 FLJ25078 ENSG00000162757 Chromosome 1 open reading frame 74 1 209779208-209784559 Predicted intracellular proteins Evidence at protein level HPA028496 Uncertain Approved Plasma membrane
Cytosol Cervical cancer:8.52e-6 (unfavourable) Expressed in all Mixed lymph node: 5.1 C1QBP gC1Q-R, gC1qR, HABP1, p32, SF2p32 ENSG00000108561 Complement component 1, q subcomponent binding protein 17 5432777-5448830 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA026483 Supported Approved Plasma membrane
Mitochondria Expressed in all Expressed in all rectum: 159.4 C2orf72 LOC257407 ENSG00000204128 Chromosome 2 open reading frame 72 2 231037490-231049719 Predicted intracellular proteins Evidence at protein level HPA044962 Uncertain Approved Nucleus
Plasma membrane Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 2.8;colon: 3.0;liver: 4.7 stomach: 1.3 C3orf14 HT021 ENSG00000114405 Chromosome 3 open reading frame 14 3 62318973-62336213 Predicted intracellular proteins Evidence at transcript level HPA048286 Approved Approved Plasma membrane
Cytosol Renal cancer:4.33e-5 (favourable) Expressed in all Mixed breast: 61.4 C3orf38 MGC26717 ENSG00000179021 Chromosome 3 open reading frame 38 3 88149743-88168729 Predicted intracellular proteins Evidence at protein level HPA034736, HPA034737 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Ovarian cancer:3.55e-4 (favourable), Prostate cancer:4.12e-4 (unfavourable) Expressed in all Expressed in all testis: 58.7 C4orf22 ENSG00000197826 Chromosome 4 open reading frame 22 4 80335720-80963756 Predicted intracellular proteins Evidence at transcript level HPA043383 Approved Approved Plasma membrane
Cytosol Not detected Group enriched 23 fallopian tube: 30.3;testis: 47.2 lung: 1.7 C5orf45 DKFZp686L2452, LOC51149, MGC65027, MGC78537 ENSG00000161010 Chromosome 5 open reading frame 45 5 179835133-179862173 Predicted intracellular proteins Evidence at protein level HPA043975 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.64e-5 (unfavourable) Expressed in all Mixed fallopian tube: 21.2 C7orf43 FLJ10925 ENSG00000146826 Chromosome 7 open reading frame 43 7 100154420-100158715 Predicted intracellular proteins Evidence at protein level HPA019359, HPA029463, HPA029464 Approved Validated Vesicles
Plasma membrane
Microtubule organizing center Pancreatic cancer:6.19e-5 (favourable) Expressed in all Expressed in all testis: 33.4 C8orf33 FLJ20989 ENSG00000182307 Chromosome 8 open reading frame 33 8 145052378-145056030 Predicted intracellular proteins Evidence at protein level HPA024812, HPA026104 Approved Uncertain Nucleoplasm
Plasma membrane Breast cancer:2.77e-4 (unfavourable), Liver cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.8 C8orf37 CORD16, FLJ30600, RP64 ENSG00000156172 Chromosome 8 open reading frame 37 8 95244919-95269201 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024198 Approved Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:4.63e-4 (unfavourable) Expressed in all Mixed fallopian tube: 6.3 C8orf4 hTC-1, TC-1 ENSG00000176907 Chromosome 8 open reading frame 4 8 40153455-40155308 Predicted intracellular proteins Evidence at protein level HPA027188 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Mixed placenta: 231.6 C9 ENSG00000113600 Complement component 9 5 39284262-39424868 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002151, HPA029577 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enriched 119 liver: 728.8 epididymis: 6.1 C9orf91 DKFZp547P234, FLJ38045 ENSG00000157693 Chromosome 9 open reading frame 91 9 114611206-114646422 Predicted membrane proteins Evidence at transcript level HPA017199 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 CA14 ENSG00000118298 Carbonic anhydrase XIV 1 150257159-150265078 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008482 Approved Approved Plasma membrane Group enriched Tissue enhanced cerebral cortex: 10.6;seminal vesicle: 21.1 skeletal muscle: 9.4 CA9 CAIX, MN ENSG00000107159 Carbonic anhydrase IX 9 35673856-35681159 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005100, CAB017107, HPA055207 Supported Validated Plasma membrane
Cytosol Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable) Mixed Tissue enhanced gallbladder: 36.1;stomach: 92.4 small intestine: 14.8 CACNA1E BII, CACH6, CACNL1A6, Cav2.3 ENSG00000198216 Calcium channel, voltage-dependent, R type, alpha 1E subunit 1 181413102-181808084 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA042515 Approved Plasma membrane
Actin filaments
Cytosol Mixed Tissue enriched 7 cerebral cortex: 10.3 adrenal gland: 1.3 CALCRL CGRPR, CRLR ENSG00000064989 Calcitonin receptor-like 2 187343129-187448460 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA008070, HPA046515 Uncertain Supported Plasma membrane Expressed in all Tissue enhanced lung: 114.4 adipose tissue: 76.3 CALD1 CDM, H-CAD, L-CAD ENSG00000122786 Caldesmon 1 7 134744252-134970728 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000006, HPA008066, HPA017330 Supported Validated Plasma membrane
Actin filaments Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 1285.3 smooth muscle: 1186.8 CALML5 CLSP ENSG00000178372 Calmodulin-like 5 10 5498697-5499555 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040725 Supported Approved Plasma membrane
Cytosol Head and neck cancer:2.59e-5 (favourable) Group enriched Group enriched 8 salivary gland: 262.7;skin: 651.2 breast: 55.1 CALN1 ENSG00000183166 Calneuron 1 7 71779491-72447151 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036278, HPA036708 Approved Uncertain Vesicles
Plasma membrane Mixed Group enriched 5 adrenal gland: 14.8;cerebral cortex: 46.5 testis: 6.0 CAMK2A CAMKA, CaMKIINalpha, KIAA0968 ENSG00000070808 Calcium/calmodulin-dependent protein kinase II alpha 5 150219491-150290291 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004330, HPA051783, HPA051785, HPA053973 Supported Supported Plasma membrane
Cell Junctions Tissue enriched Tissue enriched 9 cerebral cortex: 284.4 skeletal muscle: 33.3 CAMK2B CAM2, CAMK2, CAMKB ENSG00000058404 Calcium/calmodulin-dependent protein kinase II beta 7 44217150-44334577 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006849, HPA026307, HPA051783, HPA051785, HPA053973 Supported Supported Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 214.7 skeletal muscle: 46.1 CAMK2D CAMKD ENSG00000145349 Calcium/calmodulin-dependent protein kinase II delta 4 113451032-113761927 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026281, HPA051783, HPA051785, HPA053973 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all parathyroid gland: 106.2 CAMK2G CAMKG ENSG00000148660 Calcium/calmodulin-dependent protein kinase II gamma 10 73812501-73874591 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040656, HPA051783, HPA051785, HPA053973 Approved Approved Plasma membrane
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 119.4 CAP2 ENSG00000112186 CAP, adenylate cyclase-associated protein, 2 (yeast) 6 17393216-17557792 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA050530, HPA054147 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Tissue enhanced cerebral cortex: 125.5;skeletal muscle: 220.9 heart muscle: 69.1 CAPS CAPS1, MGC126562 ENSG00000105519 Calcyphosine 19 5911707-5916208 Predicted intracellular proteins Evidence at protein level HPA043520 Supported Supported Nucleus
Plasma membrane
Cytosol Endometrial cancer:7.63e-5 (favourable), Head and neck cancer:8.60e-4 (favourable) Tissue enriched Tissue enriched 10 fallopian tube: 493.6 cervix, uterine: 51.4 CAPS CAPS1, MGC126562 ENSG00000283027 Calcyphosine 19 5914407-5915322 Predicted intracellular proteins Evidence at protein level HPA043520 Supported Supported Nucleus
Plasma membrane
Cytosol Tissue enriched 9 fallopian tube: 68.8 endometrium,lung: 7.3 CASP4 ICE(rel)II, ICH-2, TX ENSG00000196954 Caspase 4, apoptosis-related cysteine peptidase 11 104942866-104969436 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA027588, CAB037167 Approved Approved Plasma membrane
Cytosol Renal cancer:3.27e-11 (unfavourable) Expressed in all Expressed in all placenta: 71.5 CAV3 LGMD1C, LQT9, VIP-21, VIP21 ENSG00000182533 Caveolin 3 3 8733800-8841808 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB017518, CAB018557, HPA054488 Supported Supported Vesicles
Plasma membrane Tissue enhanced Group enriched 6 heart muscle: 13.0;skeletal muscle: 63.3 esophagus: 6.0 CBWD1 ENSG00000172785 COBW domain containing 1 9 121038-179147 Predicted intracellular proteins Evidence at protein level HPA042759, HPA042813 Approved Approved Plasma membrane Mixed Expressed in all adrenal gland: 45.0 CBWD2 ENSG00000136682 COBW domain containing 2 2 113437691-113496189 Predicted intracellular proteins Evidence at protein level HPA042759, HPA042813 Approved Approved Plasma membrane Endometrial cancer:3.22e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.6 CBWD3 bA561O23.1 ENSG00000196873 COBW domain containing 3 9 68232003-68300015 Predicted intracellular proteins Evidence at transcript level HPA042759, HPA042813 Uncertain Approved Plasma membrane Not detected Expressed in all appendix: 25.9 CBWD5 ENSG00000147996 COBW domain containing 5 9 65668805-65734041 Predicted intracellular proteins Evidence at transcript level HPA042759, HPA042813 Approved Approved Plasma membrane Mixed Expressed in all breast: 21.6 CBWD7 ENSG00000215126 COBW domain containing 7 9 41131306-41199261 Predicted intracellular proteins Evidence at transcript level HPA042759, HPA042813 Approved Approved Plasma membrane Not detected Tissue enhanced adrenal gland: 4.9 breast: 2.8 CC2D1A FLJ20241, MRT3 ENSG00000132024 Coiled-coil and C2 domain containing 1A 19 13906201-13930879 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA005436, CAB015220 Supported Supported Nucleoli fibrillar center
Plasma membrane
Cytosol Head and neck cancer:7.02e-4 (favourable) Expressed in all Expressed in all duodenum: 36.6 CCBE1 FLJ30681, KIAA1983 ENSG00000183287 Collagen and calcium binding EGF domains 1 18 59430940-59697380 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041361, HPA041374 Uncertain Validated Plasma membrane
Cytosol Mixed Tissue enhanced ovary: 40.6 cervix, uterine: 15.9 CCDC107 MGC31967 ENSG00000159884 Coiled-coil domain containing 107 9 35658290-35661511 Predicted membrane proteins Evidence at protein level HPA016857, HPA050442 Validated Nucleoplasm
Plasma membrane Expressed in all Expressed in all adipose tissue: 63.0 CCDC112 MGC39633 ENSG00000164221 Coiled-coil domain containing 112 5 115267188-115296831 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045120, HPA050621 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.51e-6 (unfavourable) Expressed in all Tissue enriched 6 testis: 73.4 cerebral cortex: 13.2 CCDC115 ccp1, FLJ30131, MGC12981 ENSG00000136710 Coiled-coil domain containing 115 2 130338241-130342349 Predicted intracellular proteins Evidence at protein level HPA034598 Approved Supported Vesicles
Plasma membrane Breast cancer:7.59e-4 (favourable) Expressed in all Expressed in all ovary: 55.3 CCDC124 ENSG00000007080 Coiled-coil domain containing 124 19 17933016-17943991 Predicted intracellular proteins Evidence at protein level HPA041708, HPA046765 Supported Validated Plasma membrane
Cytosol Liver cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 72.6 CCDC144NL MGC87631 ENSG00000205212 Coiled-coil domain containing 144 family, N-terminal like 17 20836447-20896140 Predicted intracellular proteins Evidence at transcript level HPA023457 Uncertain Approved Nucleus
Plasma membrane Not detected Tissue enriched 7 testis: 4.3 endometrium,prostate,seminal vesicle: 0.5 CCDC15 FLJ13215 ENSG00000149548 Coiled-coil domain containing 15 11 124954121-125041489 Predicted intracellular proteins Evidence at transcript level HPA040450, HPA041738 Uncertain Approved Plasma membrane
Cytosol Mixed Tissue enriched 5 testis: 18.8 breast: 3.5 CCDC154 C16orf29, LOC645811 ENSG00000197599 Coiled-coil domain containing 154 16 1434383-1444556 Predicted intracellular proteins Evidence at protein level HPA041158, HPA043535, HPA048237 Uncertain Approved Golgi apparatus
Plasma membrane Mixed Tissue enhanced testis: 6.5 prostate: 3.7 CCDC24 MGC45441 ENSG00000159214 Coiled-coil domain containing 24 1 43991359-43996528 Predicted intracellular proteins Evidence at protein level HPA035424, HPA061710 Uncertain Validated Plasma membrane
Cytosol Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 18.1 testis: 15.2 CCDC62 CT109, ERAP75, FLJ40344, TSP-NY ENSG00000130783 Coiled-coil domain containing 62 12 122774327-122827528 Predicted intracellular proteins Evidence at protein level HPA039021, HPA058741 Approved Approved Nucleoplasm
Plasma membrane Not detected Tissue enriched 143 testis: 115.3 spleen: 0.8 CCDC69 DKFZP434C171, FLJ13705 ENSG00000198624 Coiled-coil domain containing 69 5 151181052-151224145 Predicted intracellular proteins Evidence at protein level HPA043648, HPA052896 Uncertain Approved Golgi apparatus
Plasma membrane
Actin filaments Breast cancer:3.21e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 113.1 CCDC8 3M3, DKFZp564K0322, PPP1R20 ENSG00000169515 Coiled-coil domain containing 8 19 46410372-46413584 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041993 Uncertain Approved Nucleus
Plasma membrane
Cytosol Renal cancer:1.72e-5 (favourable) Mixed Tissue enhanced ovary: 45.4 fallopian tube: 37.4 CCDC81 FLJ16339, FLJ23514 ENSG00000149201 Coiled-coil domain containing 81 11 86374736-86423109 Predicted intracellular proteins Evidence at protein level HPA040745, HPA040827 Uncertain Uncertain Plasma membrane Tissue enhanced Group enriched 11 fallopian tube: 45.5;testis: 10.9 endometrium: 2.6 CCDC83 CT148, FLJ42119, MGC34732 ENSG00000150676 Coiled-coil domain containing 83 11 85855101-85920021 Predicted intracellular proteins Evidence at transcript level HPA039707, HPA039882 Uncertain Nucleus
Plasma membrane
Cytosol Not detected Tissue enriched 132 testis: 63.3 cerebral cortex,endometrium,parathyroid gland: 0.4 CCDC93 FLJ10996 ENSG00000125633 Coiled-coil domain containing 93 2 117915478-118014133 Predicted intracellular proteins Evidence at protein level HPA054183 Approved Supported Vesicles
Plasma membrane Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 24.5 CCDC97 FLJ40267, MGC20255 ENSG00000142039 Coiled-coil domain containing 97 19 41310189-41324883 Predicted intracellular proteins Evidence at protein level HPA043320, HPA043572 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.09e-4 (unfavourable) Expressed in all Expressed in all testis: 58.7 CCND3 ENSG00000112576 Cyclin D3 6 41934933-42050357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000116, HPA055107 Approved Supported Plasma membrane
Focal adhesion sites
Cytosol Thyroid cancer:8.08e-6 (favourable) Expressed in all Expressed in all lymph node: 161.4 CCNT2 ENSG00000082258 Cyclin T2 2 134918235-134959342 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005559 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.25e-5 (unfavourable), Prostate cancer:2.44e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 27.7 CCNYL1 FLJ40432 ENSG00000163249 Cyclin Y-like 1 2 207711540-207761839 Predicted intracellular proteins Evidence at protein level HPA046825 Approved Approved Plasma membrane Expressed in all Expressed in all testis: 30.3 CCT3 Cctg, TRIC5 ENSG00000163468 Chaperonin containing TCP1, subunit 3 (gamma) 1 156308968-156367873 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006543 Approved Supported Plasma membrane
Cytosol Liver cancer:3.87e-7 (unfavourable), Renal cancer:6.34e-4 (unfavourable) Expressed in all Expressed in all testis: 205.6 CD163 M130, MM130 ENSG00000177575 CD163 molecule 12 7470813-7503893 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002432, HPA046404, HPA051974 Supported Approved Plasma membrane Ovarian cancer:7.27e-4 (unfavourable) Expressed in all Mixed appendix: 224.6 CD248 CD164L1, TEM1 ENSG00000174807 CD248 molecule, endosialin 11 66314487-66317044 CD markers, Predicted membrane proteins Evidence at protein level HPA051856 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:2.69e-7 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 136.1 placenta: 96.3 CD2AP CMS ENSG00000198087 CD2-associated protein 6 47477789-47627263 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003267, HPA003326, CAB004352 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable) Expressed in all Expressed in all small intestine: 66.9 CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011442, HPA035832, HPA064807 Approved Supported Nucleus
Plasma membrane Mixed Tissue enhanced spleen: 33.6 bone marrow: 20.9 CD34 ENSG00000174059 CD34 molecule 1 207880972-207911402 CD markers, Predicted membrane proteins Evidence at protein level CAB000018, HPA036722, HPA036723 Supported Approved Nucleus
Plasma membrane
Cell Junctions Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable) Expressed in all Expressed in all placenta: 313.8 CD38 ENSG00000004468 CD38 molecule 4 15778275-15853230 Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002493, HPA022132, CAB025255, HPA052381 Supported Approved Plasma membrane Endometrial cancer:9.68e-4 (favourable) Expressed in all Mixed lymph node,seminal vesicle: 27.3 CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Supported Supported Plasma membrane Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 538.7 spleen: 224.0 CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Supported Validated Golgi apparatus
Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 505.8 CD46 MCP, MGC26544, MIC10, TLX, TRA2.10 ENSG00000117335 CD46 molecule, complement regulatory protein 1 207752057-207795513 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB010401, HPA016903 Supported Approved Plasma membrane Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 483.7 CD47 IAP, MER6, OA3 ENSG00000196776 CD47 molecule 3 108043298-108091025 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016055, HPA044659 Approved Supported Golgi apparatus
Vesicles
Plasma membrane Thyroid cancer:7.29e-5 (favourable), Renal cancer:1.69e-4 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all lung: 204.9 CD48 BCM1, BLAST, hCD48, mCD48, SLAMF2 ENSG00000117091 CD48 molecule 1 160678746-160711851 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002497, HPA055146 Supported Supported Nucleoli fibrillar center
Plasma membrane
Cytosol Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable) Expressed in all Tissue enhanced lymph node: 315.8;spleen: 216.7;tonsil: 235.9 appendix: 153.7 CD79B B29, IGB ENSG00000007312 CD79b molecule, immunoglobulin-associated beta 17 63928740-63932354 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA009178, CAB009751 Approved Uncertain Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:2.35e-4 (favourable) Expressed in all Group enriched 5 appendix: 94.7;lymph node: 315.6;spleen: 160.3;tonsil: 196.1 bone marrow: 36.2 CD81 TAPA-1, TAPA1, TSPAN28 ENSG00000110651 CD81 molecule 11 2376177-2397419 CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002507, HPA007234 Supported Supported Plasma membrane Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 2246.2 CD8B CD8B1 ENSG00000172116 CD8b molecule 2 86815339-86861924 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004353, HPA029164 Approved Supported Plasma membrane Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable) Mixed Tissue enhanced cervix, uterine: 60.5;lymph node: 40.2 parathyroid gland: 22.4 CD9 BA2, MIC3, MRP-1, P24, TSPAN29 ENSG00000010278 CD9 molecule 12 6199715-6238271 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002490 Supported Supported Plasma membrane Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1009.8 CD93 C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4 ENSG00000125810 CD93 molecule 20 23079349-23086340 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA009300, HPA012368 Supported Approved Vesicles
Plasma membrane Renal cancer:2.74e-4 (unfavourable) Expressed in all Expressed in all placenta: 195.4 CD99L2 CD99B, MIC2L1 ENSG00000102181 CD99 molecule-like 2 X 150766337-150898816 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038782, HPA038783 Supported Uncertain Golgi apparatus
Plasma membrane
Intermediate filaments Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 143.9 CDAN1 CDA-I, CDAI ENSG00000140326 Codanin 1 15 42723559-42737126 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039404, HPA040787 Supported Validated Plasma membrane
Cytosol Liver cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all ovary: 15.1 CDC42EP1 Borg5, CEP1, MSE55 ENSG00000128283 CDC42 effector protein (Rho GTPase binding) 1 22 37560447-37569405 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006379 Approved Supported Plasma membrane
Actin filaments Expressed in all Expressed in all stomach: 107.7 CDC42EP4 BORG4, CEP4, KAIA1777, MGC17125, MGC3740 ENSG00000179604 CDC42 effector protein (Rho GTPase binding) 4 17 73283624-73312175 Predicted intracellular proteins Evidence at protein level HPA023335, HPA024797 Approved Supported Validated Plasma membrane
Actin filaments
Microtubules Expressed in all Expressed in all cerebral cortex: 102.1 CDC42SE1 SCIP1, SPEC1 ENSG00000197622 CDC42 small effector 1 1 151050971-151070325 Predicted intracellular proteins Evidence at protein level HPA027634 Approved Supported Plasma membrane Renal cancer:2.19e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 117.1 CDH1 CD324, UVO, uvomorulin ENSG00000039068 Cadherin 1, type 1 16 68737225-68835548 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Renal cancer:2.06e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 467.0 thyroid gland: 264.7 CDH13 CDHH ENSG00000140945 Cadherin 13 16 82626803-83800640 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001380, CAB025863 Supported Supported Plasma membrane Renal cancer:1.73e-6 (unfavourable) Expressed in all Tissue enhanced endometrium: 82.5 cervix, uterine: 72.5 CDH2 CD325, CDHN, NCAD ENSG00000170558 Cadherin 2, type 1, N-cadherin (neuronal) 18 27950966-28177446 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000141, CAB018580, HPA058574 Supported Supported Plasma membrane
Cell Junctions Expressed in all Tissue enhanced heart muscle: 125.8;parathyroid gland: 124.0 adrenal gland: 87.7 CDH26 VR20 ENSG00000124215 Cadherin 26 20 59958427-60034011 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015722, HPA047578 Uncertain Approved Plasma membrane
Microtubules Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable) Group enriched Tissue enhanced prostate: 19.8 urinary bladder: 6.3 CDH4 ENSG00000179242 Cadherin 4, type 1, R-cadherin (retinal) 20 61252426-61940617 Predicted membrane proteins Evidence at protein level HPA015613 Validated Plasma membrane Group enriched Tissue enhanced cerebral cortex: 6.0;spleen: 4.9 seminal vesicle: 1.3 CDH8 ENSG00000150394 Cadherin 8, type 2 16 61647242-62037035 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014908, HPA058444 Approved Supported Plasma membrane Tissue enhanced Group enriched 8 cerebral cortex: 27.9;seminal vesicle: 6.9 ovary: 2.1 CDIPT PIS, PIS1 ENSG00000103502 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 16 29858357-29863736 Enzymes, Predicted membrane proteins Evidence at protein level HPA056597 Approved Approved Nucleoplasm
Nuclear membrane
Plasma membrane Cervical cancer:9.40e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 110.5 CDK16 FLJ16665, PCTAIRE, PCTAIRE1, PCTGAIRE, PCTK1 ENSG00000102225 Cyclin-dependent kinase 16 X 47217860-47229997 Enzymes, Predicted intracellular proteins Evidence at protein level HPA000974, HPA001366, CAB016535 Approved Uncertain Plasma membrane
Microtubules
Cytosol Liver cancer:2.02e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 97.2 CDK5 PSSALRE ENSG00000164885 Cyclin-dependent kinase 5 7 151053812-151058530 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB008909, HPA018977, HPA064535 Approved Supported Nucleus
Plasma membrane
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 50.0 CDV3 H41 ENSG00000091527 CDV3 homolog (mouse) 3 133573730-133590261 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029761, HPA029762, HPA029763 Supported Validated Nucleoli
Plasma membrane
Cytosol Liver cancer:5.21e-6 (unfavourable) Expressed in all Expressed in all lymph node: 187.9 CEACAM5 CD66e, CEA ENSG00000105388 Carcinoembryonic antigen-related cell adhesion molecule 5 19 41708585-41729798 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000021, CAB000022, HPA011041, HPA019758 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced colon: 1030.9;rectum: 1100.3 appendix: 268.1 CECR6 ENSG00000183307 Cat eye syndrome chromosome region, candidate 6 22 17116299-17121367 Predicted membrane proteins Evidence at protein level HPA068790 Approved Nucleoplasm
Vesicles
Plasma membrane Tissue enhanced Group enriched 7 cerebral cortex: 15.0;prostate: 10.9 testis: 1.9 CELSR1 ADGRC1, CDHF9, FMI2, HFMI2, ME2 ENSG00000075275 Cadherin, EGF LAG seven-pass G-type receptor 1 22 46360834-46537170 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052976, HPA060521, HPA067269 Uncertain Supported Plasma membrane Expressed in all Mixed fallopian tube: 15.4 CENPJ BM032, CPAP, LAP, LIP1, MCPH6, Sas-4, SASS4, SCKL4 ENSG00000151849 Centromere protein J 13 24882284-24922889 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA060426 Approved Nucleoplasm
Plasma membrane
Centrosome Renal cancer:1.75e-5 (unfavourable) Expressed in all Tissue enhanced testis: 43.4 thyroid gland: 20.5 CEP162 C6orf84, KIAA1009, QN1 ENSG00000135315 Centrosomal protein 162kDa 6 84124241-84227635 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030170, HPA030171, HPA030172, HPA030173 Supported Validated Plasma membrane
Cytosol Expressed in all Mixed testis: 15.7 CEP295 KIAA1731 ENSG00000166004 Centrosomal protein 295kDa 11 93661639-93730358 Predicted intracellular proteins Evidence at protein level HPA038595, HPA038596, HPA038597 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 22.2 CEP55 C10orf3, CT111, FLJ10540 ENSG00000138180 Centrosomal protein 55kDa 10 93496632-93529092 Predicted intracellular proteins Evidence at protein level HPA023430 Approved Supported Plasma membrane
Microtubule organizing center Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable) Expressed in all Tissue enhanced testis: 39.1 lymph node: 17.8 CEP57L1 bA487F23.2, C6orf182, MGC21731 ENSG00000183137 Centrosomal protein 57kDa-like 1 6 109095110-109163932 Predicted intracellular proteins Evidence at protein level HPA040378 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 47.4 CEP89 CCDC123, FLJ14640 ENSG00000121289 Centrosomal protein 89kDa 19 32875925-32971991 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039382, HPA040056 Uncertain Supported Plasma membrane
Cytosol Liver cancer:8.78e-5 (unfavourable) Expressed in all Mixed fallopian tube: 14.8 CFAP157 C9orf117 ENSG00000160401 Cilia and flagella associated protein 157 9 127706989-127716002 Predicted intracellular proteins Evidence at protein level HPA021474, HPA021786 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.45e-4 (favourable) Mixed Tissue enriched 8 fallopian tube: 93.9 lung: 12.2 CFAP97 DKFZp434F1728, hmw, KIAA1430 ENSG00000164323 Cilia and flagella associated protein 97 4 185159665-185209504 Predicted intracellular proteins Evidence at protein level HPA049446, HPA053335 Approved Supported Nucleoli
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 67.5 CFD ADN, DF, PFD ENSG00000197766 Complement factor D (adipsin) 19 859643-863630 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA052799 Uncertain Plasma membrane Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable) Expressed in all Tissue enriched 7 adipose tissue: 378.7 breast: 52.3 CFL2 NEM7 ENSG00000165410 Cofilin 2 (muscle) 14 34706769-34714823 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037078, HPA045599 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:2.16e-5 (unfavourable) Expressed in all Expressed in all skeletal muscle: 242.8 CFLAR c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT ENSG00000003402 CASP8 and FADD-like apoptosis regulator 2 201116104-201176687 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA019044, CAB022157, CAB025216 Uncertain Supported Nucleus
Nuclear bodies
Plasma membrane
Cytosol Head and neck cancer:2.79e-4 (favourable) Expressed in all Expressed in all bone marrow: 160.5 CGN KIAA1319 ENSG00000143375 Cingulin 1 151510510-151538692 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017193, HPA027586, HPA027587, HPA027657 Supported Supported Plasma membrane
Cell Junctions Renal cancer:5.84e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 73.3 small intestine: 63.2 CHD9 BC022889, FLJ12178, KIAA0308 ENSG00000177200 Chromodomain helicase DNA binding protein 9 16 53055033-53329150 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042053, HPA049420 Approved Approved Plasma membrane
Cytosol Renal cancer:1.84e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.8 CHMP2A BC-2, CHMP2, VPS2, VPS2A ENSG00000130724 Charged multivesicular body protein 2A 19 58551566-58555124 Predicted intracellular proteins Evidence at protein level HPA041153, HPA042031 Supported Approved Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 191.1 CHRM3 ENSG00000133019 Cholinergic receptor, muscarinic 3 1 239386565-239915452 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA024106, HPA048036 Approved Supported Plasma membrane Mixed Tissue enhanced cerebral cortex: 15.7 esophagus: 8.5 CHRNA1 CHRNA ENSG00000138435 Cholinergic receptor, nicotinic, alpha 1 (muscle) 2 174747592-174764472 Disease related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA071554 Supported Plasma membrane Tissue enhanced Tissue enhanced skeletal muscle: 7.2 prostate: 2.6 CHRNA5 ENSG00000169684 Cholinergic receptor, nicotinic, alpha 5 (neuronal) 15 78565520-78595269 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054381 Approved Approved Plasma membrane
Focal adhesion sites Lung cancer:3.64e-5 (unfavourable) Mixed Mixed gallbladder: 6.9 CIB1 CALMYRIN, CIB, KIP, SIP2-28 ENSG00000185043 Calcium and integrin binding 1 (calmyrin) 15 90229975-90234047 Predicted intracellular proteins Evidence at protein level CAB012991, HPA048825 Approved Supported Nucleoplasm
Plasma membrane Endometrial cancer:2.26e-5 (favourable) Expressed in all Expressed in all fallopian tube: 204.7 CKAP5 ch-TOG, KIAA0097, TOG, TOGp ENSG00000175216 Cytoskeleton associated protein 5 11 46743048-46846308 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039377, HPA040375 Supported Approved Nucleoli
Plasma membrane
Cytosol Liver cancer:1.03e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.4 CLCN5 ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN ENSG00000171365 Chloride channel, voltage-sensitive 5 X 49922615-50099235 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000401, HPA003213 Uncertain Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable) Expressed in all Tissue enhanced epididymis: 33.2;kidney: 51.6 placenta: 9.5 CLCN6 CLC-6, KIAA0046 ENSG00000011021 Chloride channel, voltage-sensitive 6 1 11806096-11843144 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA032097 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 31.2 CLDN23 CLDNL ENSG00000253958 Claudin 23 8 8701938-8704106 Predicted membrane proteins, Transporters Evidence at protein level HPA070578 Uncertain Nucleus
Plasma membrane Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable) Expressed in all Tissue enhanced colon: 24.1;stomach: 24.9 small intestine: 16.9 CLDN4 CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8 ENSG00000189143 Claudin 4 7 73799542-73832693 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002610 Supported Supported Plasma membrane Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable) Mixed Mixed colon: 212.3 CLEC2A INPE5792, KACL, PILAR, UNQ5792 ENSG00000188393 C-type lectin domain family 2, member A 12 9898673-9932381 Predicted membrane proteins Evidence at protein level HPA048530, HPA072407 Approved Uncertain Plasma membrane Tissue enhanced Tissue enriched 14 skin: 67.7 breast: 4.7 CLIC2 XAP121 ENSG00000155962 Chloride intracellular channel 2 X 155276211-155334657 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA047381, HPA060101 Uncertain Approved Plasma membrane Renal cancer:1.74e-5 (unfavourable) Expressed in all Mixed spleen: 63.7 CLIC5 DFNB102 ENSG00000112782 Chloride intracellular channel 5 6 45898451-46080395 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA074371 Supported Nuclear speckles
Plasma membrane Tissue enhanced Tissue enhanced lung: 116.4;skeletal muscle: 119.2 heart muscle: 72.3 CLTB Lcb ENSG00000175416 Clathrin, light chain B 5 176392455-176416569 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003692, HPA036458 Approved Supported Vesicles
Plasma membrane
Cytosol Renal cancer:7.89e-5 (unfavourable) Expressed in all Expressed in all esophagus: 243.7 CMTM4 CKLFSF4 ENSG00000183723 CKLF-like MARVEL transmembrane domain containing 4 16 66614750-66696707 Predicted membrane proteins Evidence at protein level HPA014704, HPA023890 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:4.72e-9 (favourable) Expressed in all Tissue enhanced thyroid gland: 63.9 parathyroid gland: 47.2 CMTM7 CKLFSF7, FLJ30992 ENSG00000153551 CKLF-like MARVEL transmembrane domain containing 7 3 32391671-32483067 Predicted membrane proteins, Transporters Evidence at protein level HPA077409 Approved Plasma membrane Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Mixed fallopian tube: 60.9 CNGA1 CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49 ENSG00000198515 Cyclic nucleotide gated channel alpha 1 4 47935977-48016672 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA076168 Approved Vesicles
Plasma membrane Mixed Mixed liver: 14.2 CNKSR2 CNK2, KIAA0902, KSR2 ENSG00000149970 Connector enhancer of kinase suppressor of Ras 2 X 21374418-21654695 Predicted intracellular proteins Evidence at protein level HPA001502 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 9 cerebral cortex: 54.1 adrenal gland: 5.8 CNNM1 ACDP1 ENSG00000119946 Cyclin and CBS domain divalent metal cation transport mediator 1 10 99329099-99394330 Predicted membrane proteins Evidence at protein level HPA040408 Approved Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 10.2;testis: 16.7 ovary: 3.0 CNNM4 ACDP4, KIAA1592 ENSG00000158158 Cyclin and CBS domain divalent metal cation transport mediator 4 2 96760902-96811891 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017732 Supported Uncertain Plasma membrane
Actin filaments Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all rectum: 37.5 CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR ENSG00000118432 Cannabinoid receptor 1 (brain) 6 88139864-88166359 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB005603, HPA042256 Approved Approved Plasma membrane
Actin filaments Tissue enriched Tissue enhanced cerebral cortex: 32.2 adipose tissue: 12.1 CNTD1 CNTD, FLJ40137 ENSG00000176563 Cyclin N-terminal domain containing 1 17 42798792-42811587 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA023324 Uncertain Nucleoplasm
Plasma membrane
Focal adhesion sites Mixed Tissue enriched 32 testis: 72.3 stomach: 2.2 COBL KIAA0633 ENSG00000106078 Cordon-bleu WH2 repeat protein 7 51016212-51316818 Predicted intracellular proteins Evidence at protein level HPA019033, HPA019167 Supported Approved Plasma membrane
Cell Junctions Renal cancer:5.21e-12 (favourable) Mixed Mixed cerebral cortex: 61.6 COBLL1 KIAA0977 ENSG00000082438 Cordon-bleu WH2 repeat protein-like 1 2 164653624-164843679 Predicted intracellular proteins Evidence at protein level HPA044933, HPA053344 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:5.27e-13 (favourable) Expressed in all Mixed placenta: 76.5 COL16A1 ENSG00000084636 Collagen, type XVI, alpha 1 1 31652247-31704319 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027235, HPA027237 Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:4.00e-9 (unfavourable), Glioma:7.08e-4 (unfavourable) Expressed in all Tissue enhanced ovary: 181.4 cervix, uterine: 127.5 COL6A2 ENSG00000142173 Collagen, type VI, alpha 2 21 46098097-46132849 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007029, HPA030920, HPA038799 Supported Approved Plasma membrane
Cytosol Renal cancer:8.72e-14 (unfavourable) Expressed in all Expressed in all placenta: 470.8 COLQ EAD ENSG00000206561 Collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase 3 15450133-15521751 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045876 Approved Plasma membrane
Cell Junctions Mixed Tissue enhanced parathyroid gland: 19.2 fallopian tube: 17.4 COMMD10 PTD002 ENSG00000145781 COMM domain containing 10 5 116084991-116412762 Predicted intracellular proteins Evidence at protein level HPA045441, HPA075641 Approved Uncertain Plasma membrane
Cytosol Stomach cancer:2.99e-4 (unfavourable), Thyroid cancer:6.93e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 46.7 COMMD4 FLJ20452 ENSG00000140365 COMM domain containing 4 15 75335891-75343224 Predicted intracellular proteins Evidence at protein level HPA066957 Uncertain Supported Nucleus
Plasma membrane Expressed in all Expressed in all testis: 76.3 COMTD1 FLJ23841 ENSG00000165644 Catechol-O-methyltransferase domain containing 1 10 75233969-75236030 Predicted intracellular proteins Evidence at protein level HPA042165 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.88e-4 (favourable) Expressed in all Mixed duodenum: 14.0 COPRS C17orf79, COPR5, HSA272196, TTP1 ENSG00000172301 Coordinator of PRMT5, differentiation stimulator 17 31851864-31859337 Predicted intracellular proteins Evidence at protein level HPA052552 Approved Supported Nucleus
Plasma membrane
Cytosol Liver cancer:3.69e-4 (unfavourable) Expressed in all Expressed in all testis: 266.6 COQ7 CAT5, CLK-1 ENSG00000167186 Coenzyme Q7 homolog, ubiquinone (yeast) 16 19067599-19080095 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067252, HPA071922 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.23e-12 (favourable) Expressed in all Expressed in all parathyroid gland: 38.6 CORIN ATC2, CRN, Lrp4, PRSC, TMPRSS10 ENSG00000145244 Corin, serine peptidase 4 47593998-47838106 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070941 Approved Nuclear bodies
Plasma membrane
Actin filaments Mixed Tissue enhanced heart muscle: 45.0 skin: 9.5 CORO1B coronin-2 ENSG00000172725 Coronin, actin binding protein, 1B 11 67435510-67443821 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017616, HPA040113, HPA070456 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.65e-4 (favourable) Expressed in all Expressed in all prostate: 77.2 CORO2A IR10, WDR2 ENSG00000106789 Coronin, actin binding protein, 2A 9 98120975-98192640 Predicted intracellular proteins Evidence at protein level HPA041161, HPA041302 Supported Approved Plasma membrane
Cytosol Renal cancer:6.56e-4 (unfavourable) Mixed Mixed small intestine: 39.4 CORO2B ClipinC, KIAA0925 ENSG00000103647 Coronin, actin binding protein, 2B 15 68578969-68727806 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017960 Approved Approved Plasma membrane
Focal adhesion sites Group enriched Tissue enhanced cerebral cortex: 73.5;fallopian tube: 36.2 ovary: 17.8 COX6B2 COXVIB2, CT59, FLJ32865 ENSG00000160471 Cytochrome c oxidase subunit VIb polypeptide 2 (testis) 19 55349306-55354814 Predicted intracellular proteins, Transporters Evidence at protein level HPA035014 Approved Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:9.70e-5 (unfavourable) Mixed Tissue enriched 14 testis: 74.6 rectum: 5.4 CPPED1 CSTP1, FLJ11151 ENSG00000103381 Calcineurin-like phosphoesterase domain containing 1 16 12659799-12804017 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040938, HPA041970 Uncertain Supported Plasma membrane
Cytosol Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable) Expressed in all Expressed in all spleen: 41.6 CREB3L1 OASIS ENSG00000157613 CAMP responsive element binding protein 3-like 1 11 46277661-46321422 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA024069, CAB026151 Supported Uncertain Plasma membrane
Cytosol Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable) Expressed in all Mixed stomach: 66.1 CREB5 CRE-BPA, H_GS165L15.1 ENSG00000146592 CAMP responsive element binding protein 5 7 28299321-28825894 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA050020, HPA061622 Approved Nucleus
Vesicles
Plasma membrane Mixed Mixed gallbladder: 18.6 CRIP2 CRP2, ESP1 ENSG00000182809 Cysteine-rich protein 2 14 105472962-105480170 Predicted intracellular proteins Evidence at protein level HPA042664 Approved Approved Nucleus
Nucleoli
Plasma membrane Expressed in all Tissue enhanced heart muscle: 343.0 fallopian tube: 114.8 CRK ENSG00000167193 V-crk avian sarcoma virus CT10 oncogene homolog 17 1420689-1463162 Predicted intracellular proteins Evidence at protein level CAB010485, HPA068087 Approved Approved Plasma membrane Expressed in all Expressed in all thyroid gland: 60.9 CRLF3 CREME9, CYTOR4 ENSG00000176390 Cytokine receptor-like factor 3 17 30769388-30824776 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007596 Supported Supported Plasma membrane
Cytosol Renal cancer:1.31e-7 (unfavourable) Expressed in all Mixed lymph node: 39.9 CROCC ROLT, rootletin ENSG00000058453 Ciliary rootlet coiled-coil, rootletin 1 16740273-16972979 Predicted intracellular proteins Evidence at protein level HPA021191, HPA021762 Supported Supported Plasma membrane
Centrosome Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable) Expressed in all Mixed skin: 11.7 CRTC1 FLJ14027, KIAA0616, MECT1, TORC1 ENSG00000105662 CREB regulated transcription coactivator 1 19 18683677-18782333 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA022035 Approved Supported Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 23.8 CRYAB CRYA2, HSPB5 ENSG00000109846 Crystallin, alpha B 11 111908565-111923722 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002053, CAB040560, HPA057100 Supported Validated Plasma membrane
Cytosol Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable) Group enriched Tissue enhanced heart muscle: 3940.2 cerebral cortex: 1892.7 CRYL1 GDH, lambda-CRY, MGC149525, MGC149526 ENSG00000165475 Crystallin, lambda 1 13 20403667-20525857 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040403 Supported Approved Nucleus
Nucleoli
Golgi apparatus
Plasma membrane Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable) Expressed in all Expressed in all kidney: 335.8 CSF1 M-CSF, MCSF, MGC31930 ENSG00000184371 Colony stimulating factor 1 (macrophage) 1 109910242-109930992 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA076624 Supported Plasma membrane Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 66.1 CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 150.2 CSPG4 HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2 ENSG00000173546 Chondroitin sulfate proteoglycan 4 15 75674322-75712848 Predicted membrane proteins Evidence at protein level HPA002951, CAB016189, HPA042785, HPA050008 Approved Approved Nucleus
Plasma membrane Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable) Expressed in all Mixed adipose tissue: 31.9 CST6 ENSG00000175315 Cystatin E/M 11 66011841-66013505 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB019316, HPA044963 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 9 skin: 213.3 breast: 24.7 CTNNA1 CAP102 ENSG00000044115 Catenin (cadherin-associated protein), alpha 1, 102kDa 5 138610967-138935034 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021089, HPA046119, HPA063535 Approved Validated Plasma membrane
Cell Junctions Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 215.4 CTNNB1 armadillo, beta-catenin, CTNNB ENSG00000168036 Catenin (cadherin-associated protein), beta 1, 88kDa 3 41194837-41260096 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000108, CAB001950, HPA029159, HPA029160 Supported Validated Plasma membrane Colorectal cancer:7.54e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 285.2 CTNNBIP1 ICAT, MGC15093 ENSG00000178585 Catenin, beta interacting protein 1 1 9848276-9910336 Predicted intracellular proteins Evidence at protein level HPA042617 Approved Plasma membrane
Cell Junctions
Mitochondria Endometrial cancer:5.68e-6 (favourable) Expressed in all Expressed in all skin: 288.8 CTNND1 CTNND, KIAA0384, p120, p120cas, p120ctn ENSG00000198561 Catenin (cadherin-associated protein), delta 1 11 57753243-57819546 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003837, HPA015954, HPA015955 Supported Validated Plasma membrane Pancreatic cancer:3.02e-4 (unfavourable), Renal cancer:3.54e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 192.9 CTSF CATSF, CLN13 ENSG00000174080 Cathepsin F 11 66563463-66568841 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002141, HPA031431, HPA055610 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:8.92e-7 (favourable) Expressed in all Expressed in all ovary: 140.1 CTSV CTSL2, CTSU ENSG00000136943 Cathepsin V 9 97029679-97039643 Enzymes, Predicted secreted proteins Evidence at protein level CAB017112 Uncertain Approved Nucleus
Nucleoli fibrillar center
Plasma membrane
Cytosol Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 68.9;skin: 64.3;testis: 131.2 placenta: 25.7 CTTN EMS1 ENSG00000085733 Cortactin 11 70398404-70436584 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011235, HPA057242 Supported Supported Golgi apparatus
Vesicles
Plasma membrane
Cytosol Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 109.3 CTXN1 FLJ25968 ENSG00000178531 Cortexin 1 19 7924485-7926166 Predicted membrane proteins Evidence at transcript level HPA016669 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 100.8 endometrium: 22.7 CUTA ACHAP, C6orf82 ENSG00000112514 CutA divalent cation tolerance homolog (E. coli) 6 33416442-33418317 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016787, HPA064369 Uncertain Approved Plasma membrane
Focal adhesion sites Lung cancer:8.50e-4 (favourable) Expressed in all Expressed in all thyroid gland: 292.6 CX3CL1 ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1 ENSG00000006210 Chemokine (C-X3-C motif) ligand 1 16 57372458-57385048 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026192, HPA040361 Approved Supported Plasma membrane Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 100.4 lung: 69.4 CXADR CAR ENSG00000154639 Coxsackie virus and adenovirus receptor 21 17512382-17593579 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003342, CAB005103, HPA030411, HPA030412 Supported Validated Plasma membrane
Cell Junctions Head and neck cancer:3.50e-4 (favourable) Expressed in all Mixed skin: 59.6 CYFIP2 PIR121 ENSG00000055163 Cytoplasmic FMR1 interacting protein 2 5 157266079-157395595 Predicted intracellular proteins Evidence at protein level CAB055519, HPA068106, HPA071459 Uncertain Approved Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:3.21e-12 (favourable), Endometrial cancer:2.42e-6 (unfavourable), Pancreatic cancer:1.18e-4 (favourable) Expressed in all Expressed in all kidney: 165.0 CYP20A1 CYP-M ENSG00000119004 Cytochrome P450, family 20, subfamily A, polypeptide 1 2 203238449-203305840 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055872, HPA058461 Uncertain Approved Plasma membrane
Cell Junctions
Actin filaments Expressed in all Mixed thyroid gland: 18.7 CYP24A1 CP24, CYP24, P450-CC24 ENSG00000019186 Cytochrome P450, family 24, subfamily A, polypeptide 1 20 54153449-54173973 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA022261, HPA063771 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Mixed Tissue enhanced endometrium: 24.8;urinary bladder: 52.7 placenta: 13.9 CYTH2 ARNO, CTS18.1, cytohesin-2, PSCD2, PSCD2L, Sec7p-L, Sec7p-like ENSG00000105443 Cytohesin 2 19 48469032-48482314 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB014872 Uncertain Supported Golgi apparatus
Plasma membrane
Cytosol Liver cancer:1.19e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable) Expressed in all Mixed testis: 31.4 DAAM1 KIAA0666 ENSG00000100592 Dishevelled associated activator of morphogenesis 1 14 59188646-59371405 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026605, HPA064789 Uncertain Approved Plasma membrane
Cytosol Renal cancer:3.77e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.1 DAB2 DOC-2 ENSG00000153071 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) 5 39371675-39462300 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009314, HPA028888 Supported Supported Nucleoli
Vesicles
Plasma membrane Liver cancer:7.38e-6 (unfavourable), Stomach cancer:9.67e-4 (unfavourable) Expressed in all Expressed in all placenta: 319.5 DAGLB DAGLBETA, KCCR13L ENSG00000164535 Diacylglycerol lipase, beta 7 6409126-6484190 Predicted membrane proteins Evidence at protein level HPA069377 Supported Plasma membrane Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 20.6 DBN1 D0S117E ENSG00000113758 Drebrin 1 5 177456608-177474401 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051452, HPA056940 Supported Supported Plasma membrane
Actin filaments Renal cancer:8.28e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 83.2 DCAF16 C4orf30, FLJ20280 ENSG00000163257 DDB1 and CUL4 associated factor 16 4 17800655-17810758 Predicted intracellular proteins Evidence at protein level HPA042487 Uncertain Approved Plasma membrane
Cytosol Lung cancer:5.78e-4 (favourable), Liver cancer:6.40e-4 (unfavourable), Urothelial cancer:7.67e-4 (favourable) Expressed in all Expressed in all endometrium: 22.9 DCBLD2 CLCP1, ESDN ENSG00000057019 Discoidin, CUB and LCCL domain containing 2 3 98795941-98901689 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016909 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.32e-5 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Stomach cancer:2.87e-4 (unfavourable) Expressed in all Mixed testis: 44.8 DCHS1 CDH25, CDHR6, FIB1, FLJ11790, KIAA1773, PCDH16 ENSG00000166341 Dachsous cadherin-related 1 11 6621323-6655854 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA017970, HPA050246 Approved Approved Plasma membrane Renal cancer:9.32e-4 (unfavourable) Expressed in all Mixed endometrium: 29.5 DCHS2 CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ ENSG00000197410 Dachsous cadherin-related 2 4 154232037-154491716 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064159 Uncertain Approved Vesicles
Plasma membrane Not detected Mixed endometrium: 4.0 DCTN6 WS-3 ENSG00000104671 Dynactin 6 8 30156297-30183640 Predicted intracellular proteins Evidence at protein level HPA024049, HPA024558 Approved Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:5.42e-4 (favourable), Liver cancer:5.51e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 94.2 DCUN1D2 C13orf17, FLJ10704, FLJ20092 ENSG00000150401 DCN1, defective in cullin neddylation 1, domain containing 2 13 113455819-113490952 Predicted intracellular proteins Evidence at protein level HPA039349 Uncertain Approved Plasma membrane
Cytosol Pancreatic cancer:5.65e-5 (favourable) Expressed in all Expressed in all heart muscle: 65.3 DDAH1 DDAH ENSG00000153904 Dimethylarginine dimethylaminohydrolase 1 1 85318481-85578363 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006308 Supported Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:5.21e-6 (favourable), Colorectal cancer:5.99e-4 (favourable) Expressed in all Mixed kidney: 119.5 DDIAS C11orf82, FLJ25416, FLJ38838, noxin ENSG00000165490 DNA damage-induced apoptosis suppressor 11 82899975-82958277 Predicted secreted proteins Evidence at protein level HPA038540, HPA038541 Approved Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 20.1 skeletal muscle: 6.4 DDIT4L REDD2, Rtp801L ENSG00000145358 DNA-damage-inducible transcript 4-like 4 100185870-100190782 Predicted intracellular proteins Evidence at protein level HPA050903 Uncertain Nucleoplasm
Plasma membrane
Actin filaments Endometrial cancer:5.77e-4 (favourable) Tissue enhanced Tissue enhanced skeletal muscle: 113.3 cervix, uterine: 33.1 DDR2 NTRKR3, TKT, TYRO10 ENSG00000162733 Discoidin domain receptor tyrosine kinase 2 1 162631373-162787400 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA070112 Supported Plasma membrane
Actin filaments Renal cancer:1.73e-7 (unfavourable) Expressed in all Mixed adrenal gland: 94.0 DDX60L FLJ31033 ENSG00000181381 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 4 168356735-168537786 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043211, HPA055501 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable) Expressed in all Mixed bone marrow: 33.7 DENND6B AFI1B, FAM116B, MGC33692 ENSG00000205593 DENN/MADD domain containing 6B 22 50309030-50327060 Predicted intracellular proteins Evidence at protein level HPA018934, HPA021653, HPA029570 Uncertain Uncertain Plasma membrane Endometrial cancer:5.93e-5 (favourable), Colorectal cancer:1.41e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 21.3 cerebral cortex: 12.0 DFFA DFF-45, DFF1, DFF45, ICAD ENSG00000160049 DNA fragmentation factor, 45kDa, alpha polypeptide 1 10456522-10472526 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002679, HPA018859, HPA019938, HPA025230 Supported Supported Plasma membrane
Cytosol Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 28.8 DGKG DAGK3 ENSG00000058866 Diacylglycerol kinase, gamma 90kDa 3 186105668-186362237 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036577 Approved Approved Vesicles
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 21.3 placenta: 11.1 DHDDS DS, FLJ13102, HDS, RP59 ENSG00000117682 Dehydrodolichyl diphosphate synthase subunit 1 26432282-26471294 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA026721, HPA026727 Uncertain Uncertain Plasma membrane Renal cancer:4.08e-7 (favourable) Expressed in all Expressed in all adipose tissue: 54.6 DHPS MIG13 ENSG00000095059 Deoxyhypusine synthase 19 12675717-12681902 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA014461, HPA029413 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 63.4 DHRS7B CGI-93, DKFZp566O084, MGC8916, SDR32C1 ENSG00000109016 Dehydrogenase/reductase (SDR family) member 7B 17 21123364-21193265 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012132, HPA016873 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.4 DIAPH1 DFNA1, hDIA1, LFHL1 ENSG00000131504 Diaphanous-related formin 1 5 141515016-141619055 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004916, HPA076913 Approved Approved Plasma membrane Renal cancer:1.29e-5 (favourable), Pancreatic cancer:7.81e-5 (unfavourable) Expressed in all Expressed in all lymph node: 73.7 DIAPH3 AN, AUNA1, DRF3, FLJ34705, NSDAN ENSG00000139734 Diaphanous-related formin 3 13 59665583-60163987 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032151 Supported Plasma membrane
Microtubules Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Mixed Tissue enriched 7 testis: 33.9 placenta: 5.0 DIS3L DIS3L1, FLJ38088, KIAA1955, MGC4562 ENSG00000166938 DIS3 like exosome 3'-5' exoribonuclease 15 66293217-66333898 Predicted intracellular proteins Evidence at protein level HPA041805 Approved Approved Plasma membrane
Centrosome
Cytosol Expressed in all Expressed in all parathyroid gland: 26.1 DLEU1 BCMS, BCMS1, DLB1, LEU1, LINC00021, NCRNA00021, XTP6 ENSG00000176124 Deleted in lymphocytic leukemia 1 (non-protein coding) 13 50082171-50723236 Predicted intracellular proteins Evidence at protein level CAB017848, HPA039465 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed testis: 9.3 DLG1 dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97 ENSG00000075711 Discs, large homolog 1 (Drosophila) 3 197042560-197299300 Predicted intracellular proteins Evidence at protein level CAB016307, HPA069593 Supported Uncertain Vesicles
Plasma membrane Expressed in all Expressed in all thyroid gland: 94.5 DLG2 chapsyn-110, PPP1R58, PSD-93, PSD93 ENSG00000150672 Discs, large homolog 2 (Drosophila) 11 83455012-85627922 Predicted intracellular proteins Evidence at protein level HPA021307, HPA023896, CAB072341 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 73.0 thyroid gland: 25.9 DMWD D19S593E, DMR-N9, gene59 ENSG00000185800 Dystrophia myotonica, WD repeat containing 19 45782947-45792802 Predicted intracellular proteins Evidence at protein level HPA068172, HPA069843 Approved Approved Plasma membrane
Actin filaments Liver cancer:1.47e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.8 DNAAF1 CILD13, FLJ25330, LRRC50, ODA7 ENSG00000154099 Dynein, axonemal, assembly factor 1 16 84145287-84178767 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041166 Uncertain Approved Nuclear speckles
Plasma membrane
Cytosol Endometrial cancer:2.14e-4 (favourable) Tissue enhanced Group enriched 20 fallopian tube: 34.1;testis: 80.2 lung: 2.8 DNAJA4 PRO1472 ENSG00000140403 DnaJ (Hsp40) homolog, subfamily A, member 4 15 78264086-78282196 Predicted intracellular proteins Evidence at protein level CAB004646, HPA041790 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.08e-7 (favourable), Glioma:8.35e-4 (unfavourable) Expressed in all Expressed in all testis: 95.2 DNAJB4 HLJ1 ENSG00000162616 DnaJ (Hsp40) homolog, subfamily B, member 4 1 77979175-78017964 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004995, HPA028383, HPA028385 Approved Validated Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.28e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 74.0 DNAJC6 KIAA0473, PARK19 ENSG00000116675 DnaJ (Hsp40) homolog, subfamily C, member 6 1 65248219-65415869 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA031182, HPA054917 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.81e-4 (favourable) Tissue enhanced Tissue enriched 10 cerebral cortex: 163.3 adrenal gland: 15.7 DNAJC9 JDD1, SB73 ENSG00000213551 DnaJ (Hsp40) homolog, subfamily C, member 9 10 73183362-73248862 Predicted intracellular proteins Evidence at protein level HPA035215, HPA035216 Supported Supported Nucleoplasm
Plasma membrane Prostate cancer:7.07e-5 (unfavourable), Lung cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 37.4 DOCK4 FLJ34238, KIAA0716 ENSG00000128512 Dedicator of cytokinesis 4 7 111726110-112206411 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA071516 Supported Nucleoli
Golgi apparatus
Plasma membrane
Cytosol Expressed in all Tissue enhanced cerebral cortex: 31.8 lung: 27.6 DPP3 ENSG00000254986 Dipeptidyl-peptidase 3 11 66480013-66509657 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035780, HPA035781 Approved Validated Nuclear speckles
Plasma membrane
Cytosol Stomach cancer:1.34e-4 (favourable) Expressed in all Expressed in all colon: 30.0 DPYSL2 CRMP2, DHPRP2, DRP-2, DRP2 ENSG00000092964 Dihydropyrimidinase-like 2 8 26514275-26658178 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002381, CAB018719 Supported Supported Plasma membrane
Cytosol Urothelial cancer:5.41e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 381.2 DQX1 FLJ23757 ENSG00000144045 DEAQ box RNA-dependent ATPase 1 2 74518131-74526336 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039158 Supported Approved Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 14.8;small intestine: 13.8 colon: 5.6 DROSHA Etohi2, HSA242976, RN3, RNASE3L, RNASEN ENSG00000113360 Drosha, ribonuclease type III 5 31400497-31532196 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031150 Approved Nucleoplasm
Plasma membrane Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.0 DSC3 CDHF3, DSC, DSC1, DSC2, DSC4 ENSG00000134762 Desmocollin 3 18 30990008-31042815 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037328, HPA049265, HPA073937 Supported Validated Plasma membrane
Cell Junctions Urothelial cancer:1.04e-5 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 119.5;skin: 455.7 tonsil: 25.9 DSEL C18orf4, FLJ11477, NCAG1 ENSG00000171451 Dermatan sulfate epimerase-like 18 67506582-67516980 Predicted membrane proteins Evidence at protein level HPA060942 Approved Nucleoplasm
Plasma membrane Tissue enhanced Mixed cerebral cortex: 5.3 DUS1L DUS1, PP3111 ENSG00000169718 Dihydrouridine synthase 1-like 17 82057506-82065887 Predicted intracellular proteins Evidence at protein level HPA023384 Uncertain Approved Plasma membrane Renal cancer:5.89e-5 (unfavourable) Expressed in all Expressed in all skin: 99.1 DUSP15 bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY ENSG00000149599 Dual specificity phosphatase 15 20 31847637-31870747 Enzymes, Predicted intracellular proteins Evidence at protein level HPA076649 Approved Plasma membrane
Cytosol Renal cancer:5.40e-7 (favourable) Mixed Tissue enhanced testis: 77.1 parathyroid gland: 16.0 DXO DOM3Z ENSG00000204348 Decapping exoribonuclease 6 31969810-31972292 Predicted intracellular proteins Evidence at protein level HPA046708 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:4.77e-6 (unfavourable), Pancreatic cancer:5.87e-4 (favourable) Expressed in all Mixed testis: 5.7 DYSF FER1L1, LGMD2B ENSG00000135636 Dysferlin 2 71453722-71686768 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002510, HPA017071, HPA021945 Supported Supported Plasma membrane
Microtubule organizing center Expressed in all Mixed skeletal muscle: 32.8 DYX1C1 CILD25, DNAAF4, EKN1, FLJ37882 ENSG00000256061 Dyslexia susceptibility 1 candidate 1 15 55410525-55508234 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA051048 Uncertain Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 20.4 fallopian tube: 17.5 EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Approved Plasma membrane
Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 178.8 cerebral cortex: 89.1 EEF2 EEF-2, EF2 ENSG00000167658 Eukaryotic translation elongation factor 2 19 3976056-3985469 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007795, HPA040534, HPA057351 Approved Validated Plasma membrane
Cytosol Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all ovary: 1621.9 EEPD1 KIAA1706 ENSG00000122547 Endonuclease/exonuclease/phosphatase family domain containing 1 7 36153149-36301543 Predicted intracellular proteins Evidence at protein level HPA053668 Approved Nuclear speckles
Vesicles
Plasma membrane Expressed in all Expressed in all cerebral cortex: 27.2 EFCAB1 FLJ11767 ENSG00000034239 EF-hand calcium binding domain 1 8 48710789-48735311 Predicted intracellular proteins Evidence at protein level HPA023527, HPA069955 Supported Approved Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced fallopian tube: 148.1;testis: 46.9 ovary: 23.8 EFCAB2 CFAP200, DRC8, MGC12458 ENSG00000203666 EF-hand calcium binding domain 2 1 244969705-245127164 Predicted intracellular proteins Evidence at protein level HPA031206, HPA031207 Approved Approved Plasma membrane
Cytosol Thyroid cancer:6.51e-4 (unfavourable) Mixed Expressed in all fallopian tube: 57.4 EFCAB7 KIAA1799, RP4-534K7.1 ENSG00000203965 EF-hand calcium binding domain 7 1 63523372-63572693 Predicted intracellular proteins Evidence at protein level HPA029611, HPA029612, HPA029613 Supported Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Glioma:4.84e-4 (favourable) Mixed Mixed testis: 24.5 EFHC1 EJM, EJM1, FLJ10466 ENSG00000096093 EF-hand domain (C-terminal) containing 1 6 52420308-52495785 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA035307 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 27.2 thyroid gland: 7.5 EFNB1 CFNS, Elk-L, EPLG2, LERK2 ENSG00000090776 Ephrin-B1 X 68828997-68842147 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB031489, HPA067188 Uncertain Supported Plasma membrane Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable) Expressed in all Mixed adipose tissue: 37.7 EFR3A KIAA0143 ENSG00000132294 EFR3 homolog A 8 131904088-132013642 Predicted intracellular proteins Evidence at protein level HPA022859, HPA023092, HPA023402 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 67.5 EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55256620 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Supported Validated Plasma membrane Urothelial cancer:2.04e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 97.3 skin: 58.9 EHBP1 KIAA0903, NACSIN ENSG00000115504 EH domain binding protein 1 2 62673851-63046487 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035468, HPA035469 Supported Supported Plasma membrane
Cytosol Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all testis: 67.5 EHBP1L1 DKFZp762C186, TANGERIN ENSG00000173442 EH domain binding protein 1-like 1 11 65576038-65592650 Predicted intracellular proteins Evidence at protein level HPA039479 Approved Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:1.45e-4 (unfavourable) Expressed in all Mixed skeletal muscle: 88.6 EHD1 FLJ42622, FLJ44618, H-PAST, HPAST1, PAST1 ENSG00000110047 EH-domain containing 1 11 64851642-64888296 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049890, HPA049986, HPA066751, HPA067747 Approved Supported Plasma membrane Liver cancer:2.81e-5 (unfavourable) Expressed in all Expressed in all testis: 153.1 EHD2 PAST2 ENSG00000024422 EH-domain containing 2 19 47713343-47743134 Predicted intracellular proteins Evidence at protein level HPA047394, HPA049890, HPA049986, HPA066751 Approved Supported Plasma membrane Renal cancer:3.98e-4 (unfavourable), Ovarian cancer:8.75e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 208.4 smooth muscle: 110.4 EHD3 PAST3 ENSG00000013016 EH-domain containing 3 2 31234337-31269447 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049890, HPA049986, HPA066751 Approved Approved Plasma membrane Renal cancer:1.02e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 83.0 esophagus: 33.5 EHD4 PAST4 ENSG00000103966 EH-domain containing 4 15 41895939-41972578 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049890, HPA049986, HPA052729, HPA066751 Approved Approved Plasma membrane Expressed in all Expressed in all gallbladder: 37.2 EIF2B2 EIF-2Bbeta, EIF2B ENSG00000119718 Eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 14 75002911-75012366 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA005841, CAB037105, HPA048028 Supported Approved Nucleoplasm
Plasma membrane
Focal adhesion sites Liver cancer:2.26e-6 (unfavourable), Renal cancer:2.95e-4 (favourable) Expressed in all Mixed thyroid gland: 19.4 EIF5 ENSG00000100664 Eukaryotic translation initiation factor 5 14 103333544-103345025 Predicted intracellular proteins Evidence at protein level HPA000867, CAB004226 Supported Supported Plasma membrane
Cytosol Renal cancer:5.67e-7 (favourable) Expressed in all Expressed in all testis: 173.0 EIF5B DKFZp434I036, FLJ10524, IF2, KIAA0741 ENSG00000158417 Eukaryotic translation initiation factor 5B 2 99337353-99401326 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034648, HPA040095 Approved Approved Plasma membrane
Cytosol Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable) Expressed in all Expressed in all testis: 67.2 ELMO3 CED-12, CED12, ELMO-3, FLJ13824 ENSG00000102890 Engulfment and cell motility 3 16 67199111-67204029 Predicted intracellular proteins Evidence at protein level HPA021484 Approved Approved Plasma membrane
Cell Junctions Renal cancer:2.77e-5 (favourable) Expressed in all Mixed skin: 39.4 ELN SVAS, WBS, WS ENSG00000049540 Elastin 7 74027789-74069907 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010750, HPA018111, HPA056941 Supported Approved Plasma membrane Thyroid cancer:6.29e-4 (unfavourable) Expressed in all Mixed smooth muscle: 124.5 ENAH FLJ10773, MENA, NDPP1 ENSG00000154380 Enabled homolog (Drosophila) 1 225486835-225653142 Predicted intracellular proteins Evidence at protein level HPA028448, HPA028696 Supported Validated Plasma membrane
Focal adhesion sites
Cytosol Expressed in all Mixed smooth muscle: 80.4 ENC1 ENC-1, KLHL37, NRPB, PIG10, TP53I10 ENSG00000171617 Ectodermal-neural cortex 1 (with BTB domain) 5 74627406-74641424 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA078061 Uncertain Plasma membrane
Cytoplasmic bodies Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable) Expressed in all Tissue enriched 15 cerebral cortex: 462.7 gallbladder: 30.9 ENKD1 C16orf48, DKFZP434A1319 ENSG00000124074 Enkurin domain containing 1 16 67662945-67667265 Predicted intracellular proteins Evidence at protein level HPA041163, HPA041478 Approved Supported Plasma membrane
Centrosome
Cytosol Endometrial cancer:1.68e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 32.0 ENO1 ENO1L1, MBP-1, MPB1, PPH ENSG00000074800 Enolase 1, (alpha) 1 8861002-8879249 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018614, HPA068284, CAB069394 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable) Expressed in all Expressed in all appendix: 789.1 ENO2 ENSG00000111674 Enolase 2 (gamma, neuronal) 12 6913745-6923698 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000063, HPA068284, CAB073539 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 432.2 parathyroid gland: 64.5 ENO3 ENSG00000108515 Enolase 3 (beta, muscle) 17 4948092-4957131 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000793, HPA068284 Approved Validated Plasma membrane
Cytosol Colorectal cancer:7.33e-4 (unfavourable) Expressed in all Tissue enriched 19 skeletal muscle: 5975.8 heart muscle: 311.9 ENOX1 cCNOX, CNOX, FLJ10094, PIG38 ENSG00000120658 Ecto-NOX disulfide-thiol exchanger 1 13 43213518-43786908 Predicted intracellular proteins Evidence at protein level HPA038355 Approved Supported Plasma membrane Mixed Tissue enhanced testis: 18.1 cerebral cortex: 11.5 EPB41 4.1R, EL1 ENSG00000159023 Erythrocyte membrane protein band 4.1 1 28887091-29120046 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA028076, HPA028412, HPA028414 Supported Supported Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable) Expressed in all Expressed in all lymph node: 51.3 EPB41L1 4.1N, KIAA0338 ENSG00000088367 Erythrocyte membrane protein band 4.1-like 1 20 36091504-36232799 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA054104, HPA056817 Approved Supported Plasma membrane Renal cancer:4.39e-10 (favourable), Endometrial cancer:6.46e-5 (unfavourable), Pancreatic cancer:9.30e-4 (unfavourable) Expressed in all Mixed adrenal gland: 163.2 EPB41L2 4.1-G ENSG00000079819 Erythrocyte membrane protein band 4.1-like 2 6 130839347-131063322 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005730, HPA006642 Supported Validated Nucleus
Plasma membrane
Cell Junctions Liver cancer:2.41e-5 (unfavourable), Ovarian cancer:2.16e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 139.6 EPB41L3 4.1B, DAL1, KIAA0987 ENSG00000082397 Erythrocyte membrane protein band 4.1-like 3 18 5392381-5630700 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028605 Approved Validated Plasma membrane Mixed Expressed in all testis: 121.4 EPB41L4A NBL4 ENSG00000129595 Erythrocyte membrane protein band 4.1 like 4A 5 112142441-112419316 Predicted intracellular proteins Evidence at protein level HPA036580 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:3.65e-5 (favourable) Mixed Expressed in all parathyroid gland: 26.9 EPB41L4B EHM2 ENSG00000095203 Erythrocyte membrane protein band 4.1 like 4B 9 109171975-109320964 Predicted intracellular proteins Evidence at protein level HPA042862 Approved Approved Plasma membrane
Cytosol Breast cancer:1.02e-4 (unfavourable) Mixed Mixed thyroid gland: 74.5 EPB41L5 BE37, FLJ12957, KIAA1548, YMO1, YRT ENSG00000115109 Erythrocyte membrane protein band 4.1 like 5 2 120013005-120179119 Predicted intracellular proteins Evidence at protein level HPA037563, HPA037564 Uncertain Supported Plasma membrane Renal cancer:2.28e-6 (favourable) Expressed in all Mixed testis: 56.3 EPCAM 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1 ENSG00000119888 Epithelial cell adhesion molecule 2 47345158-47387601 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003809, HPA026761, CAB030012, CAB055098, HPA067463 Supported Supported Plasma membrane Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable) Mixed Tissue enhanced rectum: 691.1;small intestine: 728.8 colon: 672.2 EPHB1 EPHT2, Hek6 ENSG00000154928 EPH receptor B1 3 134597801-135260467 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067740 Approved Approved Endoplasmic reticulum
Plasma membrane
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 23.7;testis: 22.9 thyroid gland: 12.0 EPHB2 DRT, EPHT3, ERK, Hek5, Tyro5 ENSG00000133216 EPH receptor B2 1 22710839-22921500 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013647, HPA071200 Approved Supported Nucleus
Plasma membrane Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable) Tissue enhanced Mixed rectum: 27.8 EPS8L2 FLJ21935, FLJ22171, MGC3088 ENSG00000177106 EPS8-like 2 11 694438-727727 Predicted intracellular proteins Evidence at protein level HPA041143 Approved Supported Plasma membrane
Cytosol Glioma:1.80e-4 (unfavourable) Expressed in all Mixed small intestine: 112.7 ERAP1 A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP ENSG00000164307 Endoplasmic reticulum aminopeptidase 1 5 96760810-96808100 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025095, HPA042317 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all placenta: 68.5 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Approved Supported Plasma membrane
Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 122.9 ERBB2IP ERBIN, LAP2 ENSG00000112851 Erbb2 interacting protein 5 65926475-66082549 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA048606, HPA059863 Approved Supported Nuclear speckles
Plasma membrane Expressed in all Expressed in all testis: 49.9 ERBB3 HER3, LCCS2 ENSG00000065361 Erb-b2 receptor tyrosine kinase 3 12 56079857-56103505 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025331, HPA045396 Uncertain Approved Plasma membrane
Actin filaments Expressed in all Mixed small intestine: 88.5 ERC1 CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2 ENSG00000082805 ELKS/RAB6-interacting/CAST family member 1 12 990509-1495933 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019513, HPA019523, HPA024130 Approved Supported Vesicles
Plasma membrane
Cytosol Urothelial cancer:7.01e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 17.1 ETNK1 EKI, EKI1 ENSG00000139163 Ethanolamine kinase 1 12 22625075-22690665 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010712, HPA029407 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable) Expressed in all Expressed in all stomach: 45.8 ETS2 ENSG00000157557 V-ets avian erythroblastosis virus E26 oncogene homolog 2 21 38805307-38824955 Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level HPA003176 Supported Nucleoplasm
Plasma membrane Expressed in all Expressed in all spleen: 256.3 EVA1A FAM176A, FLJ13391, TMEM166 ENSG00000115363 Eva-1 homolog A (C. elegans) 2 75469302-75569722 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008055 Approved Supported Vesicles
Plasma membrane Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable) Mixed Tissue enhanced liver: 98.5 lung: 31.1 EXOC1 BM-102, FLJ10893, SEC3, SEC3L1, Sec3p ENSG00000090989 Exocyst complex component 1 4 55853616-55905034 Predicted intracellular proteins Evidence at protein level HPA037706, HPA044873 Uncertain Approved Plasma membrane
Microtubules
Cytosol Urothelial cancer:5.50e-5 (favourable), Liver cancer:2.63e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.4 EXOC3L1 EXOC3L, FLJ35539, FLJ35587 ENSG00000179044 Exocyst complex component 3-like 1 16 67184366-67190204 Predicted intracellular proteins Evidence at transcript level HPA029574 Uncertain Approved Vesicles
Plasma membrane Expressed in all Tissue enhanced spleen: 30.6 placenta: 8.4 EXOC7 EXO70, Exo70p, KIAA1067, YJL085W ENSG00000182473 Exocyst complex component 7 17 76081017-76121576 Predicted intracellular proteins Evidence at protein level HPA022840, HPA022842 Supported Approved Vesicles
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 100.5 EZR VIL2 ENSG00000092820 Ezrin 6 158765741-158819412 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004035, HPA021616, CAB047324 Supported Validated Plasma membrane Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 528.6 F2RL1 GPR11, PAR2 ENSG00000164251 Coagulation factor II (thrombin) receptor-like 1 5 76818933-76835315 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB012989, HPA014091 Approved Approved Plasma membrane Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable) Expressed in all Mixed colon: 59.9 FABP2 I-FABP ENSG00000145384 Fatty acid binding protein 2, intestinal 4 119317250-119322390 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034607, CAB047325, CAB047326 Supported Approved Plasma membrane
Actin filaments
Cytosol Group enriched Group enriched 12 duodenum: 268.5;small intestine: 565.3 rectum: 34.6 FABP5 E-FABP, KFABP, PA-FABP ENSG00000164687 Fatty acid binding protein 5 (psoriasis-associated) 8 81280363-81284777 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB017831, CAB040577, HPA051895 Supported Supported Plasma membrane
Cytosol Renal cancer:4.69e-10 (unfavourable) Expressed in all Expressed in all esophagus: 1671.2 FAIM FAIM1, FLJ10582 ENSG00000158234 Fas apoptotic inhibitory molecule 3 138608606-138633376 Predicted intracellular proteins Evidence at protein level HPA042440, HPA052209 Approved Approved Plasma membrane
Cytosol Liver cancer:3.96e-5 (unfavourable), Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all fallopian tube: 60.5 FAM101B MGC45871 ENSG00000183688 Family with sequence similarity 101, member B 17 439978-445939 Predicted intracellular proteins Evidence at protein level HPA030879 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Renal cancer:1.54e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 98.8 placenta: 30.3 FAM126A DRCTNNB1A , HCC, HYCC1, hyccin ENSG00000122591 Family with sequence similarity 126, member A 7 22889371-23014130 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042873 Approved Supported Plasma membrane
Cytosol Renal cancer:6.04e-7 (unfavourable), Stomach cancer:5.99e-4 (unfavourable), Urothelial cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all testis: 33.2 FAM129A C1orf24, GIG39, NIBAN ENSG00000135842 Family with sequence similarity 129, member A 1 184790724-184974550 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028172, HPA028231, HPA028657 Approved Supported Plasma membrane
Cytosol Urothelial cancer:4.52e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 105.0 FAM129B bA356B19.6, C9orf88, DKFZP434H0820, FLJ13518, FLJ22151, FLJ22298, MINERVA ENSG00000136830 Family with sequence similarity 129, member B 9 127505339-127578989 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021284, HPA021417, HPA023261, HPA024312 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all esophagus: 363.7 FAM163B C9orf166 ENSG00000196990 Family with sequence similarity 163, member B 9 133578415-133586197 Predicted membrane proteins Evidence at transcript level HPA067336 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Tissue enriched Tissue enriched 6 cerebral cortex: 103.9 adrenal gland: 16.5 FAM171A1 C10orf38, FLJ12884 ENSG00000148468 Family with sequence similarity 171, member A1 10 15211643-15371062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051345 Approved Approved Nucleoplasm
Plasma membrane Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable) Expressed in all Mixed cerebral cortex: 73.4 FAM193A C4orf8, RES4-22 ENSG00000125386 Family with sequence similarity 193, member A 4 2625261-2732565 Predicted intracellular proteins Evidence at protein level HPA043116 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:4.80e-4 (favourable) Expressed in all Expressed in all testis: 41.5 FAM210B C20orf108, dJ1167H4.1, DKFZP434A1114 ENSG00000124098 Family with sequence similarity 210, member B 20 56358915-56368663 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042652 Approved Approved Plasma membrane
Cytosol Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable) Expressed in all Expressed in all ovary: 131.1 FAM213B C1orf93, MGC26818 ENSG00000157870 Family with sequence similarity 213, member B 1 2586491-2591469 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006403 Approved Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable) Expressed in all Mixed small intestine: 14.9 FAM222A C12orf34, FLJ14721 ENSG00000139438 Family with sequence similarity 222, member A 12 109714228-109770507 Predicted intracellular proteins Evidence at protein level HPA040181 Uncertain Approved Nucleoplasm
Plasma membrane
Focal adhesion sites
Mitochondria Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 20.1;testis: 16.6 adrenal gland: 9.9 FAM45A ENSG00000119979 Family with sequence similarity 45, member A 10 119104086-119137984 Predicted intracellular proteins Evidence at protein level HPA041159 Approved Plasma membrane
Centrosome
Cytosol Expressed in all Expressed in all thyroid gland: 31.7 FAM47E FLJ42946, LOC100129583 ENSG00000189157 Family with sequence similarity 47, member E 4 76214040-76283780 Predicted intracellular proteins Evidence at transcript level HPA053331 Uncertain Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced fallopian tube: 26.5 thyroid gland: 13.8 FAM47E-STBD1 ENSG00000272414 FAM47E-STBD1 readthrough 4 76251721-76311129 Predicted intracellular proteins Evidence at transcript level HPA053331 Approved Uncertain Plasma membrane
Cytosol Not detected Expressed in all adipose tissue: 33.0 FAM72A MGC57827, RP11-312O7.1 ENSG00000196550 Family with sequence similarity 72, member A 1 206186179-206204414 Predicted intracellular proteins Evidence at protein level HPA043271, HPA067321 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Mixed lymph node: 12.8 FAM72B RP11-439A17.6 ENSG00000188610 Family with sequence similarity 72, member B 1 121167646-121185539 Predicted intracellular proteins Evidence at transcript level HPA043271, HPA067321 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Tissue enhanced lymph node: 9.8 tonsil: 6.4 FAM72C RP5-998N21.9 ENSG00000263513 Family with sequence similarity 72, member C 1 143955364-143971965 Predicted intracellular proteins Evidence at transcript level HPA043271, HPA067321 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Tissue enhanced lymph node: 5.6;tonsil: 4.4 testis: 3.0 FAM72D ENSG00000215784 Family with sequence similarity 72, member D 1 145096000-145112696 Predicted intracellular proteins Evidence at transcript level HPA043271, HPA067321 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Tissue enhanced lymph node: 5.7 tonsil: 4.2 FANCG FAG, XRCC9 ENSG00000221829 Fanconi anemia, complementation group G 9 35073835-35080016 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008105, HPA045335 Approved Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:2.38e-7 (unfavourable), Liver cancer:2.02e-4 (unfavourable) Expressed in all Mixed fallopian tube: 8.5 FARS2 dJ236A3.1, FARS1 ENSG00000145982 Phenylalanyl-tRNA synthetase 2, mitochondrial 6 5261044-5771580 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA018148, HPA028836 Approved Approved Plasma membrane Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable) Expressed in all Expressed in all thyroid gland: 24.3 FAS APO-1, APT1, CD95, FAS1, TNFRSF6 ENSG00000026103 Fas cell surface death receptor 10 88990531-89015785 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027444 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed lung: 39.5 FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Supported Validated Plasma membrane
Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 283.6 FBLN2 ENSG00000163520 Fibulin 2 3 13549131-13638422 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001934, CAB018622 Supported Supported Plasma membrane Liver cancer:3.17e-4 (favourable), Endometrial cancer:9.48e-4 (unfavourable) Expressed in all Mixed adipose tissue: 141.5 FBLN5 ARMD3, DANCE, EVEC, UP50 ENSG00000140092 Fibulin 5 14 91869412-91947987 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA000848, HPA000868, CAB025843 Supported Approved Plasma membrane
Cytosol Liver cancer:6.75e-4 (favourable) Expressed in all Expressed in all gallbladder: 221.9 FBLN7 FLJ37440, TM14 ENSG00000144152 Fibulin 7 2 112138385-112188216 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA034992 Uncertain Approved Plasma membrane
Cell Junctions Mixed Mixed parathyroid gland: 18.3 FBP2 ENSG00000130957 Fructose-1,6-bisphosphatase 2 9 94558720-94593793 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012513, HPA055286 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 8 skeletal muscle: 266.1 stomach: 32.9 FBRSL1 KIAA1545 ENSG00000112787 Fibrosin-like 1 12 132489551-132585188 Predicted intracellular proteins Evidence at protein level HPA049880 Approved Approved Nucleus
Plasma membrane
Cytosol Renal cancer:1.17e-4 (favourable), Urothelial cancer:7.21e-4 (favourable), Prostate cancer:9.82e-4 (unfavourable) Expressed in all Expressed in all spleen: 11.5 FBXL2 FBL2, FBL3 ENSG00000153558 F-box and leucine-rich repeat protein 2 3 33277025-33403662 Predicted intracellular proteins Evidence at protein level HPA061783 Approved Nucleus
Nucleoli
Plasma membrane Renal cancer:3.35e-4 (favourable) Mixed Mixed cerebral cortex: 5.8 FBXO16 FBX16 ENSG00000214050 F-box protein 16 8 28348287-28490318 Predicted intracellular proteins Evidence at transcript level HPA053955, HPA058676 Uncertain Approved Nucleoplasm
Vesicles
Plasma membrane
Cytosol Ovarian cancer:6.70e-5 (favourable) Mixed Tissue enhanced epididymis: 26.9 thyroid gland: 12.6 FBXO38 Fbx38, FLJ13962, MOKA, SP329 ENSG00000145868 F-box protein 38 5 148383935-148442836 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA034821, HPA041444 Approved Supported Nucleoplasm
Plasma membrane
Cytokinetic bridge
Cytosol Expressed in all Expressed in all parathyroid gland: 30.2 FBXO41 Fbx41, KIAA1940 ENSG00000163013 F-box protein 41 2 73254682-73284431 Predicted intracellular proteins Evidence at protein level HPA055246, HPA058386 Approved Nucleus
Plasma membrane
Cytosol Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:5.76e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 38.4 parathyroid gland: 11.0 FCAR CD89 ENSG00000186431 Fc fragment of IgA receptor 19 54874248-54890472 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014050 Approved Supported Plasma membrane Not detected Tissue enriched 15 bone marrow: 20.8 appendix: 1.4 FCGBP FC(GAMMA)BP ENSG00000275395 Fc fragment of IgG binding protein 19 39863323-39934626 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003517, HPA003564 Supported Approved Golgi apparatus
Plasma membrane
Cytokinetic bridge Ovarian cancer:9.70e-6 (unfavourable), Head and neck cancer:1.28e-5 (favourable), Liver cancer:4.74e-5 (unfavourable), Thyroid cancer:4.27e-4 (unfavourable) Expressed in all Tissue enhanced colon: 194.4 thyroid gland: 109.6 FCHSD2 KIAA0769, SH3MD3 ENSG00000137478 FCH and double SH3 domains 2 11 72836745-73142261 Predicted intracellular proteins Evidence at protein level HPA038545, HPA038546 Uncertain Approved Nuclear speckles
Plasma membrane
Actin filaments
Focal adhesion sites Colorectal cancer:1.71e-4 (favourable) Expressed in all Expressed in all spleen: 65.0 FEN1 FEN-1, MF1, RAD2 ENSG00000168496 Flap structure-specific endonuclease 1 11 61792637-61797244 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002262, HPA006581, HPA006748 Supported Approved Nucleus
Nucleoli
Plasma membrane
Mitochondria Liver cancer:3.39e-6 (unfavourable), Renal cancer:5.73e-6 (unfavourable), Ovarian cancer:7.85e-4 (favourable), Stomach cancer:9.46e-4 (favourable) Expressed in all Mixed lymph node: 35.2 FFAR4 GPR120, GPR129, O3FAR1, PGR4 ENSG00000186188 Free fatty acid receptor 4 10 93566665-93604480 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA042563 Uncertain Uncertain Plasma membrane Tissue enhanced Tissue enhanced colon: 8.6;rectum: 12.9 lung: 5.5 FGD1 FGDY, ZFYVE3 ENSG00000102302 FYVE, RhoGEF and PH domain containing 1 X 54445454-54496166 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000911 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:2.10e-4 (unfavourable) Expressed in all Mixed endometrium: 10.1 FGR c-fgr, p55c-fgr, SRC2 ENSG00000000938 FGR proto-oncogene, Src family tyrosine kinase 1 27612064-27635277 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002024 Supported Approved Plasma membrane
Aggresome Expressed in all Tissue enhanced appendix: 87.8;bone marrow: 137.2;spleen: 92.1 lung: 56.3 FHIT AP3Aase, FRA3B ENSG00000189283 Fragile histidine triad 3 59749310-61251459 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB002684, HPA018840, HPA018909 Supported Approved Nucleoli fibrillar center
Plasma membrane Renal cancer:1.36e-4 (favourable) Mixed Expressed in all kidney: 26.6 FHL1 bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA ENSG00000022267 Four and a half LIM domains 1 X 136146702-136211359 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001040, HPA001391, CAB020817 Supported Supported Plasma membrane
Cytosol Urothelial cancer:2.11e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 3805.6 FIGN ENSG00000182263 Fidgetin 2 163593396-163736012 Predicted intracellular proteins Evidence at protein level HPA034987, HPA057919 Approved Approved Nucleoplasm
Vesicles
Plasma membrane
Cell Junctions
Cytosol Mixed Mixed ovary: 5.1 FILIP1 FILIP, KIAA1275 ENSG00000118407 Filamin A interacting protein 1 6 75291859-75493738 Predicted intracellular proteins Evidence at protein level HPA053564 Approved Uncertain Plasma membrane
Actin filaments Mixed Tissue enhanced heart muscle: 34.9 smooth muscle: 19.4 FILIP1L DOC-1, GIP130 ENSG00000168386 Filamin A interacting protein 1-like 3 99830141-100114513 Predicted intracellular proteins Evidence at protein level HPA043133 Approved Approved Plasma membrane Renal cancer:9.40e-4 (unfavourable) Expressed in all Mixed smooth muscle: 214.9 FKBP2 FKBP-13, PPIase ENSG00000173486 FK506 binding protein 2, 13kDa 11 64241003-64244132 Enzymes, Predicted secreted proteins Evidence at protein level CAB025561, HPA049405 Supported Approved Plasma membrane Expressed in all Expressed in all epididymis: 392.9 FLAD1 FAD1, PP591 ENSG00000160688 Flavin adenine dinucleotide synthetase 1 1 154983338-154993111 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028476, HPA028486, HPA028563 Approved Supported Plasma membrane
Cytosol Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable) Expressed in all Expressed in all skin: 28.6 FLCN BHD, MGC17998, MGC23445 ENSG00000154803 Folliculin 17 17212212-17237188 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015158, HPA028760 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:4.49e-4 (favourable) Expressed in all Expressed in all endometrium: 30.7 FLNA ABP-280, FLN, FLN1, OPD1, OPD2 ENSG00000196924 Filamin A, alpha X 154348524-154374638 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000356, HPA000368, HPA001016, HPA001115, HPA002925 Supported Approved Validated Plasma membrane
Actin filaments
Cytosol Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1037.9 FLNB ABP-278, FH1, FLN1L, LRS1, TABP, TAP ENSG00000136068 Filamin B, beta 3 58008400-58172251 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004747, HPA004886, CAB019322 Supported Supported Golgi apparatus
Plasma membrane
Actin filaments
Cytosol Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable) Expressed in all Expressed in all prostate: 161.4 FLNC ABP-280, ABPL, FLN2 ENSG00000128591 Filamin C, gamma 7 128830377-128859274 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006135 Supported Supported Plasma membrane
Cytosol Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable) Expressed in all Tissue enhanced skeletal muscle: 384.8 smooth muscle: 158.7 FLOT1 ENSG00000137312 Flotillin 1 6 30727709-30742733 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001393, CAB007766 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:1.49e-4 (unfavourable), Ovarian cancer:3.06e-4 (favourable), Colorectal cancer:5.78e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 18.8 FLRT3 ENSG00000125848 Fibronectin leucine rich transmembrane protein 3 20 14322988-14337616 Disease related genes, Predicted membrane proteins Evidence at protein level CAB026166, HPA056033 Supported Approved Plasma membrane
Microtubules
Cytosol Renal cancer:1.49e-7 (favourable), Lung cancer:9.85e-5 (unfavourable), Pancreatic cancer:1.54e-4 (unfavourable) Expressed in all Mixed lung: 32.3 FLT1 FLT, VEGFR1 ENSG00000102755 Fms-related tyrosine kinase 1 13 28300344-28495128 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Supported Supported Plasma membrane
Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 617.5 thyroid gland: 81.7 FLT4 PCL, VEGFR3 ENSG00000037280 Fms-related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099 Supported Nuclear speckles
Plasma membrane
Cell Junctions Expressed in all Mixed spleen: 18.6 FMN2 ENSG00000155816 Formin 2 1 240014348-240475189 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050649 Approved Plasma membrane
Actin filaments Group enriched Group enriched 6 cerebral cortex: 54.0;parathyroid gland: 32.9 adrenal gland: 7.0 FMNL2 FHOD2, KIAA1902 ENSG00000157827 Formin-like 2 2 152335237-152649834 Predicted intracellular proteins Evidence at protein level HPA005464 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Liver cancer:9.04e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 138.2 placenta: 82.3 FMNL3 DKFZp762B245, MGC45819, WBP3 ENSG00000161791 Formin-like 3 12 49636499-49708165 Predicted intracellular proteins Evidence at protein level HPA002552, HPA023201 Uncertain Supported Golgi apparatus
Vesicles
Plasma membrane
Cytosol Renal cancer:3.58e-5 (unfavourable) Expressed in all Mixed lymph node: 28.4 FOXN3 C14orf116, CHES1 ENSG00000053254 Forkhead box N3 14 89124871-89619149 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059209 Approved Approved Nucleus
Plasma membrane
Cytokinetic bridge Renal cancer:9.58e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 109.4 FRMD3 EPB41L4O, MGC20553 ENSG00000172159 FERM domain containing 3 9 83242990-83538546 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017285 Approved Approved Nucleoplasm
Golgi apparatus
Plasma membrane Thyroid cancer:1.79e-4 (favourable), Renal cancer:7.24e-4 (favourable) Tissue enhanced Tissue enhanced heart muscle: 51.7 skeletal muscle: 28.6 FSCN1 FLJ38511, p55, SNL ENSG00000075618 Fascin actin-bundling protein 1 7 5592823-5606655 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000121, HPA005723, CAB035991, HPA050654 Supported Supported Plasma membrane
Cytosol Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 85.7 spleen: 55.9 FSD1L CCDC10, CSDUFD1, FSD1CL, FSD1NL ENSG00000106701 Fibronectin type III and SPRY domain containing 1-like 9 105447796-105552433 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035138 Approved Approved Plasma membrane
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.8 testis: 13.4 FTCD ENSG00000160282 Formimidoyltransferase cyclodeaminase 21 46136262-46155567 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020073, HPA030928, HPA030929, HPA036114 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable) Tissue enriched Group enriched 18 kidney: 100.1;liver: 184.7 testis: 7.7 FUT2 SE, Se2, SEC2, sej ENSG00000176920 Fucosyltransferase 2 (secretor status included) 19 48695971-48705950 Blood group antigen proteins, Enzymes, Predicted membrane proteins Evidence at transcript level HPA014402 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:5.83e-4 (favourable) Mixed Tissue enhanced duodenum: 52.9 stomach: 32.5 FXYD3 MAT-8, PLML ENSG00000089356 FXYD domain containing ion transport regulator 3 19 35115879-35124324 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010856 Supported Supported Plasma membrane Renal cancer:1.15e-6 (unfavourable) Expressed in all Tissue enhanced colon: 1480.8;rectum: 1982.1 prostate: 686.5 FYB FYB-120/130, SLAP-130 ENSG00000082074 FYN binding protein 5 39105236-39274528 Predicted intracellular proteins Evidence at protein level CAB025336, HPA026796 Supported Approved Plasma membrane Renal cancer:2.24e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 131.1;lymph node: 111.3;spleen: 116.6 tonsil: 67.0 FYN MGC45350, SLK, SYN ENSG00000010810 FYN proto-oncogene, Src family tyrosine kinase 6 111660332-111873452 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005034, CAB018387, HPA023887, HPA063770 Approved Validated Plasma membrane
Cytosol Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 166.6 FZD1 DKFZp564G072 ENSG00000157240 Frizzled class receptor 1 7 91264364-91271326 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013008 Approved Supported Plasma membrane Renal cancer:8.87e-7 (favourable) Expressed in all Mixed thyroid gland: 32.3 FZD4 CD344, EVR1 ENSG00000174804 Frizzled class receptor 4 11 86945679-86955391 CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA042328, HPA074833 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.60e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 127.0 seminal vesicle: 42.1 FZD6 Hfz6 ENSG00000164930 Frizzled class receptor 6 8 103298433-103332866 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017991 Approved Approved Plasma membrane Pancreatic cancer:1.20e-6 (unfavourable) Expressed in all Mixed parathyroid gland: 45.3 GAB2 KIAA0571 ENSG00000033327 GRB2-associated binding protein 2 11 78215297-78418348 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA000271, HPA001368, CAB022159 Approved Supported Plasma membrane Renal cancer:9.32e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 35.6 GADL1 ENSG00000144644 Glutamate decarboxylase-like 1 3 30726200-30894765 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039160, HPA040229 Uncertain Approved Plasma membrane
Cytosol Not detected Tissue enhanced skeletal muscle: 9.0 thyroid gland: 2.5 GAGE1 CT4.1 ENSG00000205777 G antigen 1 X 49589496-49608536 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 245 testis: 182.5 stomach: 0.7 GAGE10 ENSG00000215274 G antigen 10 X 49303669-49319844 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enhanced ovary: 1.1;testis: 1.5 fallopian tube: 0.7 GAGE12C ENSG00000237671 G antigen 12C X 49532211-49539538 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 472 testis: 47.1 all non-specific tissues: 0.0 GAGE12D ENSG00000227488 G antigen 12D X 49541767-49549094 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 472 testis: 47.1 all non-specific tissues: 0.0 GAGE12E ENSG00000216649 G antigen 12E X 49551333-49558649 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 25 testis: 4.3 stomach: 0.1 GAGE12G ENSG00000215269 G antigen 12G X 49570434-49577754 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 12 testis: 124.2 stomach: 10.2 GAGE12H ENSG00000224902 G antigen 12H X 49579983-49587301 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Approved Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 404 testis: 40.3 all non-specific tissues: 0.0 GAGE12J GAGE11 ENSG00000224659 G antigen 12J X 49322057-49329384 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 47 testis: 42.7 epididymis: 0.9 GAGE13 GAGE12A ENSG00000274274 G antigen 13 X 49331616-49338952 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Tissue enriched 438 testis: 43.8 all non-specific tissues: 0.0 GAGE2A CT4.2, GAGE2 ENSG00000189064 G antigen 2A X 49589529-49596827 Predicted intracellular proteins Evidence at protein level HPA043232 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Mixed Tissue enriched 575 testis: 181.3 cerebral cortex: 0.3 GAGE2E GAGE8 ENSG00000275113 G antigen 2E X 49341192-49345922 Predicted intracellular proteins Evidence at transcript level HPA043232 Approved Uncertain Golgi apparatus
Plasma membrane
Cytosol Not detected Group enriched 61 stomach: 15.3;testis: 9.8 small intestine: 0.2 GALNT10 GalNAc-T10 ENSG00000164574 Polypeptide N-acetylgalactosaminyltransferase 10 5 154190730-154420984 Enzymes, Predicted secreted proteins Evidence at protein level HPA007525 Approved Approved Nucleoplasm
Golgi apparatus
Plasma membrane Endometrial cancer:3.33e-6 (favourable), Ovarian cancer:5.69e-4 (unfavourable) Expressed in all Expressed in all ovary: 81.4 GALNT15 GALNT7, GALNTL2, pp-GalNAc-T15 ENSG00000131386 Polypeptide N-acetylgalactosaminyltransferase 15 3 16174649-16231992 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017076, HPA051551 Uncertain Approved Vesicles
Plasma membrane Tissue enriched Tissue enhanced adipose tissue: 36.2;cerebral cortex: 41.4;placenta: 42.6 breast: 18.3 GAP43 B-50, PP46 ENSG00000172020 Growth associated protein 43 3 115623324-115721490 Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB004417, HPA013392, HPA015600 Supported Validated Plasma membrane Tissue enriched Tissue enriched 37 cerebral cortex: 346.9 appendix: 9.4 GAPDH GAPD ENSG00000111640 Glyceraldehyde-3-phosphate dehydrogenase 12 6533927-6538374 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005197, CAB016392, HPA040067, HPA061280 Supported Validated Plasma membrane
Cytosol Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable) Expressed in all Expressed in all skeletal muscle: 9875.4 GAS2 ENSG00000148935 Growth arrest-specific 2 11 22625642-22813055 Predicted intracellular proteins Evidence at protein level HPA058904 Supported Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Renal cancer:6.13e-4 (favourable) Tissue enhanced Tissue enhanced liver: 20.3 kidney: 5.8 GAS2L1 GAR22 ENSG00000185340 Growth arrest-specific 2 like 1 22 29306582-29312785 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019858 Approved Approved Plasma membrane
Cell Junctions Renal cancer:8.44e-4 (favourable) Expressed in all Expressed in all testis: 32.2 GAS7 KIAA0394, MGC1348 ENSG00000007237 Growth arrest-specific 7 17 9910609-10198551 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA004838, HPA064678 Supported Approved Plasma membrane
Actin filaments
Focal adhesion sites Urothelial cancer:6.89e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 155.2 cervix, uterine: 47.5 GAS8 DRC4, GAS11 ENSG00000141013 Growth arrest-specific 8 16 90019629-90044975 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041311, HPA048238 Approved Approved Plasma membrane
Cytosol Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable) Expressed in all Mixed fallopian tube: 22.6 GBP4 Mpa2 ENSG00000162654 Guanylate binding protein 4 1 89181148-89198932 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030101, HPA062039 Approved Uncertain Plasma membrane Renal cancer:1.30e-5 (unfavourable), Ovarian cancer:9.29e-5 (favourable) Expressed in all Mixed lung: 47.2 GCA GCL ENSG00000115271 Grancalcin, EF-hand calcium binding protein 2 162318840-162371595 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035033, HPA035034 Supported Supported Plasma membrane
Cytosol Expressed in all Tissue enhanced bone marrow: 214.9 appendix: 90.2 GCC1 FLJ22035, GCC1P, GCC88, MGC20706 ENSG00000179562 GRIP and coiled-coil domain containing 1 7 127580618-127593611 Predicted intracellular proteins Evidence at protein level HPA019369, HPA021323 Supported Validated Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 18.7 GCLM GLCLR ENSG00000023909 Glutamate-cysteine ligase, modifier subunit 1 93885205-93909456 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB009568, HPA023696, CAB040554 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:9.83e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 28.1 GFOD1 ADG-90, C6orf114, FLJ20330 ENSG00000145990 Glucose-fructose oxidoreductase domain containing 1 6 13357830-13487662 Predicted intracellular proteins Evidence at protein level HPA029096 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:2.29e-5 (unfavourable), Renal cancer:6.72e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 22.4 GFRA3 GFRa-3 ENSG00000146013 GDNF family receptor alpha 3 5 138252379-138274671 Predicted membrane proteins Evidence at protein level HPA020731 Approved Uncertain Plasma membrane
Cytosol Mixed Mixed seminal vesicle: 8.0 GHR GHBP ENSG00000112964 Growth hormone receptor 5 42423777-42721878 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA045339, HPA057705 Supported Supported Plasma membrane
Cytosol
Cytoplasmic bodies Liver cancer:2.73e-6 (favourable) Mixed Group enriched 5 adipose tissue: 91.1;liver: 110.5 prostate: 18.4 GINM1 C6orf72, dJ12G14.2 ENSG00000055211 Glycoprotein integral membrane 1 6 149566294-149591748 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017210, HPA041679 Approved Approved Nucleoli fibrillar center
Plasma membrane Expressed in all Expressed in all thyroid gland: 118.1 GIPC1 C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2 ENSG00000123159 GIPC PDZ domain containing family, member 1 19 14477760-14496149 Predicted intracellular proteins Evidence at protein level HPA043958, HPA061786 Approved Approved Nucleus
Plasma membrane
Cell Junctions Expressed in all Expressed in all esophagus: 104.4 GLIS2 NPHP7 ENSG00000126603 GLIS family zinc finger 2 16 4314761-4339597 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056976 Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.06e-6 (favourable), Endometrial cancer:1.59e-5 (unfavourable) Expressed in all Mixed gallbladder: 9.7 GLO1 GLOD1 ENSG00000124767 Glyoxalase I 6 38675925-38703141 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB040541, CAB040542, HPA059791 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:5.21e-4 (unfavourable) Expressed in all Expressed in all prostate: 274.7 GLP2R ENSG00000065325 Glucagon-like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022690, HPA049244 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced gallbladder: 19.4 duodenum: 10.4 GLRX GRX, GRX1 ENSG00000173221 Glutaredoxin (thioltransferase) 5 95751319-95823005 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008634, HPA046431, CAB069419 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all kidney: 217.3 GMIP ARHGAP46 ENSG00000089639 GEM interacting protein 19 19629476-19643667 Predicted intracellular proteins Evidence at protein level HPA042484, HPA045481 Approved Validated Nucleoplasm
Plasma membrane
Cytosol Renal cancer:3.97e-5 (unfavourable), Stomach cancer:3.03e-4 (favourable), Urothelial cancer:5.15e-4 (favourable) Expressed in all Mixed spleen: 47.6 GNAI2 GIP, GNAI2B ENSG00000114353 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 3 50226292-50259355 Predicted intracellular proteins Evidence at protein level HPA007704 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Breast cancer:1.03e-4 (favourable) Expressed in all Expressed in all spleen: 329.9 GNAQ G-ALPHA-q, GAQ ENSG00000156052 Guanine nucleotide binding protein (G protein), q polypeptide 9 77716087-78031458 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB010036, HPA048886 Uncertain Approved Nuclear speckles
Plasma membrane
Cytosol Renal cancer:1.11e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 85.1 GNAS GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI ENSG00000087460 GNAS complex locus 20 58839718-58911192 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010337, HPA018122, HPA027478, HPA028386 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable) Expressed in all Expressed in all thyroid gland: 1471.9 GNB1 ENSG00000078369 Guanine nucleotide binding protein (G protein), beta polypeptide 1 1 1785285-1891117 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040736 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:3.61e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 448.5 GNB2 ENSG00000172354 Guanine nucleotide binding protein (G protein), beta polypeptide 2 7 100673531-100679174 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010032, HPA040736 Approved Approved Plasma membrane Expressed in all Expressed in all esophagus: 236.4 GNB3 ENSG00000111664 Guanine nucleotide binding protein (G protein), beta polypeptide 3 12 6839954-6847393 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040736 Approved Uncertain Golgi apparatus
Plasma membrane Tissue enhanced Mixed smooth muscle: 3.7 GNB4 ENSG00000114450 Guanine nucleotide binding protein (G protein), beta polypeptide 4 3 179396089-179451590 Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB018383, CAB018737, HPA040736 Supported Approved Plasma membrane Renal cancer:1.39e-6 (unfavourable) Expressed in all Mixed skin: 37.8 GOLPH3L GPP34R ENSG00000143457 Golgi phosphoprotein 3-like 1 150646225-150697144 Predicted intracellular proteins Evidence at protein level HPA028558 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 51.2 GPAT3 AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324 ENSG00000138678 Glycerol-3-phosphate acyltransferase 3 4 83535914-83605875 Enzymes, Predicted membrane proteins Evidence at protein level HPA029414, CAB033749 Approved Uncertain Plasma membrane
Cytosol Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable) Mixed Tissue enhanced kidney: 89.3 duodenum: 41.9 GPATCH1 ECGP, FLJ10206, FLJ38686, GPATC1 ENSG00000076650 G patch domain containing 1 19 33080880-33130542 Predicted intracellular proteins Evidence at protein level HPA043430, HPA043604 Approved Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Endometrial cancer:8.20e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 8.5 GPBP1 DKFZp761C169, vasculin ENSG00000062194 GC-rich promoter binding protein 1 5 57173948-57264679 Predicted intracellular proteins Evidence at protein level HPA037773 Approved Approved Vesicles
Plasma membrane
Cytosol Urothelial cancer:4.15e-5 (favourable) Expressed in all Expressed in all testis: 138.1 GPBP1L1 SP192 ENSG00000159592 GC-rich promoter binding protein 1-like 1 1 45627304-45688113 Predicted intracellular proteins Evidence at protein level HPA028593 Approved Approved Nucleoplasm
Plasma membrane
Focal adhesion sites Expressed in all Expressed in all testis: 106.6 GPC1 glypican ENSG00000063660 Glypican 1 2 240435671-240468078 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030571 Approved Supported Plasma membrane
Cytosol Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable) Expressed in all Tissue enhanced skin: 266.0 prostate: 57.7 GPC3 DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1 ENSG00000147257 Glypican 3 X 133535745-133985895 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006316 Approved Plasma membrane Stomach cancer:4.83e-4 (unfavourable) Expressed in all Tissue enriched 6 placenta: 838.1 lung: 130.8 GPI AMF, NLK ENSG00000105220 Glucose-6-phosphate isomerase 19 34359480-34402156 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018655, HPA024305, CAB040563, HPA052171 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 308.2 GPR1 ENSG00000183671 G protein-coupled receptor 1 2 206175316-206218047 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010525 Uncertain Supported Vesicles
Plasma membrane Mixed Tissue enhanced placenta: 11.2 esophagus: 5.5 GPR142 PGR2 ENSG00000257008 G protein-coupled receptor 142 17 74367407-74372622 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA031392 Uncertain Uncertain Plasma membrane
Cell Junctions
Cytosol Tissue enhanced Not detected appendix: 0.1 GPR156 GABABL, PGR28 ENSG00000175697 G protein-coupled receptor 156 3 120164645-120285094 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028642, HPA028644 Uncertain Supported Plasma membrane Mixed Tissue enhanced testis: 5.1 fallopian tube: 1.8 GPR157 FLJ12132 ENSG00000180758 G protein-coupled receptor 157 1 9100305-9129170 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA028697 Uncertain Uncertain Nucleoli
Plasma membrane
Cell Junctions Expressed in all Mixed parathyroid gland: 23.9 GPR160 GPCR1, GPCR150 ENSG00000173890 G protein-coupled receptor 160 3 170037929-170085403 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006970 Approved Supported Plasma membrane Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 426.5 small intestine: 111.2 GPR173 SREB3 ENSG00000184194 G protein-coupled receptor 173 X 53049091-53080615 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA003905 Approved Plasma membrane
Cytosol Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 19.1 ovary: 9.0 GPR27 SREB1 ENSG00000170837 G protein-coupled receptor 27 3 71754050-71756496 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029395 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments
Cytosol Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 45.7 cerebral cortex: 24.9 GPR50 H9, Mel1c ENSG00000102195 G protein-coupled receptor 50 X 151176653-151181465 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA049862, HPA054678 Supported Supported Nucleoplasm
Plasma membrane Mixed Not detected placenta: 0.6 GPR63 PSP24(beta), PSP24B ENSG00000112218 G protein-coupled receptor 63 6 96794126-96837463 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA039103 Approved Approved Nucleus
Plasma membrane
Cytosol Mixed Mixed testis: 4.6 GPRC5A PEIG-1, RAI3, RAIG1, TIG1 ENSG00000013588 G protein-coupled receptor, class C, group 5, member A 12 12890782-12917937 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007928, HPA046526 Approved Validated Vesicles
Plasma membrane Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable) Mixed Tissue enhanced lung: 302.3 thyroid gland: 90.7 GPRIN1 GRIN1, KIAA1893 ENSG00000169258 G protein regulated inducer of neurite outgrowth 1 5 176595802-176610133 Predicted intracellular proteins Evidence at protein level HPA036478, HPA070892 Supported Supported Vesicles
Plasma membrane Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 27.9 duodenum: 3.9 GRAMD1A FLJ90346, KIAA1533 ENSG00000089351 GRAM domain containing 1A 19 34994784-35026471 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008852, HPA012570 Approved Approved Plasma membrane
Cytosol Renal cancer:7.95e-12 (unfavourable) Expressed in all Expressed in all appendix: 36.8 GRAMD1C DKFZp434C0328 ENSG00000178075 GRAM domain containing 1C 3 113828182-113947174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012316 Approved Uncertain Plasma membrane
Cytosol Renal cancer:4.22e-15 (favourable) Mixed Mixed testis: 28.3 GRB7 ENSG00000141738 Growth factor receptor-bound protein 7 17 39737927-39747291 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB005226, HPA057084, CAB073538 Approved Supported Plasma membrane Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable) Mixed Mixed fallopian tube: 34.9 GRK5 GPRK5 ENSG00000198873 G protein-coupled receptor kinase 5 10 119207589-119459742 Enzymes, Predicted intracellular proteins Evidence at protein level CAB025579, HPA046838 Approved Approved Nuclear membrane
Nuclear speckles
Plasma membrane Renal cancer:2.38e-7 (unfavourable) Expressed in all Expressed in all parathyroid gland: 77.1 GRPR BB2 ENSG00000126010 Gastrin-releasing peptide receptor X 16123556-16153021 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA069604 Validated Plasma membrane Tissue enhanced Tissue enhanced pancreas: 4.2 breast: 2.6 GSR ENSG00000104687 Glutathione reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane
Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 77.8 GTSE1 B99, GTSE-1 ENSG00000075218 G-2 and S-phase expressed 1 22 46296741-46330810 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029457, HPA060544 Uncertain Approved Plasma membrane
Centrosome Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable) Mixed Tissue enhanced testis: 12.5 lymph node: 10.7 GUCA1A C6orf131, COD3, CORD14, dJ139D8.6, GCAP, GCAP1, GUCA, GUCA1 ENSG00000048545 Guanylate cyclase activator 1A (retina) 6 42155406-42180056 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA005561 Supported Approved Uncertain Plasma membrane Tissue enriched Tissue enriched 19 testis: 30.0 cerebral cortex: 1.6 HAPLN3 EXLD1, HsT19883 ENSG00000140511 Hyaluronan and proteoglycan link protein 3 15 88877288-88895626 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039237 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.18e-13 (unfavourable) Expressed in all Tissue enhanced appendix: 14.3;lymph node: 11.0 spleen: 4.0 HARBI1 C11orf77, FLJ32675 ENSG00000180423 Harbinger transposase derived 1 11 46602861-46617909 Predicted intracellular proteins Evidence at protein level HPA038671, HPA045457 Uncertain Validated Plasma membrane
Cytosol Expressed in all Tissue enhanced testis: 21.7 parathyroid gland: 5.2 HAS1 HAS ENSG00000105509 Hyaluronan synthase 1 19 51713112-51723994 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA067602 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enhanced adipose tissue: 26.9 appendix: 9.1 HAUS4 C14orf94, FLJ20424 ENSG00000092036 HAUS augmin-like complex, subunit 4 14 22946228-22957161 Predicted intracellular proteins Evidence at protein level HPA029803, HPA071195 Approved Supported Plasma membrane
Focal adhesion sites Urothelial cancer:2.24e-4 (unfavourable) Expressed in all Expressed in all ovary: 61.7 HAUS7 UCHL5IP, UIP1 ENSG00000213397 HAUS augmin-like complex, subunit 7 X 153447666-153495516 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003614 Approved Nucleoli
Plasma membrane
Centrosome
Cytosol Renal cancer:3.94e-4 (unfavourable), Cervical cancer:6.12e-4 (favourable) Expressed in all Mixed skin: 64.0 HCFC2 HCF-2 ENSG00000111727 Host cell factor C2 12 104064457-104106524 Predicted intracellular proteins Evidence at protein level HPA006227 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 17.0 HCK JTK9 ENSG00000101336 HCK proto-oncogene, Src family tyrosine kinase 20 32052188-32101856 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005195, HPA063768 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:1.66e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 142.6;spleen: 108.6 lung: 67.5 HCLS1 CTTNL, HS1 ENSG00000180353 Hematopoietic cell-specific Lyn substrate 1 3 121631399-121660927 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019143 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all spleen: 275.8 HDAC8 HDACL1, MRXS6, RPD3, WTS ENSG00000147099 Histone deacetylase 8 X 72329516-72573103 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048560 Supported Supported Nucleus
Plasma membrane Expressed in all Expressed in all epididymis: 26.9 HELZ DHRC, HUMORF5, KIAA0054 ENSG00000198265 Helicase with zinc finger 17 67070438-67245989 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028276 Approved Approved Nucleoli
Plasma membrane
Actin filaments Expressed in all Expressed in all parathyroid gland: 32.3 HENMT1 C1orf59, FLJ30525, HEN1 ENSG00000162639 HEN1 methyltransferase homolog 1 (Arabidopsis) 1 108648290-108661526 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028464, HPA028497 Uncertain Approved Plasma membrane
Focal adhesion sites Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable) Expressed in all Tissue enriched 8 testis: 127.7 lymph node: 15.0 HERPUD1 HERP, KIAA0025, Mif1, SUP ENSG00000051108 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 16 56932048-56944863 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037041, CAB037104, HPA040754, HPA041219 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.41e-9 (favourable) Expressed in all Expressed in all prostate: 379.0 HIF1A bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8 ENSG00000100644 Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 14 61695513-61748259 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000907, HPA001275, CAB017442 Supported Supported Nucleoplasm
Nuclear bodies
Plasma membrane Expressed in all Expressed in all bone marrow: 292.9 HIF3A bHLHe17, IPAS, MOP7, PASD7 ENSG00000124440 Hypoxia inducible factor 3, alpha subunit 19 46297046-46343433 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA041141 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:6.90e-9 (unfavourable) Mixed Tissue enhanced placenta: 39.5 spleen: 20.3 HINT1 HINT, PKCI-1, PRKCNH1 ENSG00000169567 Histidine triad nucleotide binding protein 1 5 131159027-131171735 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044577 Approved Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 174.4 HIP1R FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655 ENSG00000130787 Huntingtin interacting protein 1 related 12 122834453-122862960 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB017187, HPA038135, HPA038136 Approved Validated Vesicles
Plasma membrane
Cytosol Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 53.3 HLA-A ENSG00000206503 Major histocompatibility complex, class I, A 6 29941260-29945884 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB078470 Supported Golgi apparatus
Plasma membrane Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable) Expressed in all Mixed gallbladder: 342.4 HMGCS1 HMGCS ENSG00000112972 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 5 43289395-43313512 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB032907, HPA036913, HPA036914 Approved Supported Nucleus
Plasma membrane
Cytosol Renal cancer:3.87e-6 (favourable) Expressed in all Expressed in all liver: 208.6 HMOX1 bK286B10, HO-1 ENSG00000100292 Heme oxygenase 1 22 35380361-35394214 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000635, CAB017444 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 435.2 HN1L C16orf34, FLJ13092, KIAA1426, L11 ENSG00000206053 Hematological and neurological expressed 1-like 16 1678256-1702280 Predicted intracellular proteins Evidence at protein level HPA041888, HPA041908 Approved Validated Plasma membrane
Cytosol Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 100.6 HOMER3 HOMER-3 ENSG00000051128 Homer scaffolding protein 3 19 18929201-18941261 Predicted intracellular proteins Evidence at protein level CAB032656, HPA040999 Supported Supported Plasma membrane
Cytosol
Cytoplasmic bodies Colorectal cancer:4.24e-5 (unfavourable), Liver cancer:4.93e-5 (unfavourable) Expressed in all Expressed in all spleen: 153.4 HPS3 BLOC2S1, SUTAL ENSG00000163755 Hermansky-Pudlak syndrome 3 3 149129584-149173732 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046281, HPA052778 Approved Approved Golgi apparatus
Plasma membrane Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable) Expressed in all Mixed spleen: 22.5 HRH1 ENSG00000196639 Histamine receptor H1 3 11137093-11263557 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029740 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 12.4 HSH2D ALX, FLJ14886, HSH2 ENSG00000196684 Hematopoietic SH2 domain containing 19 16134028-16158575 Predicted intracellular proteins Evidence at protein level HPA036616 Approved Plasma membrane
Focal adhesion sites
Cytosol Renal cancer:6.49e-6 (unfavourable), Colorectal cancer:9.46e-6 (unfavourable), Urothelial cancer:3.47e-5 (favourable) Mixed Mixed tonsil: 34.1 HSPB1 CMT2F, Hs.76067, Hsp25, HSP27, HSP28 ENSG00000106211 Heat shock 27kDa protein 1 7 76302544-76304295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000497, CAB004439, CAB047330, CAB047331, CAB047332 Supported Validated Plasma membrane
Cytosol Colorectal cancer:9.94e-5 (unfavourable) Expressed in all Expressed in all esophagus: 1622.3 HSPG2 perlecan, PRCAN, SJS1 ENSG00000142798 Heparan sulfate proteoglycan 2 1 21822245-21937297 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB009820, HPA018892, CAB020718 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:2.82e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 135.3 HTR1B 5-HT1B, 5-HT1DB, HTR1D2, S12 ENSG00000135312 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 6 77462205-77463464 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA028808 Approved Uncertain Plasma membrane Mixed Tissue enhanced placenta: 13.7;stomach: 5.8 cerebral cortex: 2.8 HTR7 5-HT7 ENSG00000148680 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled 10 90740823-90857698 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022708 Uncertain Supported Nuclear speckles
Plasma membrane
Cytosol Group enriched Group enriched 8 parathyroid gland: 43.9;testis: 16.0 urinary bladder: 3.9 HTRA1 ARMD7, HtrA, IGFBP5-protease, PRSS11 ENSG00000166033 HtrA serine peptidase 1 10 122461525-122514908 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036655 Approved Supported Plasma membrane Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable) Expressed in all Mixed ovary: 502.5 HUNK ENSG00000142149 Hormonally up-regulated Neu-associated kinase 21 31873315-32044633 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027295, HPA027372 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.48e-5 (favourable) Mixed Mixed placenta: 6.8 HYDIN CILD5, DKFZp434D0513, KIAA1864, PPP1R31 ENSG00000157423 HYDIN, axonemal central pair apparatus protein 16 70807378-71230722 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA067155, HPA074129 Supported Approved Plasma membrane
Cytosol Not detected Tissue enhanced fallopian tube: 9.3;testis: 6.4 parathyroid gland: 5.3 HYI HT036 ENSG00000178922 Hydroxypyruvate isomerase (putative) 1 43451003-43453989 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040092 Uncertain Approved Golgi apparatus
Plasma membrane
Cytosol Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 80.3 HYLS1 FLJ32915 ENSG00000198331 Hydrolethalus syndrome 1 11 125883614-125900648 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041210 Uncertain Supported Plasma membrane
Cytosol Liver cancer:1.92e-4 (unfavourable) Expressed in all Tissue enriched 6 testis: 37.4 smooth muscle: 6.6 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 IFFO2 ENSG00000169991 Intermediate filament family orphan 2 1 18904281-18956686 Predicted intracellular proteins Evidence at protein level HPA015987, HPA064603 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 72.6 IFIT5 RI58 ENSG00000152778 Interferon-induced protein with tetratricopeptide repeats 5 10 89414586-89421001 Predicted intracellular proteins Evidence at protein level HPA037957, HPA062180 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed parathyroid gland: 35.6 IFNGR1 CD119, IFNGR ENSG00000027697 Interferon gamma receptor 1 6 137197484-137219449 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029213, HPA063871 Approved Supported Endoplasmic reticulum
Vesicles
Plasma membrane Renal cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all spleen: 225.2 IFRD1 PC4, TIS7 ENSG00000006652 Interferon-related developmental regulator 1 7 112422968-112481017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024122 Approved Approved Plasma membrane
Cytosol Ovarian cancer:5.45e-4 (favourable) Expressed in all Expressed in all bone marrow: 130.1 IGFL2 UNQ645 ENSG00000204866 IGF-like family member 2 19 46143106-46161299 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA059137 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 6 skin: 35.5 parathyroid gland: 5.7 IKZF3 Aiolos, ZNFN1A3 ENSG00000161405 IKAROS family zinc finger 3 (Aiolos) 17 39757715-39864188 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017105, HPA024377 Supported Uncertain Plasma membrane
Cytosol Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable) Mixed Tissue enhanced lymph node: 45.2;spleen: 32.2;tonsil: 40.9 appendix: 26.4 IKZF5 FLJ22973, Pegasus, ZNFN1A5 ENSG00000095574 IKAROS family zinc finger 5 (Pegasus) 10 122990806-123008817 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015297, HPA051574 Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all bone marrow: 21.4 IL12RB1 CD212, IL12RB ENSG00000096996 Interleukin 12 receptor, beta 1 19 18058995-18098944 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074414 Approved Plasma membrane Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable) Mixed Tissue enhanced lymph node: 26.3 spleen: 21.1 IL12RB2 ENSG00000081985 Interleukin 12 receptor, beta 2 1 67307364-67396900 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024168 Uncertain Uncertain Plasma membrane
Cytosol Tissue enhanced Tissue enhanced placenta: 11.7 cerebral cortex: 4.5 IL13 ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600 ENSG00000169194 Interleukin 13 5 132656263-132661110 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042421 Approved Plasma membrane
Cytosol Not detected Tissue enriched 10 testis: 19.9 gallbladder: 2.0 IL15RA CD215, IL-15RA ENSG00000134470 Interleukin 15 receptor, alpha 10 5937569-5978187 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026215 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.5 IL16 FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16 ENSG00000172349 Interleukin 16 15 81159575-81314058 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005247, HPA018467 Supported Approved Nuclear speckles
Plasma membrane
Cytosol Expressed in all Tissue enhanced lymph node: 156.4;tonsil: 128.4 spleen: 120.1 IL21R CD360 ENSG00000103522 Interleukin 21 receptor 16 27402162-27452042 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA042296 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:7.29e-4 (favourable) Mixed Tissue enhanced appendix: 16.4;lymph node: 29.2;tonsil: 18.0 spleen: 7.7 IL6ST CD130, GP130 ENSG00000134352 Interleukin 6 signal transducer 5 55935095-55994993 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010558, CAB025784 Uncertain Supported Golgi apparatus
Plasma membrane Renal cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all placenta: 327.1 IL7R CD127 ENSG00000168685 Interleukin 7 receptor 5 35852695-35879603 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010215 Approved Supported Plasma membrane Expressed in all Expressed in all appendix: 188.9 INO80B hIes2, HMGA1L4, HMGIYL4, IES2, PAP-1BP, PAPA-1, ZNHIT4 ENSG00000115274 INO80 complex subunit B 2 74455023-74457960 Predicted intracellular proteins Evidence at protein level HPA042717 Supported Nucleus
Plasma membrane
Cytosol Renal cancer:1.56e-5 (unfavourable), Breast cancer:2.89e-4 (favourable), Stomach cancer:8.44e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 42.0 INTS12 INT12, PHF22, SBBI22 ENSG00000138785 Integrator complex subunit 12 4 105682627-105895986 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA035772, HPA041814 Approved Approved Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Liver cancer:2.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 33.5 IQGAP1 HUMORFA01, KIAA0051, p195, SAR1 ENSG00000140575 IQ motif containing GTPase activating protein 1 15 90388218-90502243 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013302, HPA014055 Supported Supported Plasma membrane
Cell Junctions Pancreatic cancer:5.67e-5 (unfavourable) Expressed in all Expressed in all endometrium: 119.6 IQGAP2 ENSG00000145703 IQ motif containing GTPase activating protein 2 5 76403249-76708132 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004241, HPA037403, HPA037404 Approved Approved Vesicles
Plasma membrane Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 124.6 testis: 91.6 ISLR HsT17563 ENSG00000129009 Immunoglobulin superfamily containing leucine-rich repeat 15 74173671-74176872 Predicted secreted proteins Evidence at protein level HPA040326, HPA050811 Approved Approved Golgi apparatus
Plasma membrane Renal cancer:4.89e-8 (unfavourable) Expressed in all Mixed endometrium: 198.5 ITGA3 CD49c, GAP-B3, MSK18, VCA-2, VLA3a ENSG00000005884 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 17 50055968-50090481 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008572, CAB018594 Supported Supported Plasma membrane Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable) Expressed in all Mixed lung: 99.1 ITGA7 ENSG00000135424 Integrin, alpha 7 12 55684568-55716043 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008427 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 154.2 smooth muscle: 135.5 ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB003434 Approved Supported Endoplasmic reticulum
Plasma membrane
Focal adhesion sites Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1058.2 ITGB4 CD104 ENSG00000132470 Integrin, beta 4 17 75721328-75757818 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002422, CAB005258, HPA036348, HPA036349 Supported Supported Nucleus
Plasma membrane
Cell Junctions Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable) Expressed in all Mixed skin: 84.4 ITGB5 ENSG00000082781 Integrin, beta 5 3 124761948-124901418 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001820, CAB022050 Approved Approved Plasma membrane
Mitochondria Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Expressed in all placenta: 116.8 ITGB7 ENSG00000139626 Integrin, beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane
Cytosol Mixed Mixed spleen: 32.8 ITGB8 ENSG00000105855 Integrin, beta 8 7 20330702-20415754 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA027796, HPA027797 Approved Approved Plasma membrane
Cytosol Renal cancer:1.77e-4 (favourable) Mixed Mixed cerebral cortex: 30.9 ITSN1 ITSN, MGC134948, MGC134949, SH3D1A, SH3P17 ENSG00000205726 Intersectin 1 (SH3 domain protein) 21 33642400-33899861 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018007 Approved Supported Plasma membrane Expressed in all Expressed in all adipose tissue: 61.3 ITSN2 KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP ENSG00000198399 Intersectin 2 2 24202864-24360714 Predicted intracellular proteins Evidence at protein level HPA036475 Approved Approved Vesicles
Plasma membrane Head and neck cancer:2.98e-4 (favourable) Expressed in all Expressed in all thyroid gland: 84.6 IYD C6orf71, DEHAL1, dJ422F24.1 ENSG00000009765 Iodotyrosine deiodinase 6 150368892-150405969 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA059627 Supported Supported Plasma membrane Liver cancer:6.22e-4 (favourable) Tissue enriched Tissue enriched 28 thyroid gland: 792.4 kidney: 27.9 JAG1 AGS, AHD, AWS, CD339, HJ1, JAGL1 ENSG00000101384 Jagged 1 20 10637684-10674107 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB010343, HPA021555 Supported Supported Golgi apparatus
Plasma membrane Pancreatic cancer:4.10e-6 (unfavourable) Expressed in all Expressed in all placenta: 96.3 JAK2 JTK10 ENSG00000096968 Janus kinase 2 9 4985033-5128183 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013089, HPA040820, HPA043870 Approved Supported Nucleoplasm
Plasma membrane
Focal adhesion sites Expressed in all Mixed appendix: 25.4 JMJD4 FLJ12517 ENSG00000081692 Jumonji domain containing 4 1 227730425-227735411 Predicted intracellular proteins Evidence at protein level HPA027260, HPA052861 Uncertain Approved Vesicles
Plasma membrane Renal cancer:3.16e-4 (unfavourable) Expressed in all Expressed in all testis: 12.9 JUP CTNNG, DP3, DPIII, PDGB, PKGB ENSG00000173801 Junction plakoglobin 17 41754604-41786931 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002139, HPA032047 Supported Validated Vesicles
Plasma membrane
Cell Junctions Renal cancer:2.06e-10 (favourable) Expressed in all Group enriched 6 esophagus: 493.6;skin: 787.3 fallopian tube: 112.6 KANK1 ANKRD15, KANK, KIAA0172 ENSG00000107104 KN motif and ankyrin repeat domains 1 9 470291-746106 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005539, HPA056090 Approved Supported Plasma membrane Expressed in all Mixed smooth muscle: 54.8 KANK3 ANKRD47, FLJ46061 ENSG00000186994 KN motif and ankyrin repeat domains 3 19 8322584-8343262 Predicted intracellular proteins Evidence at protein level HPA051153 Approved Approved Plasma membrane Renal cancer:1.69e-5 (favourable) Expressed in all Tissue enhanced spleen: 25.4 adipose tissue: 22.0 KANSL2 C12orf41, FLJ20436, NSL2 ENSG00000139620 KAT8 regulatory NSL complex subunit 2 12 48653401-48682238 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038497, HPA038498 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:4.32e-4 (favourable), Liver cancer:4.98e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 31.9 KATNB1 ENSG00000140854 Katanin p80 (WD repeat containing) subunit B 1 16 57735730-57757250 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041165, HPA041839 Supported Supported Plasma membrane
Microtubules
Cytosol Liver cancer:3.93e-4 (unfavourable), Pancreatic cancer:8.44e-4 (favourable), Endometrial cancer:9.24e-4 (favourable) Expressed in all Expressed in all testis: 45.4 KCNB2 Kv2.2 ENSG00000182674 Potassium channel, voltage gated Shab related subfamily B, member 2 8 72537391-72938349 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA065970 Approved Nucleoli
Plasma membrane
Midbody Not detected Tissue enhanced cerebral cortex: 3.2;spleen: 3.4 fallopian tube,testis: 0.7 KCNC2 Kv3.2 ENSG00000166006 Potassium channel, voltage gated Shaw related subfamily C, member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane
Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.5 prostate: 4.2 KCNJ15 IRKK, Kir1.3, Kir4.2 ENSG00000157551 Potassium channel, inwardly rectifying subfamily J, member 15 21 38157034-38307357 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA016702 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 259.2;thyroid gland: 215.5 lung: 63.5 KCNK6 K2p6.1, TWIK-2 ENSG00000099337 Potassium channel, two pore domain subfamily K, member 6 19 38319844-38332076 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022637, HPA040184 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable) Expressed in all Mixed endometrium: 22.8 KCNK7 K2p7.1 ENSG00000173338 Potassium channel, two pore domain subfamily K, member 7 11 65592855-65595996 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels Evidence at transcript level HPA077577 Approved Plasma membrane Tissue enhanced Tissue enriched 7 skin: 53.1 esophagus: 8.0 KCNS3 Kv9.3 ENSG00000170745 Potassium voltage-gated channel, modifier subfamily S, member 3 2 17877847-18361616 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014864 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.53e-4 (unfavourable) Expressed in all Tissue enhanced lung: 35.5 skeletal muscle: 29.6 KDR CD309, FLK1, VEGFR, VEGFR2 ENSG00000128052 Kinase insert domain receptor 4 55078477-55125589 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB004028 Approved Supported Plasma membrane Renal cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 118.2 thyroid gland: 54.5 KIAA0556 ENSG00000047578 KIAA0556 16 27550133-27780369 Predicted intracellular proteins Evidence at protein level HPA035089, HPA035090 Supported Approved Nuclear speckles
Plasma membrane Head and neck cancer:3.00e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 47.1 thyroid gland: 26.8 KIAA0895 ENSG00000164542 KIAA0895 7 36324221-36390125 Predicted intracellular proteins Evidence at transcript level HPA020512, HPA021036, HPA061066 Uncertain Approved Nucleus
Plasma membrane
Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 43.8 parathyroid gland: 23.4 KIAA1107 ENSG00000069712 KIAA1107 1 92167052-92184723 Predicted intracellular proteins Evidence at protein level HPA024216, HPA027327 Supported Uncertain Golgi apparatus
Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 47.0 testis: 13.4 KIAA1324 EIG121, maba1 ENSG00000116299 KIAA1324 1 109113679-109206781 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029869, HPA070749 Supported Supported Plasma membrane Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable) Mixed Mixed cervix, uterine: 128.0 KIAA1522 ENSG00000162522 KIAA1522 1 32741885-32774970 Predicted intracellular proteins Evidence at protein level HPA032050, HPA032051, HPA064839 Approved Supported Nucleoplasm
Plasma membrane
Cell Junctions Liver cancer:6.29e-7 (unfavourable), Renal cancer:1.29e-5 (favourable), Pancreatic cancer:8.25e-5 (unfavourable) Expressed in all Mixed skin: 73.0 KIAA1524 CIP2A ENSG00000163507 KIAA1524 3 108549869-108589644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039570 Approved Supported Plasma membrane
Cytosol Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable) Expressed in all Mixed testis: 10.2 KIAA1958 FLJ39294 ENSG00000165185 KIAA1958 9 112486847-112669397 Predicted intracellular proteins Evidence at protein level HPA020625 Approved Approved Plasma membrane
Cytosol Mixed Mixed ovary: 12.1 KIF17 KIAA1405, KIF17B, KIF3X, KLP-2, OSM-3 ENSG00000117245 Kinesin family member 17 1 20664014-20718017 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032085 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 6 testis: 23.7 cerebral cortex: 3.8 KIF19 FLJ37300, KIF19A ENSG00000196169 Kinesin family member 19 17 74326210-74355820 Predicted intracellular proteins Evidence at protein level HPA043638, HPA073303 Approved Approved Plasma membrane
Actin filaments
Centrosome Mixed Tissue enhanced fallopian tube: 18.7;spleen: 6.7 duodenum: 3.0 KIF21A FEOM1, FLJ20052 ENSG00000139116 Kinesin family member 21A 12 39293228-39443390 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB022079, HPA058432 Approved Supported Plasma membrane
Cytosol Renal cancer:8.07e-8 (favourable) Expressed in all Tissue enhanced cerebral cortex: 79.6 fallopian tube: 59.5 KIF26A DKFZP434N178, KIAA1236 ENSG00000066735 Kinesin family member 26A 14 104138723-104180894 Predicted intracellular proteins Evidence at protein level HPA046882, HPA060346 Uncertain Approved Nucleus
Plasma membrane
Cytosol Renal cancer:7.78e-4 (unfavourable) Group enriched Mixed adipose tissue: 5.0 KIF26B FLJ10157 ENSG00000162849 Kinesin family member 26B 1 245154985-245709431 Predicted intracellular proteins Evidence at protein level HPA027709, HPA028478, HPA028561, HPA028562 Approved Approved Plasma membrane
Microtubules Ovarian cancer:1.24e-4 (unfavourable) Mixed Mixed cerebral cortex: 2.3 KIF5C ENSG00000168280 Kinesin family member 5C 2 148875250-149026759 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035210 Approved Approved Nucleoli
Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 205.9 prostate: 42.3 KISS1R AXOR12, GPR54, HOT7T175 ENSG00000116014 KISS1 receptor 19 917287-921015 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071913 Supported Vesicles
Plasma membrane Renal cancer:3.33e-6 (unfavourable) Tissue enhanced Tissue enriched 5 cerebral cortex: 1.2 appendix,lymph node,placenta: 0.2 KIT C-Kit, CD117, PBT, SCFR ENSG00000157404 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4 54657918-54740715 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB003288, HPA004471, CAB068253, CAB072867, HPA073252 Supported Supported Plasma membrane Renal cancer:5.63e-4 (favourable) Mixed Tissue enhanced breast: 133.8 thyroid gland: 78.4 KLC1 hKLC1B, hKLC1G, hKLC1J, hKLC1N, hKLC1P, hKLC1R, hKLC1S, KLC, KNS2, KNS2A ENSG00000126214 Kinesin light chain 1 14 103561896-103714249 Predicted intracellular proteins Evidence at protein level CAB009798, HPA044617, HPA052450 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:6.75e-4 (favourable), Renal cancer:7.17e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 469.3 KLC2 FLJ12387 ENSG00000174996 Kinesin light chain 2 11 66257294-66267860 Predicted intracellular proteins Evidence at protein level HPA040416, HPA040434 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:3.16e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 64.0 KLF9 BTEB1 ENSG00000119138 Kruppel-like factor 9 9 70384597-70414624 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029308 Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:6.59e-6 (favourable) Expressed in all Expressed in all smooth muscle: 88.0 KLHL41 KBTBD10, Krp1, SARCOSIN ENSG00000239474 Kelch-like family member 41 2 169509702-169526262 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021165, HPA021753, HPA021760 Supported Supported Nucleus
Plasma membrane
Cytosol Group enriched Tissue enriched 22 skeletal muscle: 1750.9 esophagus: 80.0 KLK10 NES1, PRSSL1 ENSG00000129451 Kallikrein-related peptidase 10 19 51012739-51020175 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA017195 Uncertain Plasma membrane
Cytosol Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable) Mixed Tissue enhanced esophagus: 138.7;skin: 52.8 tonsil: 47.4 KLK7 PRSS6, SCCE ENSG00000169035 Kallikrein-related peptidase 7 19 50976482-50984099 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018994, CAB026342, HPA062126 Supported Supported Plasma membrane Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable) Tissue enhanced Group enriched 5 esophagus: 68.9;skin: 220.0 fallopian tube: 27.6 KLRC1 CD159a, NKG2, NKG2-A, NKG2-B ENSG00000134545 Killer cell lectin-like receptor subfamily C, member 1 12 10442264-10454685 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058052 Approved Plasma membrane Mixed Mixed spleen: 10.3 KLRC2 CD159c, NKG2-C ENSG00000205809 Killer cell lectin-like receptor subfamily C, member 2 12 10426854-10442300 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058052 Approved Plasma membrane Tissue enriched Group enriched 6 cerebral cortex: 17.4;spleen: 8.3 stomach: 2.0 KLRK1 CD314, D12S2489E, KLR, NKG2-D, NKG2D ENSG00000213809 Killer cell lectin-like receptor subfamily K, member 1 12 10372353-10391874 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB021896, HPA068877 Supported Supported Plasma membrane Not detected Tissue enhanced lymph node: 35.7;spleen: 53.6 tonsil: 16.7 KMT2D ALR, CAGL114, MLL2, MLL4, TNRC21 ENSG00000167548 Lysine (K)-specific methyltransferase 2D 12 49018975-49059774 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035977 Approved Approved Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 45.7 KNTC1 KIAA0166, ROD ENSG00000184445 Kinetochore associated 1 12 122527246-122626396 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA025241 Approved Supported Plasma membrane
Cytosol Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable) Expressed in all Tissue enhanced testis: 43.2 bone marrow: 27.2 KPTN 2E4 ENSG00000118162 Kaptin (actin binding protein) 19 47475144-47484268 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041710, HPA041796 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:7.91e-6 (unfavourable), Renal cancer:7.82e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 7.9 KRT75 K6HF ENSG00000170454 Keratin 75, type II 12 52424070-52434525 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019367, HPA076201 Supported Approved Plasma membrane
Cytosol Tissue enhanced Not detected breast: 0.9 KRT77 KRT1B ENSG00000189182 Keratin 77, type II 12 52689626-52703463 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA045934 Supported Approved Nuclear membrane
Plasma membrane Mixed Tissue enriched 12 skin: 309.5 breast: 25.9 KRTAP25-1 KAP25.1 ENSG00000232263 Keratin associated protein 25-1 21 30289145-30289514 Predicted intracellular proteins No evidence HPA031438 Uncertain Approved Nuclear membrane
Plasma membrane
Cytosol Not detected Not detected all non-specific tissues: 0.0 L1CAM CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1 ENSG00000198910 L1 cell adhesion molecule X 153861514-153909223 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005830, CAB010896 Approved Approved Nucleoplasm
Plasma membrane Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 36.2;cerebral cortex: 67.1 seminal vesicle: 12.7 L3MBTL1 dJ138B7.3, DKFZp586P1522, KIAA0681, L3MBTL, ZC2HC3 ENSG00000185513 L(3)mbt-like 1 (Drosophila) 20 43507680-43550950 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056389 Supported Nucleus
Plasma membrane Mixed Mixed testis: 10.1 LACE1 AFG1 ENSG00000135537 Lactation elevated 1 6 108294894-108526796 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030154, HPA030155, HPA030659 Approved Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 17.5 parathyroid gland: 8.1 LAIR1 CD305 ENSG00000167613 Leukocyte-associated immunoglobulin-like receptor 1 19 54351384-54370558 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011155 Supported Supported Plasma membrane Renal cancer:5.01e-5 (unfavourable) Expressed in all Tissue enhanced lymph node: 7.2 appendix: 4.3 LAMA4 LAMA3 ENSG00000112769 Laminin, alpha 4 6 112108760-112254939 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA015693, CAB078156 Approved Approved Plasma membrane
Cytosol Renal cancer:2.00e-4 (unfavourable) Expressed in all Mixed smooth muscle: 144.6 LAMC1 LAMB2 ENSG00000135862 Laminin, gamma 1 (formerly LAMB2) 1 183023460-183145592 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001908, HPA001909, CAB004486, CAB078163 Supported Approved Endoplasmic reticulum
Plasma membrane Urothelial cancer:8.85e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 330.2 smooth muscle: 145.7 LAMTOR1 C11orf59, FLJ20625, p18, p27RF-Rho, Pdro, Ragulator1 ENSG00000149357 Late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 11 72085895-72103387 Predicted intracellular proteins Evidence at protein level HPA002997 Approved Supported Golgi apparatus
Vesicles
Plasma membrane Liver cancer:3.63e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 142.7 LAPTM4A HUMORF13, KIAA0108, LAPTM4, MBNT, Mtrp ENSG00000068697 Lysosomal protein transmembrane 4 alpha 2 20032650-20052028 Predicted membrane proteins Evidence at protein level HPA031402, HPA031404, HPA068554 Approved Approved Golgi apparatus
Vesicles
Plasma membrane Pancreatic cancer:4.37e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 627.8 LASP1 Lasp-1, MLN50 ENSG00000002834 LIM and SH3 protein 1 17 38869859-38921770 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012072, CAB022049 Supported Supported Plasma membrane
Focal adhesion sites
Cytosol Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all small intestine: 185.0 LAX1 FLJ20340, LAX ENSG00000122188 Lymphocyte transmembrane adaptor 1 1 203765176-203776233 Predicted membrane proteins Evidence at protein level HPA002461, HPA003887, CAB025358 Supported Validated Golgi apparatus
Plasma membrane
Cytosol Mixed Tissue enhanced tonsil: 16.0 lymph node: 10.4 LCP1 CP64, L-PLASTIN, LC64P, PLS2 ENSG00000136167 Lymphocyte cytosolic protein 1 (L-plastin) 13 46125920-46211871 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019493, CAB020673 Supported Approved Plasma membrane
Actin filaments
Cytosol Expressed in all Expressed in all lymph node: 622.1 LCTL FLJ33279, KLG, KLPH ENSG00000188501 Lactase-like 15 66547179-66565979 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA071640 Approved Endoplasmic reticulum
Plasma membrane Group enriched Mixed cerebral cortex: 1.0 LENG1 ENSG00000105617 Leukocyte receptor cluster (LRC) member 1 19 54155161-54159882 Predicted intracellular proteins Evidence at protein level HPA043541 Uncertain Approved Nucleus
Plasma membrane Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable) Expressed in all Tissue enhanced spleen: 1.8 endometrium: 1.0 LGALS3 GALIG, LGALS2, MAC-2 ENSG00000131981 Lectin, galactoside-binding, soluble, 3 14 55124110-55145413 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003162, CAB005191 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all colon: 886.8 LGALS8 PCTA-1 ENSG00000116977 Lectin, galactoside-binding, soluble, 8 1 236518000-236552981 Predicted intracellular proteins Evidence at protein level HPA012734, HPA030491 Approved Approved Plasma membrane Renal cancer:4.93e-7 (unfavourable), Lung cancer:9.40e-4 (favourable) Expressed in all Expressed in all testis: 101.8 LGR6 FLJ14471 ENSG00000133067 Leucine-rich repeat containing G protein-coupled receptor 6 1 202193901-202319781 G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008556 Approved Approved Nucleoplasm
Plasma membrane Glioma:2.00e-4 (unfavourable) Tissue enhanced Tissue enhanced fallopian tube: 14.1 gallbladder: 9.6 LHX6 LHX6.1 ENSG00000106852 LIM homeobox 6 9 122202577-122229626 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047854, HPA058319 Approved Uncertain Nucleoli fibrillar center
Plasma membrane Mixed Mixed cerebral cortex: 8.1 LIG4 ENSG00000174405 Ligase IV, DNA, ATP-dependent 13 108207439-108218368 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001334 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 20.1 LIMA1 EPLIN ENSG00000050405 LIM domain and actin binding 1 12 50175788-50283546 Predicted intracellular proteins Evidence at protein level HPA023871, HPA052645 Supported Validated Plasma membrane
Actin filaments
Focal adhesion sites
Cytosol Head and neck cancer:1.76e-6 (unfavourable), Renal cancer:2.79e-4 (favourable) Expressed in all Expressed in all rectum: 146.2 LINGO1 FLJ14594, LERN1, LRRN6A ENSG00000169783 Leucine rich repeat and Ig domain containing 1 15 77613027-77820900 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074653 Approved Plasma membrane Renal cancer:3.23e-7 (unfavourable) Expressed in all Tissue enriched 13 cerebral cortex: 131.2 heart muscle,placenta: 9.7 LMCD1 ENSG00000071282 LIM and cysteine-rich domains 1 3 8501707-8574673 Predicted intracellular proteins Evidence at protein level HPA024059 Approved Supported Nucleus
Plasma membrane
Cell Junctions
Cytosol Renal cancer:8.66e-5 (unfavourable) Expressed in all Mixed skeletal muscle: 201.9 LMTK2 AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100 ENSG00000164715 Lemur tyrosine kinase 2 7 98106885-98209633 Enzymes, Predicted membrane proteins Evidence at protein level HPA010657, HPA041836 Uncertain Approved Nuclear speckles
Plasma membrane
Microtubule organizing center
Cytosol Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 28.0 LNX2 MGC46315, PDZRN1 ENSG00000139517 Ligand of numb-protein X 2 13 27545911-27620404 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040698 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-13 (favourable) Expressed in all Expressed in all testis: 23.2 LONRF1 FLJ23749, RNF191 ENSG00000154359 LON peptidase N-terminal domain and ring finger 1 8 12721894-12756073 Predicted intracellular proteins Evidence at protein level HPA023584, HPA024814 Uncertain Approved Plasma membrane
Centrosome
Cytosol Expressed in all Expressed in all skin: 30.8 LONRF3 FLJ22612, RNF127 ENSG00000175556 LON peptidase N-terminal domain and ring finger 3 X 118974614-119018355 Predicted intracellular proteins Evidence at protein level HPA050422 Uncertain Approved Nucleus
Plasma membrane Pancreatic cancer:4.32e-4 (unfavourable) Mixed Mixed thyroid gland: 12.5 LPAR1 edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1 ENSG00000198121 Lysophosphatidic acid receptor 1 9 110873263-111038458 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050667 Approved Nuclear speckles
Plasma membrane Expressed in all Mixed cervix, uterine: 90.9 LPAR3 Edg-7, EDG7, HOFNH30, LP-A3, LPA3, RP4-678I3 ENSG00000171517 Lysophosphatidic acid receptor 3 1 84811602-84893213 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013421 Uncertain Supported Plasma membrane Ovarian cancer:4.31e-5 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 66.2 prostate: 21.5 LPAR6 P2RY5, P2Y5 ENSG00000139679 Lysophosphatidic acid receptor 6 13 48389567-48444704 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA028934, HPA076273 Approved Supported Vesicles
Plasma membrane Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable) Expressed in all Expressed in all placenta: 100.1 LPIN2 KIAA0249 ENSG00000101577 Lipin 2 18 2916994-3013315 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB015223, HPA017857, HPA030550 Supported Supported Plasma membrane
Actin filaments
Cytosol Head and neck cancer:8.01e-4 (favourable) Expressed in all Mixed liver: 86.9 LRCH2 KIAA1495 ENSG00000130224 Leucine-rich repeats and calponin homology (CH) domain containing 2 X 115110616-115234072 Predicted intracellular proteins Evidence at protein level HPA003233 Approved Approved Nucleoli
Plasma membrane Mixed Mixed prostate: 13.3 LRP12 FLJ12929, ST7 ENSG00000147650 Low density lipoprotein receptor-related protein 12 8 104489231-104589024 Predicted membrane proteins Evidence at protein level HPA017245 Uncertain Approved Nucleoli fibrillar center
Plasma membrane
Mitochondria Endometrial cancer:2.67e-4 (unfavourable) Expressed in all Mixed endometrium: 27.6 LRRC15 LIB ENSG00000172061 Leucine rich repeat containing 15 3 194355247-194369743 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035503 Uncertain Approved Vesicles
Plasma membrane Tissue enhanced Mixed cervix, uterine,tonsil: 4.7 LRRC17 H_RG318M05.3, P37NB ENSG00000128606 Leucine rich repeat containing 17 7 102912991-102944949 Predicted secreted proteins Evidence at protein level HPA030139 Uncertain Approved Nucleoplasm
Nuclear speckles
Plasma membrane Renal cancer:4.12e-6 (unfavourable), Urothelial cancer:6.30e-4 (unfavourable) Mixed Tissue enhanced ovary: 98.8 gallbladder: 46.9 LRRC26 bA350O14.10 ENSG00000184709 Leucine rich repeat containing 26 9 137168758-137170051 Predicted membrane proteins Evidence at protein level HPA056312 Approved Supported Plasma membrane Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable) Tissue enriched Group enriched 6 colon: 10.5;prostate: 29.3;salivary gland: 26.7 small intestine: 3.6 LRRC45 MGC20806 ENSG00000169683 Leucine rich repeat containing 45 17 82023302-82031151 Predicted intracellular proteins Evidence at protein level HPA023372, HPA023382, HPA024768 Supported Supported Nucleoplasm
Plasma membrane
Centrosome
Cytosol Renal cancer:1.54e-4 (unfavourable) Expressed in all Mixed fallopian tube: 8.2 LRRC69 ENSG00000214954 Leucine rich repeat containing 69 8 91101832-91219236 Predicted intracellular proteins Evidence at transcript level HPA046337 Uncertain Approved Plasma membrane Mixed Tissue enhanced testis: 5.2 skin: 2.0 LRRFIP2 HUFI-2 ENSG00000093167 Leucine rich repeat (in FLII) interacting protein 2 3 37052656-37183689 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035956, HPA042023 Uncertain Approved Plasma membrane
Actin filaments Cervical cancer:6.31e-4 (favourable) Expressed in all Expressed in all testis: 130.5 LRRIQ3 LRRC44, MGC22773 ENSG00000162620 Leucine-rich repeats and IQ motif containing 3 1 74026015-74198187 Predicted intracellular proteins Evidence at protein level HPA030799 Approved Supported Plasma membrane Not detected Tissue enriched 11 testis: 36.9 fallopian tube: 3.4 LSP1 WP34 ENSG00000130592 Lymphocyte-specific protein 1 11 1852970-1892267 Predicted intracellular proteins Evidence at protein level CAB017781, HPA019693, HPA071843 Supported Supported Plasma membrane Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable) Expressed in all Expressed in all spleen: 286.5 LSR ILDR3, LISCH7 ENSG00000105699 Lipolysis stimulated lipoprotein receptor 19 35248330-35267964 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007270 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.09e-4 (favourable) Expressed in all Expressed in all stomach: 131.1 LTB4R2 BLT2, BLTR2, JULF2, NOP9 ENSG00000213906 Leukotriene B4 receptor 2 14 24305734-24312053 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022689, HPA029680, HPA072921 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skin: 40.6 spleen: 11.2 LUZP2 ENSG00000187398 Leucine zipper protein 2 11 24496970-25082631 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039007, HPA046161 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Group enriched Group enriched 6 adrenal gland: 8.5;cerebral cortex: 33.1 prostate: 3.3 LY6K CT97, FLJ35226, HSJ001348 ENSG00000160886 Lymphocyte antigen 6 complex, locus K 8 142700111-142705127 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017770, CAB075742, CAB075743 Supported Supported Nucleoplasm
Plasma membrane Lung cancer:9.17e-5 (unfavourable) Mixed Tissue enriched 5 testis: 30.4 adipose tissue: 5.9 LYN JTK8 ENSG00000254087 LYN proto-oncogene, Src family tyrosine kinase 8 55879813-56014168 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001231, CAB004492 Supported Supported Golgi apparatus
Vesicles
Plasma membrane Renal cancer:3.43e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 163.6 appendix: 133.8 LZTS1 FEZ1 ENSG00000061337 Leucine zipper, putative tumor suppressor 1 8 20246165-20303963 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006294, HPA022046 Approved Approved Nucleoli
Plasma membrane Renal cancer:9.28e-6 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable) Expressed in all Tissue enriched 10 parathyroid gland: 123.3 cerebral cortex,testis: 12.4 LZTS2 KIAA1813, LAPSER1 ENSG00000107816 Leucine zipper, putative tumor suppressor 2 10 100996618-101007836 Predicted intracellular proteins Evidence at protein level HPA044956 Approved Approved Plasma membrane
Cytosol Renal cancer:3.39e-4 (unfavourable), Colorectal cancer:8.23e-4 (unfavourable) Expressed in all Expressed in all endometrium: 57.8 MACF1 ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF ENSG00000127603 Microtubule-actin crosslinking factor 1 1 39081316-39487177 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013713, HPA068064, HPA068103 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Renal cancer:2.77e-5 (favourable) Expressed in all Expressed in all lung: 137.3 MADD DENN, KIAA0358, RAB3GEP ENSG00000110514 MAP-kinase activating death domain 11 47269161-47330031 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038568 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.2 MAP2K1 MAPKK1, MEK1, PRKMK1 ENSG00000169032 Mitogen-activated protein kinase kinase 1 15 66386817-66492312 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003834, HPA026430 Approved Validated Plasma membrane
Cytosol Glioma:2.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.8 MAP2K7 Jnkk2, MKK7, PRKMK7 ENSG00000076984 Mitogen-activated protein kinase kinase 7 19 7903843-7914478 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001633, CAB004262, HPA064711 Supported Approved Golgi apparatus
Plasma membrane
Cytosol Head and neck cancer:8.54e-5 (favourable), Urothelial cancer:1.56e-4 (favourable) Expressed in all Expressed in all spleen: 19.5 MAP3K6 ASK2, MAPKKK6, MEKK6 ENSG00000142733 Mitogen-activated protein kinase kinase kinase 6 1 27355184-27366892 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051192 Approved Approved Nucleus
Plasma membrane
Actin filaments
Cytosol Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable) Expressed in all Tissue enhanced skin: 114.6 esophagus: 41.3 MAP4 ENSG00000047849 Microtubule-associated protein 4 3 47850690-48089272 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038149, HPA038150 Supported Supported Plasma membrane
Microtubules
Cytosol Liver cancer:1.82e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 242.6 MAP4K1 HPK1 ENSG00000104814 Mitogen-activated protein kinase kinase kinase kinase 1 19 38587641-38618882 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007419, CAB007754 Supported Uncertain Nucleoplasm
Plasma membrane Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable) Expressed in all Tissue enhanced lymph node: 37.7;spleen: 24.2;tonsil: 28.3 appendix: 19.9 MAP4K5 GCKR, KHS, KHS1 ENSG00000012983 Mitogen-activated protein kinase kinase kinase kinase 5 14 50418501-50561126 Predicted intracellular proteins Evidence at protein level HPA036696 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all endometrium: 54.9 MAP6 FLJ41346, KIAA1878, MAP6-N, STOP ENSG00000171533 Microtubule-associated protein 6 11 75586918-75669120 Predicted intracellular proteins Evidence at protein level CAB015442, CAB022600, HPA039061, HPA039062 Supported Uncertain Plasma membrane Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 68.4;fallopian tube: 64.7 parathyroid gland: 51.7 MAPK8IP1 IB1, JIP-1, JIP1, PRKM8IP ENSG00000121653 Mitogen-activated protein kinase 8 interacting protein 1 11 45885651-45906465 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058921, HPA070332 Supported Plasma membrane Renal cancer:1.23e-11 (favourable) Expressed in all Tissue enriched 5 cerebral cortex: 177.7 parathyroid gland: 32.6 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule-associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570 Supported Supported Nuclear speckles
Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.6 skeletal muscle: 13.7 MARCH10 FLJ35757, MARCH-X, RNF190 ENSG00000173838 Membrane-associated ring finger (C3HC4) 10, E3 ubiquitin protein ligase 17 62701314-62808344 Predicted intracellular proteins Evidence at protein level HPA023322 Supported Approved Plasma membrane
Cytosol Mixed Tissue enriched 7 testis: 145.2 fallopian tube: 20.2 MARCH7 AXOT, MARCH-VII, RNF177 ENSG00000136536 Membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein ligase 2 159712457-159771027 Predicted intracellular proteins Evidence at protein level HPA014275, HPA022152 Approved Supported Plasma membrane
Cytosol Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable) Expressed in all Expressed in all testis: 111.7 MARCKS 80K-L, MACS, PKCSL ENSG00000277443 Myristoylated alanine-rich protein kinase C substrate 6 113857362-113863471 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022062, HPA051913, HPA054820 Uncertain Approved Nucleoli
Plasma membrane
Cytosol Liver cancer:2.78e-8 (unfavourable), Renal cancer:4.85e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 219.4 MARK2 EMK1, PAR-1, PAR-1B, Par1b ENSG00000072518 MAP/microtubule affinity-regulating kinase 2 11 63838928-63911019 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038790, HPA074905 Approved Supported Nucleoplasm
Plasma membrane Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all skin: 46.2 MAS1L dJ994E9.2, MAS-L, MRG ENSG00000204687 MAS1 proto-oncogene like, G protein-coupled receptor 6 29486697-29487956 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA017983 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Not detected Tissue enhanced cervix, uterine: 5.1 epididymis: 2.3 MBP ENSG00000197971 Myelin basic protein 18 76978827-77133683 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002300, HPA049222, HPA064368 Supported Supported Approved Plasma membrane Renal cancer:4.48e-12 (favourable) Group enriched Tissue enriched 30 cerebral cortex: 2938.8 parathyroid gland: 97.8 MCAM CD146, MUC18 ENSG00000076706 Melanoma cell adhesion molecule 11 119308529-119321521 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002147, HPA008848 Supported Validated Plasma membrane Renal cancer:5.14e-4 (unfavourable), Cervical cancer:7.61e-4 (unfavourable) Expressed in all Mixed adipose tissue: 365.9 MCF2L2 ARHGEF22, KIAA0861 ENSG00000053524 MCF.2 cell line derived transforming sequence-like 2 3 183178043-183428778 Disease related genes, Predicted intracellular proteins Evidence at transcript level HPA038946, HPA038947 Uncertain Approved Plasma membrane
Cytosol Not detected Group enriched 8 adrenal gland: 10.3;cerebral cortex: 17.1;parathyroid gland: 7.4;spleen: 3.5;testis: 4.6 prostate: 1.0 MCOLN1 ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1 ENSG00000090674 Mucolipin 1 19 7522626-7534009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031763, CAB032637 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable) Expressed in all Expressed in all spleen: 49.0 MCTS1 MCT-1 ENSG00000232119 Malignant T cell amplified sequence 1 X 120594010-120621074 Predicted intracellular proteins Evidence at protein level HPA001045 Supported Plasma membrane
Cytosol Head and neck cancer:3.27e-5 (unfavourable), Renal cancer:4.35e-5 (unfavourable), Breast cancer:1.38e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 50.5 MDGA1 GPIM, MAMDC3 ENSG00000112139 MAM domain containing glycosylphosphatidylinositol anchor 1 6 37630679-37699306 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031235, HPA050382 Approved Supported Golgi apparatus
Plasma membrane Mixed Mixed parathyroid gland: 10.5 ME1 ENSG00000065833 Malic enzyme 1, NADP(+)-dependent, cytosolic 6 83210389-83431071 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006493 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 53.1 MEI1 MGC40042, SPATA38 ENSG00000167077 Meiotic double-stranded break formation protein 1 22 41699499-41799456 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA049240 Approved Uncertain Nucleoplasm
Plasma membrane Cervical cancer:1.59e-6 (favourable) Tissue enhanced Mixed testis: 18.7 MERTK c-Eyk, mer, RP38, Tyro12 ENSG00000153208 MER proto-oncogene, tyrosine kinase 2 111898479-112029561 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036196, HPA075622 Approved Approved Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable) Expressed in all Mixed adrenal gland: 77.4 MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Mixed placenta: 38.7 METAP1 KIAA0094, MAP1A, MetAP1A ENSG00000164024 Methionyl aminopeptidase 1 4 98995620-99062813 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025485, HPA037997, HPA037998 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable) Expressed in all Expressed in all testis: 76.9 METAP2 MAP2, MNPEP, p67 ENSG00000111142 Methionyl aminopeptidase 2 12 95473520-95515839 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013025, HPA019095 Supported Supported Plasma membrane
Cytosol Liver cancer:4.51e-6 (unfavourable) Expressed in all Expressed in all seminal vesicle: 141.9 METTL15 FLJ33979, METT5D1 ENSG00000169519 Methyltransferase like 15 11 28108248-28527041 Predicted intracellular proteins Evidence at protein level HPA039885 Approved Golgi apparatus
Plasma membrane
Actin filaments Renal cancer:7.95e-5 (favourable) Expressed in all Mixed parathyroid gland: 14.4 METTL25 C12orf26, FLJ22789 ENSG00000127720 Methyltransferase like 25 12 82358497-82479236 Predicted intracellular proteins Evidence at protein level HPA039534, HPA041207 Uncertain Uncertain Plasma membrane
Mitochondria
Cytosol Expressed in all Mixed testis: 13.3 MFAP1 ENSG00000140259 Microfibrillar-associated protein 1 15 43804492-43824802 Predicted intracellular proteins Evidence at protein level HPA042370 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.04e-9 (favourable), Liver cancer:2.50e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 49.6 MFAP3L KIAA0626, NYD-sp9 ENSG00000198948 Microfibrillar-associated protein 3-like 4 169986597-170033031 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017986, HPA077490 Approved Supported Plasma membrane Renal cancer:1.42e-8 (favourable) Expressed in all Tissue enhanced testis: 73.6 epididymis: 46.9 MFSD2A FLJ14490, MFSD2 ENSG00000168389 Major facilitator superfamily domain containing 2A 1 39955112-39969968 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043107 Uncertain Approved Plasma membrane
Cytosol
Cytoplasmic bodies Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable) Mixed Tissue enhanced epididymis: 114.6;seminal vesicle: 109.6 testis: 63.3 MIB1 DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6 ENSG00000101752 Mindbomb E3 ubiquitin protein ligase 1 18 21704957-21870957 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019100, CAB037044 Approved Approved Nuclear membrane
Vesicles
Plasma membrane Expressed in all Expressed in all thyroid gland: 24.1 MICAL3 KIAA0819 ENSG00000243156 Microtubule associated monooxygenase, calponin and LIM domain containing 3 22 17787649-18024559 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000639, HPA003421, HPA034882 Uncertain Validated Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 69.7 MICALCL FLJ14966 ENSG00000133808 MICAL C-terminal like 11 12276080-12359144 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039895, HPA040438 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enhanced skin: 17.3;testis: 13.3 lung: 10.3 MISP C19orf21, Caprice, DKFZp686H18209 ENSG00000099812 Mitotic spindle positioning 19 751126-764318 Predicted intracellular proteins Evidence at protein level HPA049511, HPA062232 Supported Validated Plasma membrane
Focal adhesion sites Tissue enhanced Group enriched 6 colon: 96.4;duodenum: 178.1;rectum: 53.5;small intestine: 221.5 stomach: 22.1 MKLN1 TWA2 ENSG00000128585 Muskelin 1, intracellular mediator containing kelch motifs 7 131110096-131496636 Predicted intracellular proteins Evidence at protein level HPA022817, HPA041810 Approved Approved Vesicles
Plasma membrane
Cytosol Expressed in all Expressed in all prostate: 25.2 MKRN3 D15S9, MGC88288, RNF63, ZFP127, ZNF127 ENSG00000179455 Makorin ring finger protein 3 15 23565678-23630075 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA029494 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Glioma:9.23e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 5.9;placenta: 4.1;testis: 3.7 epididymis: 1.1 MLF2 NTN4 ENSG00000089693 Myeloid leukemia factor 2 12 6747996-6767475 Predicted intracellular proteins Evidence at protein level HPA010811, HPA010859 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 273.3 MLLT4 AF-6, AF6 ENSG00000130396 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 4 6 167826922-167972023 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868 Approved Validated Nucleoplasm
Plasma membrane
Cell Junctions Breast cancer:7.43e-5 (unfavourable) Expressed in all Expressed in all esophagus: 111.1 MMACHC cblC, DKFZP564I122 ENSG00000132763 Methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria 1 45500053-45513382 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA027394, HPA027399, HPA027402 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Mixed liver: 8.9 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 (membrane-inserted) 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 69.9 duodenum: 39.8 MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 (membrane-inserted) 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli
Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.1 MOCS1 MOCOD ENSG00000124615 Molybdenum cofactor synthesis 1 6 39899578-39934551 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA045783, HPA058177, HPA075505 Uncertain Approved Plasma membrane
Cytosol Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable) Expressed in all Mixed placenta: 59.8 MPHOSPH8 HSMPP8, mpp8 ENSG00000196199 M-phase phosphoprotein 8 13 19633681-19673459 Predicted intracellular proteins Evidence at protein level HPA039701, HPA040035 Supported Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all ovary: 64.5 MPHOSPH9 MPP9 ENSG00000051825 M-phase phosphoprotein 9 12 123152320-123244014 Predicted intracellular proteins Evidence at protein level HPA037485 Approved Uncertain Nucleus
Plasma membrane
Cytosol Expressed in all Mixed testis: 22.5 MPI ENSG00000178802 Mannose phosphate isomerase 15 74890005-74902219 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007200 Approved Approved Plasma membrane
Cytosol Head and neck cancer:2.39e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 51.1 MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337807-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA007619 Uncertain Plasma membrane Not detected Tissue enhanced testis: 1.8 ovary: 1.3 MPP5 FLJ12615, PALS1 ENSG00000072415 Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) 14 67241109-67335819 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000993 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.71e-12 (favourable), Liver cancer:5.62e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 44.4 MPV17L2 FKSG24, MGC12972 ENSG00000254858 MPV17 mitochondrial membrane protein-like 2 19 18193182-18196948 Predicted membrane proteins Evidence at protein level HPA043111 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 16.2 MPZL1 FLJ21047, PZR ENSG00000197965 Myelin protein zero-like 1 1 167721192-167791919 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026966, HPA063538 Approved Supported Vesicles
Plasma membrane Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable) Expressed in all Expressed in all breast: 111.3 MR1 HLALS ENSG00000153029 Major histocompatibility complex, class I-related 1 181033425-181061938 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048304 Supported Plasma membrane Expressed in all Mixed thyroid gland: 28.1 MRGPRF GPR140, GPR168, MGC21621, mrgF ENSG00000172935 MAS-related GPR, member F 11 69004395-69013409 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028811 Approved Supported Nuclear membrane
Plasma membrane Expressed in all Mixed smooth muscle: 77.8 MRPL42 HSPC204, MRP-L31, MRPL31, MRPS32, PTD007, RPML31 ENSG00000198015 Mitochondrial ribosomal protein L42 12 93467488-93516213 Predicted intracellular proteins Evidence at protein level HPA039398 Approved Supported Plasma membrane
Mitochondria Liver cancer:7.49e-4 (unfavourable), Urothelial cancer:8.12e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 56.2 MRPL44 FLJ12701, FLJ13990 ENSG00000135900 Mitochondrial ribosomal protein L44 2 223957404-223967714 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038147, HPA038148 Approved Approved Nucleus
Plasma membrane
Mitochondria Liver cancer:1.29e-4 (unfavourable), Renal cancer:2.02e-4 (favourable) Expressed in all Expressed in all kidney: 37.2 MSN ENSG00000147065 Moesin X 65588377-65741931 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338 Supported Validated Plasma membrane Renal cancer:1.60e-5 (unfavourable) Expressed in all Expressed in all lung: 421.4 MTCP1 P13MTCP1, p8MTCP1 ENSG00000214827 Mature T-cell proliferation 1 X 155061622-155147937 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA032040 Approved Nucleoplasm
Plasma membrane Renal cancer:4.52e-8 (unfavourable) Mixed Mixed testis: 8.7 MTM1 ENSG00000171100 Myotubularin 1 X 150568619-150673322 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA010008, HPA010665 Approved Supported Plasma membrane Renal cancer:7.40e-7 (favourable) Expressed in all Mixed parathyroid gland: 26.8 MTMR1 ENSG00000063601 Myotubularin related protein 1 X 150692971-150765103 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002977, HPA018502 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Expressed in all Expressed in all parathyroid gland: 26.3 MTPN GCDP, MYOTROPHIN, V-1 ENSG00000105887 Myotrophin 7 135926761-135977353 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019735 Approved Approved Plasma membrane
Cytosol Liver cancer:1.19e-4 (unfavourable), Pancreatic cancer:3.05e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 194.2 MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM ENSG00000185499 Mucin 1, cell surface associated 1 155185824-155192916 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000036, CAB001986, HPA004179, HPA007235, HPA008855 Supported Validated Vesicles
Plasma membrane Pancreatic cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced lung: 447.5;stomach: 650.2 cervix, uterine: 286.5 MUC20 FLJ14408, KIAA1359 ENSG00000176945 Mucin 20, cell surface associated 3 195720882-195741123 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042249 Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.57e-4 (favourable) Mixed Mixed colon: 10.9 MYB c-myb ENSG00000118513 V-myb avian myeloblastosis viral oncogene homolog 6 135181315-135219173 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017704 Approved Approved Nucleus
Plasma membrane Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable) Tissue enhanced Tissue enhanced breast: 25.9;rectum: 29.6 colon: 25.7 MYH11 SMHC, SMMHC ENSG00000133392 Myosin, heavy chain 11, smooth muscle 16 15703135-15857033 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002302, HPA014539, HPA015310 Supported Approved Plasma membrane
Cytosol Liver cancer:1.10e-5 (favourable) Tissue enhanced Tissue enhanced seminal vesicle: 1365.9;smooth muscle: 1008.5 prostate: 841.6 MYH9 DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA ENSG00000100345 Myosin, heavy chain 9, non-muscle 22 36281281-36388018 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001644, CAB015386 Supported Approved Plasma membrane
Actin filaments
Cytosol Expressed in all Expressed in all spleen: 313.7 MYL4 ALC1, AMLC, GT1, PRO1957 ENSG00000198336 Myosin, light chain 4, alkali; atrial, embryonic 17 47200446-47223679 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046859, HPA051884, HPA063034 Supported Approved Plasma membrane Group enriched Tissue enriched 28 heart muscle: 2225.0 bone marrow: 80.1 MYO10 KIAA0799 ENSG00000145555 Myosin X 5 16661914-16936276 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015224, HPA024223 Supported Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:2.75e-4 (favourable), Cervical cancer:4.35e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 68.5 MYO1B myr1 ENSG00000128641 Myosin IB 2 191245185-191425389 Predicted intracellular proteins Evidence at protein level HPA013607, HPA060144 Approved Validated Plasma membrane Renal cancer:2.36e-5 (unfavourable) Expressed in all Mixed liver: 130.2 MYO1C myr2 ENSG00000197879 Myosin IC 17 1464098-1492812 Predicted intracellular proteins, Transporters Evidence at protein level HPA001768, HPA005924, CAB037023 Supported Validated Nuclear bodies
Plasma membrane Lung cancer:5.22e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 191.9 MYO3A DFNB30 ENSG00000095777 Myosin IIIA 10 25934267-26212527 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048951, HPA051893 Approved Supported Plasma membrane
Actin filaments
Cytoplasmic bodies Mixed Tissue enriched 9 testis: 6.8 skin: 0.8 MYO5B KIAA1119 ENSG00000167306 Myosin VB 18 49822813-50195093 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040593, HPA040902, HPA069773 Supported Approved Plasma membrane Renal cancer:1.45e-11 (favourable), Pancreatic cancer:2.26e-5 (unfavourable) Expressed in all Mixed small intestine: 69.4 MYO9A FLJ11061, FLJ13244, MGC71859 ENSG00000066933 Myosin IXA 15 71822289-72118577 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039812, HPA040071 Approved Approved Plasma membrane Renal cancer:2.14e-4 (favourable) Mixed Tissue enhanced testis: 51.3 thyroid gland: 22.1 MYOF FER1L3, KIAA1207 ENSG00000138119 Myoferlin 10 93306429-93482317 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014245 Approved Supported Vesicles
Plasma membrane Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 100.7 MYSM1 KIAA1915 ENSG00000162601 Myb-like, SWIRM and MPN domains 1 1 58654739-58700092 Enzymes, Predicted intracellular proteins Evidence at protein level HPA054291, HPA067133 Approved Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.09e-5 (favourable) Expressed in all Mixed skin: 11.1 N4BP2 B3BP ENSG00000078177 NEDD4 binding protein 2 4 40056826-40158252 Predicted intracellular proteins Evidence at protein level HPA036770, HPA042607 Approved Approved Nucleoplasm
Plasma membrane
Centrosome Expressed in all Mixed endometrium,thyroid gland: 5.5 N6AMT2 ENSG00000150456 N-6 adenine-specific DNA methyltransferase 2 (putative) 13 20728731-20773958 Predicted intracellular proteins Evidence at protein level HPA040417, HPA042543 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.82e-4 (favourable) Expressed in all Expressed in all endometrium: 18.0 NAB1 ENSG00000138386 NGFI-A binding protein 1 (EGR1 binding protein 1) 2 190646746-190692766 Predicted intracellular proteins Evidence at protein level HPA002738 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Pancreatic cancer:1.01e-4 (unfavourable) Expressed in all Expressed in all skin: 80.7 NAIF1 bA379C10.2, C9orf90, DKFZp762G199 ENSG00000171169 Nuclear apoptosis inducing factor 1 9 128061233-128068206 Predicted intracellular proteins Evidence at protein level HPA054898 Supported Nucleoplasm
Plasma membrane Pancreatic cancer:1.02e-5 (favourable), Renal cancer:8.30e-5 (favourable), Liver cancer:1.61e-4 (unfavourable) Expressed in all Mixed testis: 4.6 NAP1L2 BPX, MGC26243 ENSG00000186462 Nucleosome assembly protein 1-like 2 X 73212299-73214848 Predicted intracellular proteins Evidence at protein level HPA054050, HPA057065 Validated Vesicles
Plasma membrane
Cytosol Pancreatic cancer:5.41e-4 (favourable) Mixed Tissue enriched 5 cerebral cortex: 90.3 parathyroid gland: 17.6 NAPG ENSG00000134265 N-ethylmaleimide-sensitive factor attachment protein, gamma 18 10525905-10552761 Predicted intracellular proteins Evidence at protein level HPA008208, HPA011389 Approved Approved Plasma membrane
Cytosol Renal cancer:8.14e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 50.6 NARFL FLJ21988, HPRN, IOP1, PRN ENSG00000103245 Nuclear prelamin A recognition factor-like 16 729753-741329 Predicted intracellular proteins Evidence at protein level HPA040851 Approved Approved Plasma membrane
Cytosol Cervical cancer:1.32e-5 (favourable), Renal cancer:9.83e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 19.4 NCAM1 CD56, NCAM ENSG00000149294 Neural cell adhesion molecule 1 11 112961247-113278436 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000142, CAB018071, HPA039835 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 335.9 adrenal gland: 87.0 NCAM2 MGC51008, NCAM21 ENSG00000154654 Neural cell adhesion molecule 2 21 20998315-21543329 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030900, HPA030901 Approved Supported Nuclear bodies
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 69.0 adrenal gland: 15.9 NCK1 NCK, NCKalpha ENSG00000158092 NCK adaptor protein 1 3 136862208-136949823 Predicted intracellular proteins Evidence at protein level CAB005063, HPA030766 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.14e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable) Expressed in all Expressed in all lymph node: 49.5 NCKAP1L HEM1 ENSG00000123338 NCK-associated protein 1-like 12 54497711-54548238 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA039490, HPA040772 Approved Uncertain Plasma membrane
Cytosol Expressed in all Mixed spleen: 55.8 NCKAP5 ERIH1, ERIH2, NAP5 ENSG00000176771 NCK-associated protein 5 2 132671799-133568463 Predicted intracellular proteins Evidence at protein level HPA034639, HPA044859 Uncertain Approved Nucleoli
Golgi apparatus
Plasma membrane
Cytosol Mixed Tissue enhanced lung: 14.2 cerebral cortex: 4.1 NCKIPSD AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH ENSG00000213672 NCK interacting protein with SH3 domain 3 48673844-48686364 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019267, HPA050005 Validated Plasma membrane
Cytosol Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 300.2 cerebral cortex: 35.1 NCOA1 bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1 ENSG00000084676 Nuclear receptor coactivator 1 2 24491914-24770702 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019402, HPA070213, HPA070520 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 58.0 NCS1 FREQ, NCS-1 ENSG00000107130 Neuronal calcium sensor 1 9 130172578-130237304 Predicted intracellular proteins Evidence at protein level CAB018587, HPA019713 Approved Validated Plasma membrane Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 178.6 seminal vesicle: 91.2 NDC1 FLJ10407, NET3, TMEM48 ENSG00000058804 NDC1 transmembrane nucleoporin 1 53765460-53838860 Predicted membrane proteins, Transporters Evidence at protein level HPA069751, HPA070882 Approved Supported Nuclear membrane
Plasma membrane
Actin filaments Liver cancer:7.52e-7 (unfavourable), Colorectal cancer:4.48e-5 (favourable), Pancreatic cancer:3.58e-4 (unfavourable) Expressed in all Mixed lymph node: 16.6 NEDD9 CAS-L, CASS2, HEF1 ENSG00000111859 Neural precursor cell expressed, developmentally down-regulated 9 6 11183298-11382348 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009720, HPA038768, HPA039270 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all lung: 109.7 NEO1 HsT17534, IGDCC2, NGN, NTN1R2 ENSG00000067141 Neogenin 1 15 73051710-73305206 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009320, HPA027804, HPA027805, HPA027806 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Renal cancer:4.39e-4 (favourable) Expressed in all Mixed parathyroid gland: 100.9 NF2 merlin ENSG00000186575 Neurofibromin 2 (merlin) 22 29603556-29698598 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003097, CAB005385 Supported Validated Nucleus
Plasma membrane
Cytosol Renal cancer:2.89e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 57.6 NFE2L2 NRF2 ENSG00000116044 Nuclear factor, erythroid 2-like 2 2 177227595-177392697 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002990, CAB020317, HPA043438 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:2.26e-4 (favourable) Expressed in all Expressed in all esophagus: 267.9 NGEF ARHGEF27 ENSG00000066248 Neuronal guanine nucleotide exchange factor 2 232878686-233013272 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008160 Approved Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced adrenal gland: 66.8;cerebral cortex: 151.9 duodenum: 44.0 NGFR CD271, p75NTR, TNFRSF16 ENSG00000064300 Nerve growth factor receptor 17 49495293-49515017 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB000143, CAB001995, HPA004765 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:3.40e-4 (unfavourable) Expressed in all Mixed adipose tissue: 32.2 NID2 ENSG00000087303 Nidogen 2 (osteonidogen) 14 52004803-52069228 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA052460, HPA058772 Supported Supported Plasma membrane Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 87.4 thyroid gland: 53.5 NKTR p104 ENSG00000114857 Natural killer cell triggering receptor 3 42600614-42648741 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022120, HPA051576 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.05e-5 (favourable), Head and neck cancer:1.26e-4 (favourable), Renal cancer:5.02e-4 (unfavourable), Prostate cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all testis: 24.3 NKX2-8 Nkx2-9, NKX2.8, NKX2H ENSG00000136327 NK2 homeobox 8 14 36580579-36582607 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA062879 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enhanced testis: 3.1 lung: 0.6 NLGN1 KIAA1070 ENSG00000169760 Neuroligin 1 3 173396284-174286644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006572, HPA006680 Approved Uncertain Nuclear bodies
Plasma membrane Group enriched Tissue enhanced cerebral cortex: 25.5 testis: 12.5 NLRX1 CLR11.3, NOD9 ENSG00000160703 NLR family member X1 11 119166568-119184016 Predicted intracellular proteins Evidence at protein level HPA061516 Supported Supported Plasma membrane
Cell Junctions
Mitochondria Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable) Expressed in all Expressed in all esophagus: 37.9 NMB MGC17211, MGC2277, MGC3936 ENSG00000197696 Neuromedin B 15 84655129-84658563 Predicted secreted proteins Evidence at protein level CAB019302 Approved Approved Nucleus
Vesicles
Plasma membrane Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 46.1;cerebral cortex: 47.3 thyroid gland: 14.7 NMBR BB1 ENSG00000135577 Neuromedin B receptor 6 142058330-142088799 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA026665 Supported Plasma membrane
Cytosol Not detected Group enriched 5 fallopian tube: 1.3;testis: 2.6 cerebral cortex: 0.3 NMT1 NMT ENSG00000136448 N-myristoyltransferase 1 17 45051610-45109016 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022949, HPA022963 Supported Supported Plasma membrane
Cytosol Liver cancer:4.94e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 58.8 NMT2 ENSG00000152465 N-myristoyltransferase 2 10 15102584-15168693 Enzymes, Predicted intracellular proteins Evidence at protein level HPA001303 Approved Supported Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 39.2 NOS1 nNOS, NOS ENSG00000089250 Nitric oxide synthase 1 (neuronal) 12 117208142-117452170 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002167, HPA058312 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skeletal muscle: 12.9 cerebral cortex: 3.0 NOTCH2 ENSG00000134250 Notch 2 1 119911553-120069626 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046392, HPA048743 Uncertain Supported Nucleoplasm
Plasma membrane Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 46.5 NPFFR2 GPR74, NPFF2, NPGPR ENSG00000056291 Neuropeptide FF receptor 2 4 72031804-72148067 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026825 Approved Plasma membrane
Actin filaments Mixed Tissue enhanced placenta: 2.3;seminal vesicle: 4.5 epididymis: 1.1 NPL C1orf13, DHDPS1, NPL1 ENSG00000135838 N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 1 182789293-182830384 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028345 Approved Vesicles
Plasma membrane Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable) Expressed in all Mixed placenta: 63.2 NPR1 ANPa, ANPRA, GUCY2A, NPRA ENSG00000169418 Natriuretic peptide receptor 1 1 153678637-153693992 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA031087 Approved Nucleus
Nucleoli
Plasma membrane Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 71.8;fallopian tube: 57.6 placenta: 25.2 NPTXR ENSG00000221890 Neuronal pentraxin receptor 22 38818452-38843982 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001079 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:2.85e-4 (unfavourable), Cervical cancer:3.93e-4 (favourable) Expressed in all Tissue enriched 14 cerebral cortex: 177.0 fallopian tube: 13.0 NRP2 VEGF165R2 ENSG00000118257 Neuropilin 2 2 205681990-205798133 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039980, HPA054974 Approved Supported Vesicles
Plasma membrane Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable) Expressed in all Mixed smooth muscle: 83.5 NSD1 ARA267, FLJ22263, KMT3B, STO ENSG00000165671 Nuclear receptor binding SET domain protein 1 5 177133025-177300215 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048431, HPA070333 Supported Nucleus
Plasma membrane Expressed in all Expressed in all testis: 43.2 NSFL1C dJ776F14.1, p47, UBX1, UBXD10, UBXN2C ENSG00000088833 NSFL1 (p97) cofactor (p47) 20 1442162-1473842 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047108, HPA050628 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.29e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 35.2 NT5E CALJA, CD73, eN, eNT, NT5 ENSG00000135318 5'-nucleotidase, ecto (CD73) 6 85449584-85495791 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017357 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 171.7 smooth muscle: 104.9 NTNG1 KIAA0976, Lmnt1 ENSG00000162631 Netrin G1 1 107140007-107483458 Predicted secreted proteins Evidence at protein level HPA065954 Supported Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.6 seminal vesicle: 6.6 NTSR1 NTR ENSG00000101188 Neurotensin receptor 1 (high affinity) 20 62708837-62762771 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA050299 Supported Plasma membrane Tissue enhanced Not detected cerebral cortex: 0.5 NUDCD3 KIAA1068 ENSG00000015676 NudC domain containing 3 7 44379121-44490880 Predicted intracellular proteins Evidence at protein level HPA019136, HPA019528, HPA019529 Approved Approved Nucleus
Plasma membrane
Cytosol Renal cancer:9.16e-4 (favourable) Expressed in all Mixed cerebral cortex: 12.4 NUDT16L1 SDOS ENSG00000168101 Nudix (nucleoside diphosphate linked moiety X)-type motif 16-like 1 16 4693694-4695859 Predicted intracellular proteins Evidence at protein level HPA044186, HPA063605 Approved Approved Plasma membrane
Cytosol Renal cancer:1.02e-6 (favourable), Lung cancer:2.79e-4 (favourable) Expressed in all Expressed in all prostate: 28.4 NUP35 MP44 ENSG00000163002 Nucleoporin 35kDa 2 183117513-183161680 Predicted intracellular proteins, Transporters Evidence at protein level HPA018401, HPA018410, HPA018441 Supported Supported Nucleoplasm
Nuclear membrane
Plasma membrane Ovarian cancer:3.45e-4 (favourable), Liver cancer:5.02e-4 (unfavourable) Expressed in all Expressed in all testis: 44.7 NUP58 KIAA0410, NUP45, NUPL1 ENSG00000139496 Nucleoporin 58kDa 13 25301524-25349800 Predicted intracellular proteins, Transporters Evidence at protein level HPA039360 Approved Approved Plasma membrane
Mitochondria
Cytosol Cervical cancer:2.57e-4 (unfavourable), Liver cancer:3.56e-4 (unfavourable) Expressed in all Expressed in all testis: 86.6 NUS1 C6orf68, MGC7199, NgBR, TANGO14 ENSG00000153989 NUS1 dehydrodolichyl diphosphate synthase subunit 6 117675502-117710640 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027504 Supported Approved Vesicles
Plasma membrane Cervical cancer:6.99e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 91.7 OAS3 ENSG00000111331 2'-5'-oligoadenylate synthetase 3, 100kDa 12 112938352-112973249 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041253, HPA041372 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.23e-5 (unfavourable) Expressed in all Mixed spleen: 34.0 OBSCN ARHGEF30, KIAA1556, KIAA1639, UNC89 ENSG00000154358 Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 1 228208130-228378876 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019497, HPA021186 Approved Approved Plasma membrane
Cytosol Endometrial cancer:1.64e-4 (unfavourable) Mixed Tissue enriched 6 skeletal muscle: 249.2 heart muscle: 38.3 OCLN PPP1R115 ENSG00000197822 Occludin 5 69492292-69558104 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005933, CAB013075, CAB068212, CAB068213, CAB068214 Supported Supported Plasma membrane
Cell Junctions Renal cancer:6.59e-11 (favourable) Mixed Tissue enhanced thyroid gland: 78.3 lung: 39.9 ODC1 ODC ENSG00000115758 Ornithine decarboxylase 1 2 10439968-10448504 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001536, CAB035996 Approved Approved Plasma membrane
Cytosol Liver cancer:3.07e-5 (unfavourable) Expressed in all Expressed in all testis: 240.7 OGT FLJ23071, HRNT1, MGC22921, O-GLCNAC ENSG00000147162 O-linked N-acetylglucosamine (GlcNAc) transferase X 71533083-71575897 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA030751, HPA030752, HPA030753, HPA030754, CAB034099 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable) Expressed in all Expressed in all spleen: 84.4 OLIG2 BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17 ENSG00000205927 Oligodendrocyte lineage transcription factor 2 21 33025845-33029196 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003254, CAB019381 Supported Uncertain Nucleoplasm
Plasma membrane Tissue enriched Tissue enriched 239 cerebral cortex: 91.2 duodenum: 0.3 OLR1 CLEC8A, LOX-1, SCARE1 ENSG00000173391 Oxidized low density lipoprotein (lectin-like) receptor 1 12 10158301-10172138 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050798 Supported Nucleoplasm
Vesicles
Plasma membrane Head and neck cancer:8.24e-5 (unfavourable) Expressed in all Group enriched 6 appendix: 42.1;cerebral cortex: 32.8;lung: 146.2;placenta: 159.6 bone marrow: 15.8 OPHN1 ARHGAP41, MRX60, OPN1 ENSG00000079482 Oligophrenin 1 X 68042344-68433913 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002919 Approved Approved Nucleus
Plasma membrane Mixed Mixed cerebral cortex: 20.3 OR2C3 OR2C4, OR2C5P, OST742 ENSG00000196242 Olfactory receptor, family 2, subfamily C, member 3 1 247530132-247533839 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA053920, HPA058578 Uncertain Supported Plasma membrane Not detected Expressed in all parathyroid gland: 26.6 OR8S1 ENSG00000197376 Olfactory receptor, family 8, subfamily S, member 1 12 48507354-48529897 G-protein coupled receptors, Predicted membrane proteins No evidence HPA045595 Uncertain Approved Plasma membrane Not detected Not detected breast,testis: 0.1 ORC1 HSORC1, ORC1L, PARC1 ENSG00000085840 Origin recognition complex, subunit 1 1 52372829-52404459 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA027450 Approved Approved Nucleus
Plasma membrane
Cytosol Colorectal cancer:1.74e-5 (favourable), Liver cancer:3.22e-5 (unfavourable), Melanoma:3.69e-4 (unfavourable) Mixed Tissue enhanced bone marrow: 18.0 lymph node: 8.0 OSBPL10 ENSG00000144645 Oxysterol binding protein-like 10 3 31657890-32077580 Predicted intracellular proteins Evidence at protein level HPA003636 Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.51e-4 (favourable), Pancreatic cancer:3.14e-4 (unfavourable), Urothelial cancer:4.85e-4 (unfavourable) Mixed Mixed testis: 31.7 OSBPL6 ORP6 ENSG00000079156 Oxysterol binding protein-like 6 2 178194481-178402891 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032131 Supported Approved Plasma membrane Mixed Tissue enhanced cerebral cortex: 15.5 skin: 9.2 OSCP1 C1orf102, NOR1 ENSG00000116885 Organic solute carrier partner 1 1 36415827-36450451 Predicted intracellular proteins, Transporters Evidence at protein level HPA028436, HPA052655 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Renal cancer:2.18e-6 (favourable), Endometrial cancer:6.88e-4 (favourable) Expressed in all Expressed in all testis: 126.0 OSGEP GCPL1, KAE1, OSGEP1, PRSMG1 ENSG00000092094 O-sialoglycoprotein endopeptidase 14 20446411-20455105 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039751 Uncertain Supported Nucleoplasm
Plasma membrane Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable) Expressed in all Mixed thyroid gland: 12.7 OSR2 FLJ90037 ENSG00000164920 Odd-skipped related transciption factor 2 8 98944403-98952104 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052425, HPA063486 Uncertain Approved Nucleus
Plasma membrane Head and neck cancer:2.44e-5 (favourable) Mixed Tissue enhanced endometrium: 204.6;fallopian tube: 143.0 ovary: 102.5 OTULIN FAM105B, FLJ34884 ENSG00000154124 OTU deubiquitinase with linear linkage specificity 5 14664664-14699711 Enzymes, Predicted intracellular proteins Evidence at protein level HPA051074 Uncertain Approved Plasma membrane
Mitochondria Renal cancer:2.59e-7 (unfavourable) Expressed in all Expressed in all bone marrow: 17.2 OXGR1 aKGR, GPR80, GPR99, P2RY15, P2Y15 ENSG00000165621 Oxoglutarate (alpha-ketoglutarate) receptor 1 13 96985719-96994730 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA067673 Supported Plasma membrane Mixed Mixed breast: 5.2 PACSIN2 SDPII ENSG00000100266 Protein kinase C and casein kinase substrate in neurons 2 22 42835412-43015145 Predicted intracellular proteins Evidence at protein level HPA049854, HPA056520 Supported Supported Nuclear speckles
Vesicles
Plasma membrane
Cytosol Renal cancer:1.09e-13 (favourable), Liver cancer:7.33e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 95.8 PACSIN3 SDPIII ENSG00000165912 Protein kinase C and casein kinase substrate in neurons 3 11 47177525-47186443 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039480, HPA043904 Approved Supported Plasma membrane
Cytosol Ovarian cancer:2.09e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 164.2 heart muscle: 89.5 PAFAH1B2 ENSG00000168092 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) 11 117144267-117176894 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA051836 Approved Supported Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 68.4 PAG1 CBP, PAG ENSG00000076641 Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 8 80967810-81112068 Predicted intracellular proteins Evidence at protein level HPA001632, HPA066527 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable) Expressed in all Mixed placenta: 22.8 PAIP1 ENSG00000172239 Poly(A) binding protein interacting protein 1 5 43526267-43557758 Predicted intracellular proteins Evidence at protein level HPA076187 Approved Plasma membrane
Cytosol Pancreatic cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all testis: 152.3 PAK1 ENSG00000149269 P21 protein (Cdc42/Rac)-activated kinase 1 11 77321707-77474635 Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003565, CAB005312 Supported Supported Validated Plasma membrane
Cytosol Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 186.8 PAK4 ENSG00000130669 P21 protein (Cdc42/Rac)-activated kinase 4 19 39125770-39182816 Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB025747, CAB044670, HPA070175, HPA072220 Uncertain Supported Plasma membrane
Cell Junctions Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all prostate: 42.2 PALLD CGI-151, KIAA0992, SIH002 ENSG00000129116 Palladin, cytoskeletal associated protein 4 168497066-168928457 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA035905 Supported Plasma membrane
Actin filaments
Cytosol Urothelial cancer:3.28e-4 (unfavourable) Expressed in all Mixed endometrium: 441.6 PALM KIAA0270 ENSG00000099864 Paralemmin 19 708939-748329 Predicted intracellular proteins Evidence at protein level HPA041713, HPA049578 Approved Validated Nucleus
Plasma membrane Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 85.1 adipose tissue: 52.9 PALM2 ENSG00000243444 Paralemmin 2 9 109640788-109946703 Predicted intracellular proteins Evidence at protein level HPA074153 Approved Plasma membrane Not detected Tissue enhanced cerebral cortex: 9.8 liver: 3.5 PALM2-AKAP2 ENSG00000157654 PALM2-AKAP2 readthrough 9 109780309-110172512 Predicted intracellular proteins Evidence at protein level HPA058905, HPA074153 Uncertain Uncertain Plasma membrane Not detected Tissue enhanced adipose tissue: 23.3 heart muscle: 19.1 PALM3 ENSG00000187867 Paralemmin 3 19 14053365-14059159 Predicted intracellular proteins Evidence at protein level HPA052794, HPA056119 Approved Approved Nucleoplasm
Nuclear bodies
Plasma membrane Endometrial cancer:7.87e-4 (unfavourable) Mixed Mixed kidney: 15.8 PALMD C1orf11, FLJ20271, PALML ENSG00000099260 Palmdelphin 1 99645943-99694541 Predicted intracellular proteins Evidence at protein level HPA017959, HPA030549 Approved Supported Plasma membrane
Actin filaments
Focal adhesion sites Head and neck cancer:5.90e-5 (favourable), Endometrial cancer:9.42e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 140.7 placenta: 60.0 PANX1 MRS1, PX1, UNQ2529 ENSG00000110218 Pannexin 1 11 94128928-94181972 Predicted membrane proteins, Transporters Evidence at protein level HPA016930 Uncertain Validated Plasma membrane Renal cancer:1.49e-7 (unfavourable), Lung cancer:7.09e-5 (unfavourable), Endometrial cancer:1.13e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex,testis: 19.4 PANX2 hPANX2, PX2 ENSG00000073150 Pannexin 2 22 50170731-50180294 Predicted membrane proteins, Transporters Evidence at transcript level HPA004624, HPA039117 Approved Approved Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.7 seminal vesicle: 2.1 PAPPA ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1 ENSG00000182752 Pregnancy-associated plasma protein A, pappalysin 1 9 116153804-116402322 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001667, CAB016724 Supported Uncertain Plasma membrane
Cytosol Mixed Tissue enriched 7 placenta: 103.9 parathyroid gland: 14.6 PAQR8 C6orf33, LMPB1, MPRB ENSG00000170915 Progestin and adipoQ receptor family member VIII 6 52361421-52407777 Predicted membrane proteins Evidence at protein level HPA064625 Supported Golgi apparatus
Plasma membrane Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable) Expressed in all Mixed cerebral cortex: 65.1 PARD6G PAR-6G, PAR6gamma ENSG00000178184 Par-6 family cell polarity regulator gamma 18 80157232-80247546 Predicted intracellular proteins Evidence at protein level HPA047017 Uncertain Approved Plasma membrane Liver cancer:3.19e-4 (unfavourable) Expressed in all Tissue enhanced skin: 45.0 thyroid gland: 30.1 PARP6 pART17 ENSG00000137817 Poly (ADP-ribose) polymerase family, member 6 15 72241181-72272999 Enzymes, Predicted intracellular proteins Evidence at protein level HPA026991 Approved Approved Plasma membrane Renal cancer:8.02e-8 (unfavourable), Cervical cancer:3.17e-5 (favourable), Colorectal cancer:3.37e-4 (unfavourable) Expressed in all Expressed in all testis: 46.7 PAWR par-4, PAR4 ENSG00000177425 PRKC, apoptosis, WT1, regulator 12 79574979-79691097 Predicted intracellular proteins Evidence at protein level HPA012640, CAB020779 Approved Validated Plasma membrane
Actin filaments Expressed in all Mixed endometrium: 45.3 PCBD2 DCOH2, DCOHM ENSG00000132570 Pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 2 5 134904906-135007959 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036428 Uncertain Approved Plasma membrane Expressed in all Expressed in all parathyroid gland: 16.0 PCDH17 PCDH68, PCH68 ENSG00000118946 Protocadherin 17 13 57631810-57729311 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026817 Uncertain Approved Vesicles
Plasma membrane
Cytosol Renal cancer:3.31e-5 (unfavourable) Mixed Tissue enhanced cerebral cortex: 25.8;spleen: 34.3 lung: 18.3 PCDH7 BH-Pcdh, PPP1R120 ENSG00000169851 Protocadherin 7 4 30720415-31146805 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011866, HPA046521 Uncertain Validated Plasma membrane
Cell Junctions Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.1 PCDHA1 ENSG00000204970 Protocadherin alpha 1 5 140786136-141012347 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA035969 Approved Approved Plasma membrane Not detected Tissue enhanced cerebral cortex: 2.8;testis: 1.6 adrenal gland: 0.4 PCDHA4 CNR1, CNRN1, CRNR1, PCDH-ALPHA4 ENSG00000204967 Protocadherin alpha 4 5 140806929-141012344 Predicted membrane proteins Evidence at protein level HPA043180, HPA073478 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Not detected Tissue enhanced cerebral cortex: 4.4 gallbladder: 2.6 PCDHB10 ENSG00000120324 Protocadherin beta 10 5 141182560-141195642 Predicted membrane proteins Evidence at protein level HPA013445, HPA014668, HPA029441 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.3 endometrium: 5.1 PCDHB11 ME2, PCDH-BETA11 ENSG00000197479 Protocadherin beta 11 5 141199582-141203779 Predicted membrane proteins Evidence at transcript level HPA045042 Uncertain Approved Plasma membrane Mixed Tissue enhanced parathyroid gland: 8.1 endometrium: 2.5 PCDHB12 PCDH-BETA12 ENSG00000120328 Protocadherin beta 12 5 141208697-141212571 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA045042 Uncertain Approved Plasma membrane Mixed Mixed endometrium: 3.6 PCDHB16 KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a ENSG00000272674 Protocadherin beta 16 5 141181399-141186399 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014668 Supported Vesicles
Plasma membrane Mixed Mixed parathyroid gland: 10.6 PCDHB4 PCDH-BETA4 ENSG00000081818 Protocadherin beta 4 5 141121799-141125623 Predicted membrane proteins Evidence at transcript level HPA014466 Approved Uncertain Plasma membrane
Intermediate filaments
Cytosol Mixed Mixed endometrium: 8.9 PCDHB6 PCDH-BETA6 ENSG00000113211 Protocadherin beta 6 5 141150022-141153287 Predicted membrane proteins Evidence at transcript level HPA029566 Uncertain Uncertain Nucleus
Plasma membrane
Cytosol Renal cancer:5.52e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 7.1 testis: 3.5 PCDHGA7 PCDH-GAMMA-A7 ENSG00000253537 Protocadherin gamma subfamily A, 7 5 141382739-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077995 Uncertain Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 7.4 thyroid gland: 3.2 PCDHGB1 PCDH-GAMMA-B1 ENSG00000254221 Protocadherin gamma subfamily B, 1 5 141350102-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA076182 Uncertain Approved Plasma membrane
Focal adhesion sites
Midbody Mixed Tissue enriched 12 cerebral cortex: 23.8 endometrium: 2.0 PCDHGC3 PC-43, PC43, PCDH-GAMMA-C3, PCDH2 ENSG00000240184 Protocadherin gamma subfamily C, 3 5 141475947-141512979 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008755, HPA077289 Approved Approved Plasma membrane Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 377.1 cervix, uterine: 93.4 PCLO ACZ, DKFZp779G1236, KIAA0559 ENSG00000186472 Piccolo presynaptic cytomatrix protein 7 82754013-83162930 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015858, HPA029579 Approved Approved Nuclear speckles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 17.5 parathyroid gland: 9.6 PCMTD1 FLJ10883 ENSG00000168300 Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 8 51817575-51899186 Predicted intracellular proteins Evidence at protein level HPA025696, HPA061444 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all parathyroid gland: 184.0 PDAP1 HASPP28, PAP, PAP1 ENSG00000106244 PDGFA associated protein 1 7 99392048-99408829 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021103, HPA050294, HPA060836 Approved Validated Plasma membrane
Cytosol Liver cancer:6.67e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 37.3 PDCD7 ES18, HES18 ENSG00000090470 Programmed cell death 7 15 65117379-65133836 Predicted intracellular proteins Evidence at protein level HPA049388 Approved Approved Nucleoli
Plasma membrane Renal cancer:1.00e-4 (unfavourable) Expressed in all Expressed in all testis: 30.7 PDE4A DPDE2 ENSG00000065989 Phosphodiesterase 4A, cAMP-specific 19 10416773-10469631 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB017632, HPA043310, HPA076091 Uncertain Supported Plasma membrane Expressed in all Mixed parathyroid gland: 33.4 PDE4D DPDE3 ENSG00000113448 Phosphodiesterase 4D, cAMP-specific 5 58969038-60522120 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA045895 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Renal cancer:4.00e-5 (favourable) Mixed Mixed bone marrow: 46.6 PDGFC fallotein, SCDGF ENSG00000145431 Platelet derived growth factor C 4 156760454-156971394 Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA009134 Approved Supported Plasma membrane
Cytosol Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 39.8 endometrium: 16.7 PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet-derived growth factor receptor, alpha polypeptide 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus
Plasma membrane
Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.0 PDHX DLDBP, E3BP, OPDX, PDX1, proX ENSG00000110435 Pyruvate dehydrogenase complex, component X 11 34915829-35020591 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038484, HPA038485 Supported Approved Nucleus
Plasma membrane
Mitochondria Renal cancer:1.83e-5 (favourable) Expressed in all Expressed in all testis: 51.8 PDLIM1 CLIM1, CLP-36, CLP36, hCLIM1 ENSG00000107438 PDZ and LIM domain 1 10 95237572-95291024 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017010, CAB072838, CAB072840 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Endometrial cancer:1.14e-5 (favourable) Expressed in all Expressed in all small intestine: 278.6 PDLIM5 Enh, LIM ENSG00000163110 PDZ and LIM domain 5 4 94451857-94668227 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013511, HPA016740, HPA020026 Approved Supported Nucleoplasm
Plasma membrane
Focal adhesion sites Tissue enriched Expressed in all skeletal muscle: 407.0 PDZD2 KIAA0300, PDZK3 ENSG00000133401 PDZ domain containing 2 5 31639410-32110931 Predicted intracellular proteins Evidence at protein level CAB020784, HPA036503, HPA036504, HPA064387 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed ovary: 18.2 PDZD8 bA129M16.2, FLJ34427, PDZK8 ENSG00000165650 PDZ domain containing 8 10 117277274-117375467 Predicted secreted proteins Evidence at protein level HPA015716, HPA051610 Uncertain Approved Nucleoli fibrillar center
Plasma membrane Pancreatic cancer:6.10e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 46.6 PEBP1 HCNP, PBP, PEBP, RKIP ENSG00000089220 Phosphatidylethanolamine binding protein 1 12 118135858-118145584 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008819, CAB009906, CAB013493 Supported Approved Plasma membrane
Cytosol Renal cancer:2.15e-13 (favourable), Pancreatic cancer:1.52e-4 (favourable) Expressed in all Expressed in all adrenal gland: 1649.3 PFAS FGARAT, KIAA0361, PURL ENSG00000178921 Phosphoribosylformylglycinamidine synthase 17 8247618-8270491 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022140, HPA022886 Supported Approved Nucleoplasm
Plasma membrane Liver cancer:9.19e-4 (unfavourable) Expressed in all Expressed in all lymph node: 11.8 PFDN1 PFD1 ENSG00000113068 Prefoldin subunit 1 5 140245039-140303121 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006499 Approved Approved Nucleoli
Plasma membrane
Cytosol Liver cancer:8.81e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 106.6 PGAP3 CAB2, MGC9753, PER1, PERLD1, PP1498 ENSG00000161395 Post-GPI attachment to proteins 3 17 39671122-39696797 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016591 Approved Approved Plasma membrane
Cytosol Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 35.5 PGLYRP4 PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67 ENSG00000163218 Peptidoglycan recognition protein 4 1 153330120-153348840 Predicted secreted proteins Evidence at protein level CAB025879 Approved Vesicles
Plasma membrane Group enriched Group enriched 5 esophagus: 5.8;skin: 18.2 tonsil: 2.2 PGRMC2 DG6, PMBP ENSG00000164040 Progesterone receptor membrane component 2 4 128269237-128288829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041172, HPA058652 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable) Expressed in all Expressed in all small intestine: 136.2 PHACTR1 dJ257A7.2, KIAA1733, RPEL1 ENSG00000112137 Phosphatase and actin regulator 1 6 12716805-13290484 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA029755, HPA029756, HPA029757 Supported Uncertain Plasma membrane Renal cancer:5.48e-6 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 27.9 bone marrow: 15.6 PHACTR4 FLJ13171, PPP1R124 ENSG00000204138 Phosphatase and actin regulator 4 1 28369582-28500369 Predicted intracellular proteins Evidence at protein level HPA028985 Approved Approved Plasma membrane
Intermediate filaments
Cytosol Head and neck cancer:1.05e-4 (favourable) Expressed in all Expressed in all esophagus: 35.9 PHF20L1 CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B ENSG00000129292 PHD finger protein 20-like 1 8 132775358-132848807 Predicted intracellular proteins Evidence at protein level HPA025060, HPA028417 Uncertain Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all thyroid gland: 37.9 PHGDH PDG, PGDH, SERA ENSG00000092621 Phosphoglycerate dehydrogenase 1 119659798-119744215 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003681, HPA021241, HPA024031, CAB068216 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 212.4 skin: 116.1 PHLDB2 FLJ21791, LL5b, LL5beta ENSG00000144824 Pleckstrin homology-like domain, family B, member 2 3 111732497-111976517 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035146, HPA035147 Approved Supported Plasma membrane
Cytosol Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable) Expressed in all Mixed placenta: 59.4 PHLDB3 FLJ40193 ENSG00000176531 Pleckstrin homology-like domain, family B, member 3 19 43474954-43504935 Predicted intracellular proteins Evidence at protein level HPA043425 Approved Approved Nuclear speckles
Plasma membrane
Cytosol Pancreatic cancer:6.36e-6 (favourable), Renal cancer:4.11e-5 (unfavourable), Stomach cancer:5.77e-4 (unfavourable) Expressed in all Expressed in all testis: 24.8 PI3 cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14 ENSG00000124102 Peptidase inhibitor 3, skin-derived 20 45174876-45176544 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB009449, HPA017737 Supported Approved Plasma membrane Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable) Tissue enhanced Group enriched 15 esophagus: 2295.1;tonsil: 1810.6 appendix: 136.9 PI4K2A DKFZP761G1923, PI4KII, PIK42A ENSG00000155252 Phosphatidylinositol 4-kinase type 2 alpha 10 97640686-97676434 Enzymes, Predicted intracellular proteins Evidence at protein level CAB030649, HPA076857 Approved Supported Plasma membrane Colorectal cancer:4.21e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.8 PI4KA PI4K-ALPHA, pi4K230, PIK4CA ENSG00000241973 Phosphatidylinositol 4-kinase, catalytic, alpha 22 20707691-20859417 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009092, HPA075515 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 114.0 PIGB ENSG00000069943 Phosphatidylinositol glycan anchor biosynthesis, class B 15 55318960-55355648 Predicted membrane proteins Evidence at protein level HPA039929 Uncertain Uncertain Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 22.8 PIGN MDC4, PIG-N ENSG00000197563 Phosphatidylinositol glycan anchor biosynthesis, class N 18 62043567-62187118 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039922, HPA040374 Approved Supported Plasma membrane
Cytosol Colorectal cancer:6.51e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 31.3 PIGW FLJ37433, Gwt1 ENSG00000277161 Phosphatidylinositol glycan anchor biosynthesis, class W 17 36535020-36539310 Disease related genes, Predicted membrane proteins Evidence at protein level HPA023499 Approved Plasma membrane Expressed in all Mixed appendix: 5.3 PIK3AP1 BCAP, FLJ35564 ENSG00000155629 Phosphoinositide-3-kinase adaptor protein 1 10 96593312-96720514 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026136, HPA038452 Supported Approved Nucleus
Plasma membrane
Cytosol Expressed in all Tissue enhanced spleen: 86.8 lymph node: 72.8 PIK3CG ENSG00000105851 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 7 106865278-106907145 Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA069976 Supported Plasma membrane Mixed Tissue enhanced bone marrow: 28.2 lymph node: 22.2 PIP4K2A PIP5K2A, PIP5KIIA, PIP5KIIalpha ENSG00000150867 Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 10 22534849-22714555 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA065440, HPA068771 Supported Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.46e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.6 PIP5K1A ENSG00000143398 Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 1 151197949-151249536 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA029366 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:4.16e-7 (unfavourable) Expressed in all Expressed in all testis: 69.4 PIRT ENSG00000233670 Phosphoinositide-interacting regulator of transient receptor potential channels 17 10822475-10838445 Predicted membrane proteins, Transporters Evidence at transcript level HPA042337 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enhanced adrenal gland: 3.1;cerebral cortex: 2.7;rectum: 2.7 colon: 2.1 PITPNM3 ACKR6, CORD5, NIR1, RDGBA3 ENSG00000091622 PITPNM family member 3 17 6451264-6556494 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA022432, HPA059005 Uncertain Approved Plasma membrane Head and neck cancer:3.67e-6 (favourable) Mixed Tissue enhanced spleen: 78.2 ovary: 33.8 PKD2L2 TRPP5 ENSG00000078795 Polycystic kidney disease 2-like 2 5 137887968-137942747 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA041903, HPA043634 Approved Approved Plasma membrane
Cytosol Not detected Tissue enriched 11 testis: 15.6 thyroid gland: 1.4 PKP4 p0071 ENSG00000144283 Plakophilin 4 2 158456964-158682879 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037334, HPA066647, HPA070648 Approved Validated Plasma membrane
Cell Junctions Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable) Expressed in all Expressed in all kidney: 65.1 PLAA DOA1, FLJ11281, FLJ12699, PLA2P, PLAP ENSG00000137055 Phospholipase A2-activating protein 9 26904083-26947463 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005035, HPA020994, HPA020996 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Ovarian cancer:7.87e-4 (favourable) Expressed in all Expressed in all testis: 37.8 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 61.3 PLAUR CD87, UPAR, URKR ENSG00000011422 Plasminogen activator, urokinase receptor 19 43646095-43670547 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050843, CAB073533 Uncertain Supported Plasma membrane Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 429.4 PLCB1 KIAA0581, PLC-I, PLC154 ENSG00000182621 Phospholipase C, beta 1 (phosphoinositide-specific) 20 8114453-8968360 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004275, CAB005334, HPA034743, HPA057910 Supported Approved Plasma membrane Mixed Tissue enhanced cerebral cortex: 66.1;parathyroid gland: 110.6 placenta: 23.5 PLCD3 ENSG00000161714 Phospholipase C, delta 3 17 45108967-45133354 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA025711 Approved Approved Plasma membrane Lung cancer:2.89e-6 (unfavourable), Thyroid cancer:4.28e-4 (favourable) Expressed in all Mixed colon: 29.9 PLCD4 ENSG00000115556 Phospholipase C, delta 4 2 218607765-218637184 Enzymes, Predicted intracellular proteins Evidence at protein level CAB009914, HPA038139, HPA038140 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Mixed Tissue enhanced skeletal muscle: 38.4 testis: 10.0 PLD1 ENSG00000075651 Phospholipase D1, phosphatidylcholine-specific 3 171600405-171810950 Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004527, HPA042396 Approved Approved Plasma membrane Urothelial cancer:4.76e-6 (unfavourable) Expressed in all Tissue enhanced gallbladder: 138.8 small intestine: 50.2 PLEKHA4 PEPP1 ENSG00000105559 Pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 19 48837097-48868632 Predicted intracellular proteins Evidence at protein level HPA042978, HPA048473 Uncertain Approved Plasma membrane
Cytokinetic bridge
Centrosome
Cytosol Breast cancer:1.97e-4 (favourable), Liver cancer:8.68e-4 (unfavourable) Expressed in all Mixed ovary: 22.5 PLEKHG3 ARHGEF43, KIAA0599 ENSG00000126822 Pleckstrin homology domain containing, family G (with RhoGef domain) member 3 14 64704102-64750247 Predicted intracellular proteins Evidence at protein level HPA063455, HPA065323 Supported Nucleoplasm
Plasma membrane
Cytokinetic bridge
Centrosome
Cytosol Renal cancer:7.39e-8 (favourable) Expressed in all Expressed in all seminal vesicle: 52.5 PLEKHG6 FLJ10665, MYOGEF ENSG00000008323 Pleckstrin homology domain containing, family G (with RhoGef domain) member 6 12 6310436-6328506 Predicted intracellular proteins Evidence at protein level HPA041459, HPA058230 Uncertain Validated Plasma membrane Mixed Tissue enhanced small intestine: 48.7 duodenum: 37.6 PLEKHH2 KIAA2028, PLEKHH1L ENSG00000152527 Pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 2 43637273-43767987 Predicted intracellular proteins Evidence at protein level HPA077225 Supported Plasma membrane Tissue enhanced Mixed endometrium: 31.8 PLEKHO2 DKFZp761K2312, PLEKHQ1, PP1628, pp9099 ENSG00000241839 Pleckstrin homology domain containing, family O member 2 15 64841883-64868007 Predicted intracellular proteins Evidence at protein level HPA040055 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all spleen: 121.4 PLIN4 KIAA1881, S3-12 ENSG00000167676 Perilipin 4 19 4502180-4518465 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044682, HPA054657 Supported Supported Vesicles
Lipid droplets
Plasma membrane
Cytosol Endometrial cancer:2.31e-4 (unfavourable), Colorectal cancer:8.31e-4 (unfavourable) Mixed Tissue enriched 14 adipose tissue: 810.9 skeletal muscle: 59.1 PLPP1 LPP1, PAP-2a, PPAP2A ENSG00000067113 Phospholipid phosphatase 1 5 55424854-55535050 Enzymes, Predicted membrane proteins Evidence at protein level CAB033331, HPA047815 Supported Supported Plasma membrane Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable) Expressed in all Mixed prostate: 344.0 PLPPR5 LPPR5, PAP2, PAP2D, PRG5 ENSG00000117598 Phospholipid phosphatase related 5 1 98890245-99005032 Predicted membrane proteins Evidence at transcript level HPA018072 Uncertain Approved Nucleus
Plasma membrane
Centrosome Renal cancer:6.22e-4 (unfavourable) Group enriched Group enriched 11 cerebral cortex: 12.0;testis: 4.0 adrenal gland: 0.7 PLS3 T-plastin ENSG00000102024 Plastin 3 X 115561174-115650861 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020433, HPA076083 Approved Approved Plasma membrane
Cytosol Head and neck cancer:6.07e-5 (unfavourable), Renal cancer:1.01e-4 (unfavourable), Thyroid cancer:3.72e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Urothelial cancer:7.04e-4 (unfavourable) Expressed in all Mixed thyroid gland: 291.7 PLSCR1 MMTRA1B ENSG00000188313 Phospholipid scramblase 1 3 146515180-146544864 Predicted intracellular proteins, Transporters Evidence at protein level HPA068923, CAB070421 Approved Approved Nucleus
Golgi apparatus
Plasma membrane Endometrial cancer:1.35e-4 (unfavourable) Expressed in all Expressed in all appendix: 117.3 PLXNA3 6.3, Plxn3, PLXN4, SEX, XAP-6 ENSG00000130827 Plexin A3 X 154458281-154477779 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA058989 Supported Vesicles
Plasma membrane
Cell Junctions Expressed in all Mixed skin: 12.1 PNCK CaMK1b, MGC45419 ENSG00000130822 Pregnancy up-regulated nonubiquitous CaM kinase X 153669730-153689010 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007458 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.04e-6 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 40.7;seminal vesicle: 51.7 smooth muscle: 22.1 PODXL Gp200, PC, PCLP ENSG00000128567 Podocalyxin-like 7 131500262-131558217 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220 Supported Approved Vesicles
Plasma membrane
Microtubule organizing center Renal cancer:2.89e-4 (favourable) Expressed in all Mixed fallopian tube: 29.2 POLE POLE1 ENSG00000177084 Polymerase (DNA directed), epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Validated Nucleus
Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.0 PPEF1 PPEF, PPP7CA ENSG00000086717 Protein phosphatase, EF-hand calcium binding domain 1 X 18675909-18827921 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034577 Uncertain Uncertain Plasma membrane
Cytokinetic bridge Mixed Tissue enriched 7 testis: 26.2 cerebral cortex: 3.6 PPFIBP1 hSGT2, hSgt2p, L2, SGT2 ENSG00000110841 PTPRF interacting protein, binding protein 1 (liprin beta 1) 12 27523431-27695564 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001924 Uncertain Approved Plasma membrane
Cytosol Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable) Expressed in all Expressed in all ovary: 106.2 PPL ENSG00000118898 Periplakin 16 4882507-4960741 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042550, HPA059859 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Ovarian cancer:2.76e-4 (unfavourable) Expressed in all Group enriched 7 esophagus: 560.8;skin: 149.9 tonsil: 54.0 PPM1A MGC9201, PP2CA, PP2Calpha ENSG00000100614 Protein phosphatase, Mg2+/Mn2+ dependent, 1A 14 60245752-60299087 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029209 Approved Supported Plasma membrane
Cytosol Renal cancer:1.57e-9 (favourable) Expressed in all Expressed in all testis: 99.7 PPM1F CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2 ENSG00000100034 Protein phosphatase, Mg2+/Mn2+ dependent, 1F 22 21919420-21952837 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030989, HPA030990 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:6.03e-5 (unfavourable) Expressed in all Expressed in all placenta: 39.4 PPP1CA PP-1A, PP1A, PP1alpha, PPP1A ENSG00000172531 Protein phosphatase 1, catalytic subunit, alpha isozyme 11 67398183-67421183 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB004545, HPA046833 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Thyroid cancer:1.17e-4 (favourable) Expressed in all Expressed in all lymph node: 168.7 PPP1CB PP-1B, PP1B, PP1beta ENSG00000213639 Protein phosphatase 1, catalytic subunit, beta isozyme 2 28751640-28802940 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022558, HPA065425, CAB069426 Supported Supported Nucleus
Plasma membrane
Cytosol Liver cancer:6.52e-6 (unfavourable) Expressed in all Expressed in all esophagus: 274.9 PPP1R12B MGC131980, MGC87886, MYPT2, PP1bp55 ENSG00000077157 Protein phosphatase 1, regulatory subunit 12B 1 202348699-202592706 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA024171, HPA024640 Supported Supported Plasma membrane
Actin filaments Expressed in all Expressed in all endometrium: 363.9 PPP1R16A MGC14333, MYPT3 ENSG00000160972 Protein phosphatase 1, regulatory subunit 16A 8 144477969-144502121 Predicted intracellular proteins Evidence at protein level HPA023755 Uncertain Approved Plasma membrane Expressed in all Expressed in all duodenum: 27.9 PPP1R16B ANKRD4, KIAA0823, TIMAP ENSG00000101445 Protein phosphatase 1, regulatory subunit 16B 20 38805705-38923024 Predicted intracellular proteins Evidence at protein level HPA049571 Supported Nuclear speckles
Plasma membrane Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 51.0 lymph node: 44.7 PPP1R18 KIAA1949, phostensin ENSG00000146112 Protein phosphatase 1, regulatory subunit 18 6 30676389-30687895 Predicted intracellular proteins Evidence at protein level HPA044745, HPA051000 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 54.0 spleen: 35.7 PPP2R1B PP2A-Abeta, PR65B ENSG00000137713 Protein phosphatase 2, regulatory subunit A, beta 11 111726908-111766427 Predicted intracellular proteins Evidence at protein level CAB004034, HPA018908 Approved Approved Nucleus
Plasma membrane
Centrosome
Cytosol Liver cancer:3.80e-4 (favourable) Expressed in all Expressed in all testis: 98.2 PPP3R1 CALNB1, CNB, CNB1 ENSG00000221823 Protein phosphatase 3, regulatory subunit B, alpha 2 68178857-68256237 Predicted intracellular proteins Evidence at protein level CAB005610, HPA047157 Approved Approved Plasma membrane
Cytosol Endometrial cancer:9.08e-6 (unfavourable), Renal cancer:1.70e-5 (unfavourable), Liver cancer:5.37e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 198.1 PPP3R2 PPP3RL ENSG00000188386 Protein phosphatase 3, regulatory subunit B, beta 9 101591615-101595001 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047157 Uncertain Approved Plasma membrane
Cytosol Not detected Tissue enriched 755 testis: 75.4 all non-specific tissues: 0.0 PPP4C PP4, PPX ENSG00000149923 Protein phosphatase 4, catalytic subunit 16 30075978-30085377 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043837 Supported Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 77.8 PPP6R3 C11orf23, DKFZp781E17107, DKFZp781E2374, DKFZp781O2362, FLJ11058, FLJ43065, KIAA1558, MGC125711, MGC125712, PP6R3, SAP190, SAPL, SAPLa, SAPS3 ENSG00000110075 Protein phosphatase 6, regulatory subunit 3 11 68460731-68615334 Predicted intracellular proteins Evidence at protein level CAB017183, HPA038467, HPA038468 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Testis cancer:8.23e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 92.1 PPTC7 TA-PP2C ENSG00000196850 PTC7 protein phosphatase homolog 12 110533245-110583320 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039335, HPA040614 Approved Approved Plasma membrane
Cytosol Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.7 PRAP1 UPA ENSG00000165828 Proline-rich acidic protein 1 10 133309410-133352683 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035360, HPA038713, HPA052451 Supported Approved Nucleoplasm
Vesicles
Plasma membrane Group enriched Group enriched 6 duodenum: 981.7;liver: 306.9;small intestine: 1145.9 kidney: 136.1 PRC1 ASE1 ENSG00000198901 Protein regulator of cytokinesis 1 15 90966038-90995629 Predicted intracellular proteins Evidence at protein level HPA034521 Supported Approved Nucleoplasm
Plasma membrane
Microtubules Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:2.76e-5 (unfavourable), Liver cancer:2.11e-4 (unfavourable) Expressed in all Expressed in all testis: 99.7 PRDX6 1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX ENSG00000117592 Peroxiredoxin 6 1 173477266-173488807 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006983, CAB008663 Supported Supported Plasma membrane
Cytosol Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 363.4 PRICKLE3 LMO6 ENSG00000012211 Prickle homolog 3 X 49175264-49186528 Predicted intracellular proteins Evidence at protein level HPA000998, HPA001442 Uncertain Approved Nucleus
Plasma membrane
Centrosome Renal cancer:5.73e-6 (unfavourable), Urothelial cancer:4.84e-5 (favourable) Expressed in all Mixed skin: 11.7 PRIMA1 PRIMA ENSG00000175785 Proline rich membrane anchor 1 14 93718298-93788481 Predicted membrane proteins Evidence at protein level HPA046671, HPA060047 Approved Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:2.62e-7 (unfavourable), Endometrial cancer:6.99e-5 (unfavourable) Mixed Mixed smooth muscle: 11.5 PRKCA PKCA ENSG00000154229 Protein kinase C, alpha 17 66302636-66810743 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003844, HPA006563, HPA006564, CAB016290 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 45.1 PRKCDBP cavin-3, CAVIN3, HSRBC, MGC20400, SRBC ENSG00000170955 Protein kinase C, delta binding protein 11 6318946-6320647 Predicted intracellular proteins Evidence at protein level HPA055136, HPA073327 Approved Approved Plasma membrane Renal cancer:5.21e-6 (unfavourable), Cervical cancer:3.75e-5 (unfavourable) Expressed in all Mixed adipose tissue: 30.5 PRKCH PKC-L, PKCL, PRKCL ENSG00000027075 Protein kinase C, eta 14 61187559-61550976 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA026294, HPA053709 Approved Approved Plasma membrane
Cytosol Head and neck cancer:8.55e-6 (favourable) Expressed in all Expressed in all lymph node: 62.3 PRKCZ PKC2 ENSG00000067606 Protein kinase C, zeta 1 2050470-2185395 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021851 Supported Approved Plasma membrane
Cytosol Renal cancer:1.64e-9 (favourable) Expressed in all Tissue enhanced cerebral cortex: 100.0 placenta: 59.9 PRKD1 PKC-mu, PKCM, PKD, PRKCM ENSG00000184304 Protein kinase D1 14 29576479-30191898 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018367, HPA029834 Uncertain Supported Plasma membrane
Cytosol Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 49.5 prostate: 29.0 PROM2 ENSG00000155066 Prominin 2 2 95274453-95291308 Predicted membrane proteins Evidence at protein level CAB046005, HPA063728 Supported Approved Nucleoplasm
Plasma membrane
Cell Junctions Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable) Mixed Tissue enhanced skin: 71.3 esophagus: 44.8 PROSER2 C10orf47, MGC35403 ENSG00000148426 Proline and serine rich 2 10 11823339-11872277 Predicted intracellular proteins Evidence at protein level HPA041337 Uncertain Uncertain Plasma membrane
Cytosol Mixed Mixed placenta: 10.8 PRR7 MGC10772 ENSG00000131188 Proline rich 7 (synaptic) 5 177446445-177456286 Predicted intracellular proteins Evidence at transcript level HPA046636 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 8.1 bone marrow: 3.7 PRRG1 PRGP1 ENSG00000130962 Proline rich Gla (G-carboxyglutamic acid) 1 X 37349275-37457295 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056029, HPA078129 Uncertain Approved Vesicles
Plasma membrane Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PRRT2 DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC ENSG00000167371 Proline-rich transmembrane protein 2 16 29811382-29815892 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014447, HPA019203 Approved Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 92.9 ovary: 51.5 PRRT3 FLJ33674 ENSG00000163704 Proline-rich transmembrane protein 3 3 9945542-9952394 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035127, HPA035128 Uncertain Approved Nucleus
Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 19.5;parathyroid gland: 27.5 fallopian tube: 12.3 PRRT4 ENSG00000224940 Proline-rich transmembrane protein 4 7 128350325-128361685 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046373, HPA052681 Uncertain Approved Nucleoplasm
Peroxisomes
Plasma membrane Mixed Group enriched 12 adipose tissue: 15.7;bone marrow: 41.2 cerebral cortex: 2.3 PRTG FLJ25756, IGDCC5 ENSG00000166450 Protogenin 15 55611546-55743090 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA032138 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Tissue enhanced thyroid gland: 18.2 testis: 6.7 PRX KIAA1620 ENSG00000105227 Periaxin 19 40393768-40413366 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001868 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Expressed in all Tissue enhanced lung: 28.9 parathyroid gland: 9.3 PSCA ENSG00000167653 Prostate stem cell antigen 8 142670308-142682724 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030783, HPA056418 Approved Supported Plasma membrane Pancreatic cancer:5.60e-5 (unfavourable) Tissue enriched Tissue enhanced stomach: 1662.7;urinary bladder: 357.0 prostate: 312.0 PSD EFA6, EFA6A, KIAA2011, PSD1, TYL ENSG00000059915 Pleckstrin and Sec7 domain containing 10 102402617-102421539 Predicted intracellular proteins Evidence at protein level HPA059237 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 77.8 endometrium: 25.4 PSMC5 p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1 ENSG00000087191 Proteasome 26S subunit, ATPase 5 17 63827152-63832026 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017871, HPA064293 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.13e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 245.8 PSMC6 p42 ENSG00000100519 Proteasome 26S subunit, ATPase 6 14 52707172-52728587 Predicted intracellular proteins Evidence at protein level HPA042823 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 91.4 PSMD9 p27, Rpn4 ENSG00000110801 Proteasome 26S subunit, non-ATPase 9 12 121888731-121918297 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040512, HPA044220 Supported Supported Plasma membrane
Cytosol Liver cancer:1.32e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 17.9 PSTPIP2 ENSG00000152229 Proline-serine-threonine phosphatase interacting protein 2 18 45983536-46072272 Predicted intracellular proteins Evidence at protein level HPA040923, HPA040944 Supported Approved Nucleus
Plasma membrane
Mitochondria Renal cancer:2.39e-7 (unfavourable) Expressed in all Tissue enhanced bone marrow: 47.3;spleen: 70.7 placenta: 17.3 PTAFR ENSG00000169403 Platelet-activating factor receptor 1 28147166-28193936 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA027543 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Expressed in all Tissue enhanced appendix: 42.1 bone marrow: 26.2 PTCHD4 C6orf138, dJ402H5.2, FLJ41841 ENSG00000244694 Patched domain containing 4 6 47878028-48068689 Predicted membrane proteins Evidence at transcript level HPA041276 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.49e-6 (favourable) Group enriched Mixed seminal vesicle: 2.8 PTK2B CADTK, CAKB, FAK2, PTK, PYK2, RAFTK ENSG00000120899 Protein tyrosine kinase 2 beta 8 27311482-27459391 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003850, HPA026091, HPA026276 Approved Validated Plasma membrane
Cytosol Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable) Expressed in all Expressed in all lymph node: 100.2 PTK6 BRK ENSG00000101213 Protein tyrosine kinase 6 20 63528001-63537370 Enzymes, Predicted intracellular proteins Evidence at protein level CAB032952, HPA036070, HPA036071 Approved Supported Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable) Mixed Tissue enhanced esophagus: 61.2;skin: 60.6 duodenum: 30.0 PTPN12 PTP-PEST, PTPG1 ENSG00000127947 Protein tyrosine phosphatase, non-receptor type 12 7 77537275-77640071 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007097 Approved Approved Plasma membrane
Cytosol Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all placenta: 106.3 PTPN13 PTP-BAS, PTP-BL, PTP1E, PTPL1 ENSG00000163629 Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) 4 86594315-86815171 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002213, HPA065290 Approved Approved Plasma membrane
Cytosol Mixed Mixed skin: 66.1 PTPN22 Lyp, Lyp1, Lyp2, PTPN8 ENSG00000134242 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 1 113813811-113871759 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004912, CAB012209, HPA013350 Approved Uncertain Nucleoplasm
Vesicles
Plasma membrane Mixed Tissue enhanced bone marrow: 24.9 lymph node: 23.6 PTPN4 PTPMEG ENSG00000088179 Protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) 2 119759631-119983818 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019351 Uncertain Approved Nucleus
Plasma membrane
Cytosol Lung cancer:5.16e-4 (favourable) Expressed in all Mixed thyroid gland: 24.4 PTPRB PTPB ENSG00000127329 Protein tyrosine phosphatase, receptor type, B 12 70515866-70637440 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004782, HPA067868 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable) Expressed in all Mixed lung: 54.1 PTPRK R-PTP-kappa ENSG00000152894 Protein tyrosine phosphatase, receptor type, K 6 127968779-128520674 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054056, HPA054822 Uncertain Supported Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable) Expressed in all Mixed gallbladder: 27.9 PTPRM hR-PTPu, PTPRL1, RPTPU ENSG00000173482 Protein tyrosine phosphatase, receptor type, M 18 7566782-8406861 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003891, CAB022442, CAB022443 Supported Approved Plasma membrane Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable) Expressed in all Mixed thyroid gland: 91.3 PTPRN2 IA-2beta, ICAAR, KIAA0387, phogrin ENSG00000155093 Protein tyrosine phosphatase, receptor type, N polypeptide 2 7 157539056-158587788 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006900, HPA026656 Approved Uncertain Vesicles
Plasma membrane Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 82.5 stomach: 39.0 PTPRR EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ ENSG00000153233 Protein tyrosine phosphatase, receptor type, R 12 70638073-70920843 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011461, HPA011851, HPA071067 Uncertain Supported Plasma membrane
Cell Junctions
Cytosol Urothelial cancer:1.40e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 20.9 endometrium: 8.9 PTPRS ENSG00000105426 Protein tyrosine phosphatase, receptor type, S 19 5158495-5340803 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054747 Approved Plasma membrane
Cytosol Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 70.8 PTRF cavin-1, CAVIN1 ENSG00000177469 Polymerase I and transcript release factor 17 42402452-42423517 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049838, HPA074213 Supported Supported Vesicles
Plasma membrane Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 342.2 PURG PURG-A, PURG-B ENSG00000172733 Purine-rich element binding protein G 8 30995802-31033715 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047746 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 6.6;testis: 4.8 endometrium: 2.6 PVR CD155, HVED, Necl-5, NECL5, PVS, Tage4 ENSG00000073008 Poliovirus receptor 19 44643798-44663583 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012568 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable) Expressed in all Expressed in all placenta: 16.9 PVRL4 LNIR, nectin-4, PRR4 ENSG00000143217 Poliovirus receptor-related 4 1 161070995-161089599 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010775 Supported Supported Plasma membrane Mixed Tissue enhanced esophagus: 46.1;skin: 79.8 placenta: 17.1 PXDC1 C6orf145 ENSG00000168994 PX domain containing 1 6 3722614-3752026 Predicted intracellular proteins Evidence at protein level HPA019246 Approved Plasma membrane Endometrial cancer:1.14e-4 (unfavourable), Colorectal cancer:3.64e-4 (unfavourable) Expressed in all Mixed placenta: 82.1 PXK FLJ20335 ENSG00000168297 PX domain containing serine/threonine kinase 3 58332880-58426126 Enzymes, Predicted intracellular proteins Evidence at protein level HPA024068 Supported Supported Plasma membrane
Microtubule organizing center
Cytosol Lung cancer:5.68e-4 (favourable) Expressed in all Expressed in all thyroid gland: 124.3 PYGL ENSG00000100504 Phosphorylase, glycogen, liver 14 50857891-50944736 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000962, HPA004119 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable) Expressed in all Mixed adipose tissue: 116.1 RAB13 ENSG00000143545 RAB13, member RAS oncogene family 1 153981617-153986358 Predicted intracellular proteins Evidence at protein level HPA003996 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all prostate: 153.9 RAB23 ENSG00000112210 RAB23, member RAS oncogene family 6 57186992-57222314 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA029135, HPA029136 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed smooth muscle: 101.8 RAB26 ENSG00000167964 RAB26, member RAS oncogene family 16 2140803-2154165 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA075624 Uncertain Vesicles
Plasma membrane
Centrosome Cervical cancer:8.20e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 21.2 liver: 11.4 RAB27B ENSG00000041353 RAB27B, member RAS oncogene family 18 54717860-54895516 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017712, HPA019849 Approved Uncertain Golgi apparatus
Plasma membrane
Cytosol Pancreatic cancer:2.13e-4 (unfavourable) Mixed Tissue enhanced stomach: 40.5 prostate: 31.5 RAB3GAP2 DKFZP434D245, KIAA0839, RAB3-GAP150, SPG69 ENSG00000118873 RAB3 GTPase activating protein subunit 2 (non-catalytic) 1 220148293-220272454 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA026273, HPA027299 Approved Supported Plasma membrane
Cytosol Breast cancer:3.05e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 34.7 RAB43 ISY1, RAB11B, RAB41 ENSG00000172780 RAB43, member RAS oncogene family 3 129087569-129122801 Predicted intracellular proteins Evidence at protein level HPA046840, HPA060085 Approved Supported Plasma membrane Mixed Mixed thyroid gland: 37.4 RAB8A MEL, RAB8 ENSG00000167461 RAB8A, member RAS oncogene family 19 16111629-16134234 Predicted intracellular proteins Evidence at protein level HPA041945 Supported Nucleus
Plasma membrane Renal cancer:6.56e-5 (unfavourable), Thyroid cancer:1.71e-4 (favourable) Expressed in all Expressed in all small intestine: 65.9 RABEPK bA65N13.1, RAB9P40 ENSG00000136933 Rab9 effector protein with kelch motifs 9 125200542-125234158 Predicted intracellular proteins Evidence at protein level HPA023920, HPA067106 Supported Uncertain Plasma membrane Expressed in all Expressed in all liver: 30.6 RABL2A ENSG00000144134 RAB, member of RAS oncogene family-like 2A 2 113627229-113643396 Predicted intracellular proteins Evidence at protein level HPA042700, HPA044007 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.20e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 31.0 cerebral cortex: 8.1 RABL2B ENSG00000079974 RAB, member of RAS oncogene family-like 2B 22 50767501-50783663 Predicted intracellular proteins Evidence at protein level HPA042700, HPA044007 Approved Uncertain Plasma membrane
Cytosol Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable) Expressed in all Expressed in all epididymis: 109.0 RAD52 ENSG00000002016 RAD52 homolog, DNA repair protein 12 912077-990053 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028957 Approved Nuclear speckles
Plasma membrane Renal cancer:2.22e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 13.5 RAI2 ENSG00000131831 Retinoic acid induced 2 X 17800049-17861337 Predicted intracellular proteins Evidence at protein level HPA051054 Uncertain Approved Plasma membrane Renal cancer:3.39e-14 (favourable), Pancreatic cancer:2.77e-4 (favourable) Expressed in all Mixed fallopian tube: 78.2 RALA RAL ENSG00000006451 V-ral simian leukemia viral oncogene homolog A (ras related) 7 39623483-39708124 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA064515, HPA065232 Approved Supported Plasma membrane Liver cancer:5.32e-5 (unfavourable), Pancreatic cancer:6.30e-4 (unfavourable), Ovarian cancer:7.46e-4 (favourable) Expressed in all Expressed in all lung: 60.5 RALGAPA2 AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2 ENSG00000188559 Ral GTPase activating protein, alpha subunit 2 (catalytic) 20 20389552-20712488 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042707, HPA043622 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.77e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 RAPH1 ALS2CR18, ALS2CR9, KIAA1681 ENSG00000173166 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 2 203394345-203535410 Predicted intracellular proteins Evidence at protein level HPA016744, HPA020027 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Mixed Expressed in all thyroid gland: 49.6 RAPSN CMS1D, CMS1E, RNF205 ENSG00000165917 Receptor-associated protein of the synapse 11 47437757-47449178 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039475 Approved Approved Plasma membrane
Centrosome
Cytosol Mixed Tissue enriched 10 skeletal muscle: 30.0 placenta: 2.9 RASAL1 RASAL ENSG00000111344 RAS protein activator like 1 (GAP1 like) 12 113098819-113136239 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA041650 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:3.26e-5 (unfavourable) Mixed Tissue enriched 6 parathyroid gland: 116.7 cerebral cortex: 19.5 RASAL2 nGAP ENSG00000075391 RAS protein activator like 2 1 178094141-178484147 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA018805, HPA020453 Approved Approved Plasma membrane
Focal adhesion sites Urothelial cancer:2.05e-4 (unfavourable) Expressed in all Mixed esophagus: 19.5 RASD1 AGS1, DEXRAS1 ENSG00000108551 RAS, dexamethasone-induced 1 17 17494437-17496395 Predicted intracellular proteins Evidence at protein level HPA047896 Uncertain Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all adipose tissue: 112.9 RASD2 MGC:4834, Rhes, TEM2 ENSG00000100302 RASD family, member 2 22 35540868-35554001 Predicted intracellular proteins Evidence at protein level HPA005839 Approved Approved Plasma membrane
Cytosol Renal cancer:2.22e-5 (unfavourable) Mixed Tissue enhanced seminal vesicle: 31.8 epididymis: 18.2 RASGRP1 CalDAG-GEFII, RASGRP ENSG00000172575 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 15 38488103-38565575 Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA046216 Supported Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 28.5;lymph node: 25.3 tonsil: 15.8 RASSF3 ENSG00000153179 Ras association (RalGDS/AF-6) domain family member 3 12 64610513-64697567 Predicted intracellular proteins Evidence at protein level CAB022664, CAB034035, HPA038469 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all smooth muscle: 85.0 RC3H1 KIAA2025, RNF198, roquin, RP5-1198E17.5 ENSG00000135870 Ring finger and CCCH-type domains 1 1 173931214-174022297 Predicted intracellular proteins Evidence at protein level HPA027428, HPA027434, HPA027448 Approved Supported Plasma membrane
Cytosol Renal cancer:7.96e-4 (unfavourable) Expressed in all Mixed bone marrow: 12.9 RCCD1 MGC14386 ENSG00000166965 RCC1 domain containing 1 15 90954870-90963125 Predicted intracellular proteins Evidence at protein level HPA039683, HPA040776 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 8.8 RCSD1 CapZIP, MGC21854, MK2S4 ENSG00000198771 RCSD domain containing 1 1 167630093-167706249 Predicted intracellular proteins Evidence at protein level HPA016597 Supported Uncertain Nucleoplasm
Plasma membrane Head and neck cancer:2.97e-4 (favourable) Expressed in all Tissue enhanced lymph node: 108.5 tonsil: 74.2 RDX DFNB24 ENSG00000137710 Radixin 11 110174880-110296722 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000263, HPA000763, CAB037312 Supported Validated Plasma membrane Expressed in all Expressed in all adrenal gland: 199.3 RECK hRECK, ST15 ENSG00000122707 Reversion-inducing-cysteine-rich protein with kazal motifs 9 36036433-36124451 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025109, HPA071729 Supported Supported Plasma membrane Stomach cancer:7.31e-4 (unfavourable) Expressed in all Mixed endometrium: 21.3 RELL1 ENSG00000181826 RELT-like 1 4 37590800-37686376 Predicted membrane proteins Evidence at protein level HPA013377 Approved Supported Plasma membrane
Microtubules Expressed in all Mixed thyroid gland: 27.6 RELN PRO1598, RL ENSG00000189056 Reelin 7 103471784-103989516 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046512 Approved Plasma membrane
Focal adhesion sites Tissue enhanced Tissue enhanced liver: 17.8 cerebral cortex: 7.3 REPS1 ENSG00000135597 RALBP1 associated Eps domain containing 1 6 138903493-138988261 Predicted intracellular proteins Evidence at protein level HPA029961, HPA029962 Approved Approved Vesicles
Plasma membrane
Cytosol Liver cancer:9.47e-4 (unfavourable) Expressed in all Expressed in all testis: 65.9 RET CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51 ENSG00000165731 Ret proto-oncogene 10 43077027-43130351 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002581, HPA008356, HPA008495, CAB018342 Approved Supported Supported Vesicles
Plasma membrane
Cytosol Endometrial cancer:5.02e-4 (unfavourable) Tissue enhanced Tissue enriched 5 parathyroid gland: 146.8 adrenal gland: 29.2 RFPL1 RNF78 ENSG00000128250 Ret finger protein-like 1 22 29438583-29442455 Predicted intracellular proteins Evidence at transcript level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Not detected Tissue enriched 6 cerebral cortex: 27.3 ovary: 4.4 RFPL2 RNF79 ENSG00000128253 Ret finger protein-like 2 22 32190435-32203477 Predicted intracellular proteins Evidence at transcript level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Prostate cancer:4.16e-4 (favourable) Tissue enriched Tissue enriched 9 prostate: 7.0 cerebral cortex: 0.8 RFPL3 ENSG00000128276 Ret finger protein-like 3 22 32354885-32361161 Predicted intracellular proteins Evidence at protein level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Not detected Tissue enriched 7 testis: 4.0 epididymis: 0.5 RGP1 KIAA0258 ENSG00000107185 RGP1 homolog, RAB6A GEF complex partner 1 9 35749287-35758575 Predicted intracellular proteins Evidence at protein level HPA020414, HPA021085 Approved Validated Plasma membrane
Cytosol Renal cancer:8.55e-13 (favourable), Liver cancer:7.09e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.4 RGS10 ENSG00000148908 Regulator of G-protein signaling 10 10 119499828-119542708 Predicted intracellular proteins Evidence at protein level CAB004559, HPA021305, HPA058485 Supported Supported Nucleus
Plasma membrane Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable) Expressed in all Expressed in all lymph node: 139.8 RHOBTB2 DBC2, KIAA0717 ENSG00000008853 Rho-related BTB domain containing 2 8 22987417-23020199 Predicted intracellular proteins Evidence at transcript level HPA060938 Approved Approved Plasma membrane Renal cancer:2.98e-4 (favourable) Expressed in all Mixed lung: 53.1 RHOJ ARHJ, FLJ14445, RASL7B, TCL ENSG00000126785 Ras homolog family member J 14 63204114-63293219 Predicted intracellular proteins Evidence at protein level HPA003050 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Renal cancer:1.31e-4 (unfavourable) Expressed in all Mixed endometrium: 47.9 RIF1 FLJ10599, FLJ12870 ENSG00000080345 Replication timing regulatory factor 1 2 151409883-151508013 Predicted intracellular proteins Evidence at protein level HPA036887, HPA036888 Supported Uncertain Nucleus
Nuclear bodies
Plasma membrane Expressed in all Expressed in all testis: 21.1 RILPL1 FLJ39378 ENSG00000188026 Rab interacting lysosomal protein-like 1 12 123470054-123533718 Predicted intracellular proteins Evidence at protein level HPA041314 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Mixed heart muscle: 43.9 RIMBP3 KIAA1666, RIMBP3.1, RIMBP3A ENSG00000275793 RIMS binding protein 3 22 18605815-18611919 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 38 testis: 45.4 parathyroid gland: 1.2 RIMBP3B ENSG00000274600 RIMS binding protein 3B 22 21383374-21389478 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 26 testis: 12.1 appendix,parathyroid gland: 0.4 RIMBP3C ENSG00000183246 RIMS binding protein 3C 22 21545357-21551461 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 32 testis: 15.7 spleen: 0.4 RIOK2 FLJ11159 ENSG00000058729 RIO kinase 2 5 97160867-97183260 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005681 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 22.0 RIOK3 SUDD ENSG00000101782 RIO kinase 3 18 23452823-23486603 Enzymes, Predicted intracellular proteins Evidence at protein level HPA001620, HPA024184 Approved Approved Golgi apparatus
Plasma membrane
Microtubule organizing center
Cytosol Pancreatic cancer:4.10e-4 (unfavourable), Prostate cancer:5.80e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 75.0 RIPK1 RIP ENSG00000137275 Receptor (TNFRSF)-interacting serine-threonine kinase 1 6 3063991-3115187 Enzymes, Predicted intracellular proteins Evidence at protein level CAB010302, HPA015257 Supported Validated Plasma membrane
Cytosol Urothelial cancer:6.71e-4 (favourable) Expressed in all Expressed in all skin: 26.1 RND1 ARHS, Rho6, RHOS ENSG00000172602 Rho family GTPase 1 12 48857145-48865898 Predicted intracellular proteins Evidence at protein level HPA077800 Supported Vesicles
Plasma membrane
Actin filaments Mixed Tissue enhanced cerebral cortex: 39.9;liver: 31.0 gallbladder: 23.7 RNF114 PSORS12, ZNF313 ENSG00000124226 Ring finger protein 114 20 49936336-49953892 Predicted intracellular proteins Evidence at protein level HPA021184 Approved Supported Plasma membrane
Cytosol Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable) Expressed in all Expressed in all testis: 149.3 RNF145 FLJ31951 ENSG00000145860 Ring finger protein 145 5 159157409-159210053 Predicted membrane proteins Evidence at protein level HPA036562 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.64e-6 (unfavourable) Expressed in all Expressed in all lung: 109.1 RNF146 dactylidin, dJ351K20.1, DKFZp434O1427 ENSG00000118518 Ring finger protein 146 6 127266610-127288567 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027158, HPA027209 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable) Expressed in all Expressed in all endometrium: 94.0 RNF149 FLJ90504 ENSG00000163162 Ring finger protein 149 2 101271219-101308701 Predicted membrane proteins Evidence at protein level HPA011424 Approved Approved Vesicles
Plasma membrane Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable) Expressed in all Expressed in all appendix: 69.4 RNF165 ARKL2, RNF111L2 ENSG00000141622 Ring finger protein 165 18 46326809-46463140 Predicted intracellular proteins Evidence at protein level HPA041615, HPA047798 Uncertain Approved Nucleus
Plasma membrane Mixed Tissue enhanced cerebral cortex: 9.3;parathyroid gland: 9.6 thyroid gland: 6.9 RNF166 MGC14381, MGC2647 ENSG00000158717 Ring finger protein 166 16 88696495-88706421 Predicted intracellular proteins Evidence at protein level HPA042970 Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:9.45e-6 (unfavourable), Pancreatic cancer:1.04e-4 (favourable) Expressed in all Expressed in all bone marrow: 57.2 RNF39 HZFw1, LIRF ENSG00000204618 Ring finger protein 39 6 30070266-30075887 Predicted intracellular proteins Evidence at protein level CAB019278, HPA047115 Uncertain Uncertain Vesicles
Plasma membrane
Centrosome Mixed Tissue enhanced skin: 3.5 breast: 2.1 ROBO1 DUTT1, FLJ21882, SAX3 ENSG00000169855 Roundabout guidance receptor 1 3 78597240-79767815 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013524, HPA052968 Uncertain Supported Plasma membrane Liver cancer:9.88e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 33.0 ROBO4 ECSM4, FLJ20798, MRB ENSG00000154133 Roundabout guidance receptor 4 11 124883691-124898500 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA065212 Approved Plasma membrane Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 59.1 adipose tissue: 45.0 ROM1 ROM, TSPAN23 ENSG00000149489 Retinal outer segment membrane protein 1 11 62611722-62615120 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028910 Supported Approved Plasma membrane
Cytosol Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 25.5 ovary: 13.2 RP11-192H23.4 ENSG00000258472 17 28455752-28614197 Predicted intracellular proteins Evidence at protein level HPA046590 Uncertain Approved Nucleoplasm
Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 2.2 lung: 1.2 RP11-298I3.5 ENSG00000259132 14 22946270-22982258 Predicted intracellular proteins Evidence at protein level HPA029803 Approved Approved Plasma membrane
Focal adhesion sites Not detected Mixed lymph node: 9.2 RP11-385D13.1 ENSG00000251537 17 15571491-15651653 Predicted intracellular proteins Evidence at protein level HPA023623, HPA066431 Uncertain Approved Plasma membrane
Cytosol Not detected Not detected skin: 0.5 RP11-73M18.2 ENSG00000256500 14 103562962-103685924 Predicted intracellular proteins Evidence at protein level HPA044617, HPA052450 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Not detected Tissue enhanced cerebral cortex: 21.6;testis: 21.5 skeletal muscle: 9.1 RP2 NM23-H10, NME10, TBCCD2 ENSG00000102218 Retinitis pigmentosa 2 (X-linked recessive) X 46836940-46882358 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000234, HPA000909 Uncertain Approved Nucleoplasm
Nuclear bodies
Plasma membrane Liver cancer:7.97e-4 (unfavourable) Expressed in all Mixed placenta: 34.8 RP5-862P8.2 ENSG00000143674 Mitogen-activated protein kinase kinase kinase MLK4 1 233327768-233385148 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007636 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed testis: 17.7 RP5-877J2.1 ENSG00000250424 7 30852273-30923812 Predicted membrane proteins Evidence at protein level HPA019206, HPA030130 Approved Approved Plasma membrane Not detected Tissue enhanced gallbladder: 1.3 fallopian tube: 1.0 RPGRIP1L CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134 ENSG00000103494 RPGRIP1-like 16 53597683-53703938 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039405, HPA040530 Uncertain Approved Plasma membrane
Cytosol Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable) Mixed Tissue enhanced testis: 27.8 parathyroid gland: 19.1 RPIA ENSG00000153574 Ribose 5-phosphate isomerase A 2 88691644-88750935 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA042620, HPA057954 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Renal cancer:8.53e-6 (unfavourable), Liver cancer:1.46e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 54.3 RPL36A L36A, RPL44 ENSG00000241343 Ribosomal protein L36a X 101390824-101396154 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA063979, HPA077586 Uncertain Supported Plasma membrane
Cytosol Renal cancer:8.81e-11 (unfavourable) Expressed in all Expressed in all ovary: 3443.9 RPL36A-HNRNPH2 ENSG00000257529 RPL36A-HNRNPH2 readthrough X 101391011-101412297 Predicted intracellular proteins Evidence at transcript level HPA077586 Approved Plasma membrane
Cytosol Not detected Mixed ovary: 2.6 RPL36AL RPL36A ENSG00000165502 Ribosomal protein L36a-like 14 49618519-49620685 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA077586 Approved Plasma membrane
Cytosol Thyroid cancer:2.83e-4 (favourable) Expressed in all Expressed in all ovary: 528.8 RPSA 37LRP, LAMR1, LRP, p40, SA ENSG00000168028 Ribosomal protein SA 3 39406689-39412542 Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level CAB009561 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all ovary: 2079.5 RRAD RAD, REM3 ENSG00000166592 Ras-related associated with diabetes 16 66921679-66925644 Predicted intracellular proteins Evidence at protein level HPA041755 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Expressed in all Tissue enhanced heart muscle: 104.7 skeletal muscle: 67.5 RSAD1 FLJ11164 ENSG00000136444 Radical S-adenosyl methionine domain containing 1 17 50478800-50485975 Predicted intracellular proteins Evidence at protein level HPA022436, HPA022967 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:5.04e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 36.0 RSBN1L FLJ42526, FLJ45813, MGC71764 ENSG00000187257 Round spermatid basic protein 1-like 7 77696443-77783022 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA020406, HPA020413 Approved Supported Nuclear speckles
Plasma membrane Lung cancer:3.74e-4 (favourable) Expressed in all Expressed in all testis: 47.0 RSPH3 dJ111C20.1, RSHL2, RSP3 ENSG00000130363 Radial spoke 3 homolog (Chlamydomonas) 6 158972871-159000187 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039109, HPA040230 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:2.19e-4 (favourable) Expressed in all Mixed parathyroid gland: 25.9 RTN4R NOGOR ENSG00000040608 Reticulon 4 receptor 22 20241415-20283246 Predicted membrane proteins Evidence at protein level CAB012443 Supported Plasma membrane
Actin filaments
Focal adhesion sites Head and neck cancer:7.73e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 23.8 spleen: 5.1 RYR2 ARVC2, ARVD2, VTSIP ENSG00000198626 Ryanodine receptor 2 (cardiac) 1 237042205-237833988 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020028 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enriched 9 heart muscle: 68.2 cerebral cortex: 8.0 S100A13 ENSG00000189171 S100 calcium binding protein A13 1 153618787-153631360 Predicted intracellular proteins Evidence at protein level HPA019592, CAB025494 Approved Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Renal cancer:1.97e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 330.1 S100A16 DT1P1A7, MGC17528, S100F ENSG00000188643 S100 calcium binding protein A16 1 153606886-153613145 Predicted intracellular proteins Evidence at protein level HPA045841 Supported Validated Plasma membrane
Cytosol Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1495.4 skin: 395.2 S100A2 CAN19, S100L ENSG00000196754 S100 calcium binding protein A2 1 153561108-153567890 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002600, CAB047340, HPA062451 Supported Supported Nucleus
Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:2.04e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1487.6;tonsil: 385.6 urinary bladder: 368.6 S100A4 18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98 ENSG00000196154 S100 calcium binding protein A4 1 153543613-153550136 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228 Supported Validated Plasma membrane Head and neck cancer:4.03e-5 (favourable), Renal cancer:2.90e-4 (unfavourable) Expressed in all Expressed in all lung: 990.8 SAMHD1 AGS5, HDDC1, Mg11, MOP-5, SBBI88 ENSG00000101347 SAM domain and HD domain 1 20 36890229-36951843 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047072 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:5.12e-4 (unfavourable) Expressed in all Expressed in all spleen: 135.3 SC5D SC5DL ENSG00000109929 Sterol-C5-desaturase 11 121292453-121308694 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA066283, HPA070248 Approved Approved Nucleoplasm
Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable) Expressed in all Expressed in all liver: 193.1 SCAMP4 FLJ33847 ENSG00000227500 Secretory carrier membrane protein 4 19 1905214-1926013 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043284 Approved Approved Golgi apparatus
Vesicles
Lipid droplets
Plasma membrane Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable) Expressed in all Expressed in all fallopian tube: 58.6 SCEL FLJ21667, MGC22531 ENSG00000136155 Sciellin 13 77535674-77645263 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039737, HPA040154 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable) Mixed Tissue enhanced esophagus: 478.3;skin: 397.8 lung: 99.0 SCIN KIAA1905 ENSG00000006747 Scinderin 7 12570577-12660179 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020518, HPA024264 Supported Approved Plasma membrane
Cytosol Renal cancer:4.26e-8 (favourable) Tissue enhanced Tissue enhanced placenta: 116.3 small intestine: 52.7 SCN1A FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI ENSG00000144285 Sodium channel, voltage gated, type I alpha subunit 2 165989160-166128047 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA078664 Approved Nucleoplasm
Nuclear bodies
Plasma membrane Tissue enriched Tissue enhanced cerebral cortex: 12.0;fallopian tube: 4.4;lung: 3.2 testis: 2.2 SCN9A ETHA, Nav1.7, NE-NA, NENA, PN1 ENSG00000169432 Sodium channel, voltage gated, type IX alpha subunit 2 166195185-166375993 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB013679, HPA061843 Uncertain Approved Plasma membrane
Actin filaments
Focal adhesion sites Renal cancer:2.30e-5 (unfavourable) Mixed Tissue enhanced testis: 9.1 placenta: 5.9 SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel, non voltage gated 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009540, HPA026884 Approved Supported Plasma membrane
Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 SCNN1G ENaCgamma, SCNEG ENSG00000166828 Sodium channel, non voltage gated 1 gamma subunit 16 23182715-23216883 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071194 Approved Nucleoplasm
Nucleoli
Plasma membrane Renal cancer:3.20e-7 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 24.5;kidney: 46.4 thyroid gland: 9.5 SCRIB KIAA0147, SCRB1, Vartul ENSG00000180900 Scribbled planar cell polarity protein 8 143790920-143815379 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015463, CAB022081, HPA023557, HPA064312 Supported Validated Nucleoplasm
Plasma membrane
Cell Junctions
Rods & Rings Expressed in all Expressed in all skin: 22.0 SDC2 CD362, fibroglycan, HSPG, HSPG1, SYND2 ENSG00000169439 Syndecan 2 8 96493351-96611780 CD markers, Predicted membrane proteins Evidence at protein level CAB025123, HPA044416 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 708.5 SDC4 amphiglycan, ryudocan, SYND4 ENSG00000124145 Syndecan 4 20 45325288-45348424 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA005716, CAB013240 Supported Approved Golgi apparatus
Plasma membrane Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all lung: 250.5 SDE2 C1orf55, FLJ35382 ENSG00000143751 SDE2 telomere maintenance homolog (S. pombe) 1 225982702-225999331 Predicted intracellular proteins Evidence at protein level HPA028467, HPA031255, HPA031256 Approved Approved Nuclear speckles
Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 21.0 SDHB SDH, SDH1 ENSG00000117118 Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 1 17018722-17054170 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002868, CAB009822, CAB068233, CAB068234, CAB068235 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Renal cancer:2.93e-7 (favourable) Expressed in all Expressed in all kidney: 213.3 SDPR cavin-2, CAVIN2, PS-p68, SDR ENSG00000168497 Serum deprivation response 2 191834302-191847255 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039325, HPA062122 Supported Supported Plasma membrane
Cytosol Renal cancer:8.45e-5 (favourable), Stomach cancer:3.69e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 165.5 SEC16B LZTR2, PGPR-p117, RGPR, Sec16S ENSG00000120341 SEC16 homolog B, endoplasmic reticulum export factor 1 177923956-177984303 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031202, HPA054292 Uncertain Approved Endoplasmic reticulum
Plasma membrane
Actin filaments Not detected Tissue enhanced duodenum: 28.9;small intestine: 31.5 liver: 18.8 SEMA3C SEMAE, SemE ENSG00000075223 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C 7 80742538-80922359 Predicted secreted proteins Evidence at protein level HPA042418 Uncertain Approved Golgi apparatus
Plasma membrane
Cytosol Pancreatic cancer:4.08e-5 (unfavourable), Head and neck cancer:5.72e-5 (unfavourable) Mixed Mixed prostate: 98.7 SEMA3D coll-2, Sema-Z2 ENSG00000153993 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 7 84995553-85186855 Predicted intracellular proteins Evidence at protein level HPA037522 Uncertain Approved Golgi apparatus
Plasma membrane Mixed Group enriched 5 spleen: 67.1;thyroid gland: 76.0 prostate: 13.5 SEMA4F SEMAM, SEMAW ENSG00000135622 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F 2 74654228-74683853 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065969 Approved Nucleus
Plasma membrane
Centrosome Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable) Expressed in all Mixed cerebral cortex: 14.2 SEMA6D FLJ11598, KIAA1479 ENSG00000137872 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 15 47184101-47774223 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043109 Approved Golgi apparatus
Plasma membrane Renal cancer:5.96e-5 (favourable) Tissue enhanced Tissue enhanced placenta: 64.3 small intestine: 45.7 SEPT3 SEP3 ENSG00000100167 Septin 3 22 41976272-41998221 Predicted intracellular proteins Evidence at protein level HPA003548, CAB017633 Supported Approved Nucleoplasm
Plasma membrane
Actin filaments Endometrial cancer:1.78e-4 (unfavourable) Tissue enhanced Tissue enriched 11 cerebral cortex: 235.5 parathyroid gland: 21.5 SERPINB3 HsT1196, SCC, SCCA1, T4-A ENSG00000057149 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 18 63637719-63661963 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:3.19e-4 (unfavourable) Tissue enhanced Group enriched 6 cervix, uterine: 297.6;esophagus: 851.2 urinary bladder: 90.5 SFSWAP SFRS8, SWAP ENSG00000061936 Splicing factor, suppressor of white-apricot family 12 131711081-131799737 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039362, HPA040063 Approved Approved Nucleus
Plasma membrane
Cytosol Renal cancer:3.33e-8 (unfavourable), Melanoma:1.10e-4 (unfavourable) Expressed in all Expressed in all skin: 18.1 SGCE DYT11 ENSG00000127990 Sarcoglycan, epsilon 7 94585230-94656209 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074790 Approved Nucleoplasm
Golgi apparatus
Vesicles
Plasma membrane Head and neck cancer:1.61e-5 (unfavourable), Stomach cancer:1.35e-4 (unfavourable) Expressed in all Mixed ovary: 132.8 SGK494 ENSG00000167524 Uncharacterized serine/threonine-protein kinase SgK494 17 28607964-28614200 Predicted intracellular proteins Evidence at protein level HPA046590 Uncertain Approved Nucleoplasm
Vesicles
Plasma membrane Mixed Mixed testis: 11.4 SH3BGR 21-GARP ENSG00000185437 SH3 domain binding glutamate-rich protein 21 39445855-39515506 Predicted intracellular proteins Evidence at protein level CAB003685, HPA030690 Supported Approved Plasma membrane
Cytosol Expressed in all Group enriched 7 heart muscle: 89.7;skeletal muscle: 436.1 prostate: 40.2 SH3D21 C1orf113, FLJ22938 ENSG00000214193 SH3 domain containing 21 1 36306387-36324886 Predicted intracellular proteins Evidence at protein level HPA042212, HPA042456, HPA066168 Approved Approved Nucleus
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable) Mixed Tissue enhanced small intestine: 28.3 skin: 17.8 SH3PXD2B FLJ20831, KIAA1295 ENSG00000174705 SH3 and PX domains 2B 5 172325181-172454523 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036471 Approved Approved Nucleus
Nucleoli fibrillar center
Plasma membrane Liver cancer:7.51e-5 (unfavourable), Renal cancer:1.90e-4 (unfavourable), Urothelial cancer:8.45e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 35.4 SHANK1 SPANK-1, SSTRIP, synamon ENSG00000161681 SH3 and multiple ankyrin repeat domains 1 19 50661827-50719450 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032129, HPA032130 Uncertain Supported Plasma membrane Tissue enhanced Tissue enriched 24 cerebral cortex: 35.9 adrenal gland: 1.5 SHROOM2 APXL ENSG00000146950 Shroom family member 2 X 9786456-9949443 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051646 Approved Approved Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.35e-7 (favourable) Expressed in all Mixed cerebral cortex: 11.8 SHTN1 KIAA1598, shootin-1, shootin1 ENSG00000187164 Shootin 1 10 116881482-117126586 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA037942, HPA037943 Supported Approved Nucleus
Plasma membrane
Cytosol Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 36.2 parathyroid gland: 18.6 SIGLEC10 MGC126774, PRO940, SIGLEC-10, SLG2 ENSG00000142512 Sialic acid binding Ig-like lectin 10 19 51410021-51417803 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025807, HPA027093 Approved Supported Plasma membrane
Actin filaments
Cytosol Renal cancer:4.74e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 49.9;spleen: 37.9 lymph node: 22.4 SIN3B KIAA0700 ENSG00000127511 SIN3 transcription regulator family member B 19 16829400-16880353 Predicted intracellular proteins Evidence at protein level HPA050329 Uncertain Approved Nucleoplasm
Plasma membrane Prostate cancer:3.58e-4 (unfavourable), Pancreatic cancer:4.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 110.4 SIPA1 SPA1 ENSG00000213445 Signal-induced proliferation-associated 1 11 65585395-65650930 Predicted intracellular proteins Evidence at protein level CAB020833, HPA039867 Supported Approved Nucleus
Nucleoli
Golgi apparatus
Plasma membrane Renal cancer:3.52e-6 (unfavourable), Colorectal cancer:9.42e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 101.8 lymph node: 72.4 SIPA1L1 E6TP1, KIAA0440 ENSG00000197555 Signal-induced proliferation-associated 1 like 1 14 71320449-71741229 Predicted intracellular proteins Evidence at protein level HPA002875 Approved Approved Plasma membrane
Actin filaments Renal cancer:6.80e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 46.2 SKA3 C13orf3, MGC4832, RAMA1 ENSG00000165480 Spindle and kinetochore associated complex subunit 3 13 21153595-21176602 Predicted intracellular proteins Evidence at protein level HPA039272 Approved Uncertain Plasma membrane
Cytosol Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable) Mixed Tissue enhanced testis: 10.2 lymph node: 5.1 SLC10A5 ENSG00000253598 Solute carrier family 10, member 5 8 81693607-81696174 Predicted membrane proteins, Transporters Evidence at protein level HPA025966 Uncertain Approved Plasma membrane Mixed Mixed liver: 3.0 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 SLC16A1 MCT, MCT1 ENSG00000155380 Solute carrier family 16 (monocarboxylate transporter), member 1 1 112911847-112957013 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003324, CAB017489, HPA071055 Supported Validated Plasma membrane
Cell Junctions Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable) Expressed in all Mixed testis: 32.0 SLC16A2 AHDS, DXS128, MCT7, MCT8, MRX22, XPCT ENSG00000147100 Solute carrier family 16, member 2 (thyroid hormone transporter) X 74421461-74533917 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA072719 Approved Plasma membrane Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable) Expressed in all Mixed liver: 41.9 SLC16A3 MCT3, MCT4 ENSG00000141526 Solute carrier family 16 (monocarboxylate transporter), member 3 17 82228397-82261129 Predicted membrane proteins, Transporters Evidence at protein level CAB017490, HPA021451 Approved Supported Nuclear membrane
Plasma membrane Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 74.4 SLC16A7 MCT2 ENSG00000118596 Solute carrier family 16 (monocarboxylate transporter), member 7 12 59596067-59789855 Predicted membrane proteins, Transporters Evidence at protein level HPA005911 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.85e-5 (favourable) Mixed Mixed adipose tissue: 24.8 SLC17A5 AST, ISSD, NSD, SD, SIALIN, SIASD, SLD ENSG00000119899 Solute carrier family 17 (acidic sugar transporter), member 5 6 73593379-73654155 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044479 Supported Plasma membrane
Cytosol Thyroid cancer:3.52e-4 (favourable) Expressed in all Tissue enriched 9 parathyroid gland: 640.5 thyroid gland: 69.8 SLC19A1 FOLT ENSG00000173638 Solute carrier family 19 (folate transporter), member 1 21 45493572-45544411 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA024802 Approved Approved Plasma membrane Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable) Expressed in all Mixed duodenum: 22.6 SLC1A5 AAAT, ASCT2, M7V1, RDRC ENSG00000105281 Solute carrier family 1 (neutral amino acid transporter), member 5 19 46774883-46788594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035239, HPA035240 Supported Validated Plasma membrane Liver cancer:1.66e-8 (unfavourable), Renal cancer:1.18e-7 (unfavourable) Expressed in all Expressed in all epididymis: 117.4 SLC2A1 CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR ENSG00000117394 Solute carrier family 2 (facilitated glucose transporter), member 1 1 42925375-42959173 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002759, HPA031345, HPA058494 Supported Supported Validated Plasma membrane Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 133.9 skin: 31.3 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC2A14 GLUT14, SLC2A3P3 ENSG00000173262 Solute carrier family 2 (facilitated glucose transporter), member 14 12 7812512-7891148 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006539 Approved Approved Plasma membrane Tissue enriched Tissue enriched 9 testis: 151.1 breast: 17.2 SLC2A3 GLUT3 ENSG00000059804 Solute carrier family 2 (facilitated glucose transporter), member 3 12 7919230-7936275 Predicted membrane proteins, Transporters Evidence at protein level CAB002763, HPA006539 Approved Approved Plasma membrane Renal cancer:6.36e-8 (unfavourable), Stomach cancer:2.89e-5 (unfavourable), Colorectal cancer:8.58e-4 (unfavourable) Tissue enriched Tissue enhanced bone marrow: 271.6 placenta: 137.6 SLC30A1 ZNT1, ZRC1 ENSG00000170385 Solute carrier family 30 (zinc transporter), member 1 1 211571568-211578742 Predicted membrane proteins, Transporters Evidence at protein level HPA015275, HPA049000 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed liver: 47.3 SLC31A2 COPT2, CTR2, hCTR2 ENSG00000136867 Solute carrier family 31 (copper transporter), member 2 9 113150942-113164137 Predicted membrane proteins, Transporters Evidence at protein level HPA014861 Approved Approved Nuclear speckles
Plasma membrane
Intermediate filaments Mixed Expressed in all salivary gland: 170.9 SLC35F5 FLJ22004 ENSG00000115084 Solute carrier family 35, member F5 2 113705011-113756823 Predicted membrane proteins, Transporters Evidence at transcript level HPA034828, HPA049229 Uncertain Uncertain Plasma membrane Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 65.7 SLC36A4 FLJ38932, PAT4 ENSG00000180773 Solute carrier family 36 (proton/amino acid symporter), member 4 11 93144171-93197964 Predicted membrane proteins, Transporters Evidence at protein level HPA017887 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Expressed in all Mixed thyroid gland: 14.7 SLC38A5 JM24, SN2 ENSG00000017483 Solute carrier family 38, member 5 X 48458537-48470256 Predicted membrane proteins, Transporters Evidence at protein level HPA047411 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable) Expressed in all Mixed pancreas: 50.0 SLC38A6 NAT-1 ENSG00000139974 Solute carrier family 38, member 6 14 60981114-61083733 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018508 Approved Approved Plasma membrane
Cell Junctions
Microtubules Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 SLC38A7 FLJ10815 ENSG00000103042 Solute carrier family 38, member 7 16 58665109-58685104 Predicted membrane proteins, Transporters Evidence at protein level HPA041777 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable) Expressed in all Mixed testis: 34.8 SLC39A10 DKFZp564L2123, FLJ90515, KIAA1265 ENSG00000196950 Solute carrier family 39 (zinc transporter), member 10 2 195575977-195737702 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA036512, HPA036513, HPA066087 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 78.0;thyroid gland: 79.0 prostate: 27.6 SLC39A14 KIAA0062, NET34, ZIP14 ENSG00000104635 Solute carrier family 39 (zinc transporter), member 14 8 22367249-22434129 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016508 Approved Approved Endoplasmic reticulum
Golgi apparatus
Plasma membrane Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable) Expressed in all Mixed liver: 202.8 SLC3A2 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE ENSG00000168003 Solute carrier family 3 (amino acid transporter heavy chain), member 2 11 62856102-62888875 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB010455, HPA017980 Supported Supported Nucleus
Plasma membrane
Cytosol Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 424.3 SLC40A1 FPN1, HFE4, IREG1, MTP1, SLC11A3 ENSG00000138449 Solute carrier family 40 (iron-regulated transporter), member 1 2 189560579-189583758 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA065634 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.55e-5 (favourable) Expressed in all Expressed in all spleen: 496.0 SLC41A3 FLJ20473 ENSG00000114544 Solute carrier family 41, member 3 3 126006355-126101561 Predicted membrane proteins, Transporters Evidence at protein level HPA045847 Approved Supported Plasma membrane Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable) Expressed in all Expressed in all testis: 79.0 SLC43A1 PB39, POV1, R00504 ENSG00000149150 Solute carrier family 43 (amino acid system L transporter), member 1 11 57484534-57515786 Predicted membrane proteins, Transporters Evidence at protein level HPA018813, HPA018826 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable) Expressed in all Expressed in all liver: 50.0 SLC45A4 KIAA1126 ENSG00000022567 Solute carrier family 45, member 4 8 141207166-141308305 Predicted membrane proteins, Transporters Evidence at protein level HPA023154 Uncertain Approved Plasma membrane Renal cancer:1.73e-6 (favourable) Expressed in all Mixed testis: 21.1 SLC46A1 HCP1, MGC9564, PCFT ENSG00000076351 Solute carrier family 46 (folate transporter), member 1 17 28394756-28407197 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011614 Approved Supported Plasma membrane
Cytosol Glioma:3.90e-4 (unfavourable) Expressed in all Expressed in all duodenum: 97.7 SLC46A3 DKFZp686A1775, FLJ42613 ENSG00000139508 Solute carrier family 46, member 3 13 28700064-28718970 Predicted membrane proteins, Transporters Evidence at protein level HPA039930 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Lung cancer:7.09e-4 (favourable) Expressed in all Expressed in all small intestine: 89.4 SLC4A2 AE2, BND3L, EPB3L1, HKB3, NBND3 ENSG00000164889 Solute carrier family 4 (anion exchanger), member 2 7 151057210-151076527 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA019339 Supported Approved Nuclear speckles
Plasma membrane
Cytosol Liver cancer:9.04e-6 (unfavourable), Renal cancer:1.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 87.8 SLC4A7 NBC3, SBC2, SLC4A6 ENSG00000033867 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 3 27372721-27484420 Predicted membrane proteins, Transporters Evidence at protein level CAB022494, HPA035857 Supported Supported Plasma membrane
Focal adhesion sites Renal cancer:7.91e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 59.2 breast: 23.6 SLC5A3 SMIT, SMIT1 ENSG00000198743 Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 21 34073570-34106260 Predicted membrane proteins, Transporters Evidence at protein level HPA029791 Approved Plasma membrane
Cytosol Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 42.0 kidney: 32.9 SLC7A2 ATRC2, CAT-2, HCAT2 ENSG00000003989 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8 17497088-17570573 Predicted membrane proteins, Transporters Evidence at protein level HPA009277 Supported Plasma membrane
Cell Junctions Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 373.7 liver: 92.6 SLC7A5 CD98, D16S469E, E16, LAT1, MPE16 ENSG00000103257 Solute carrier family 7 (amino acid transporter light chain, L system), member 5 16 87830023-87869488 Predicted membrane proteins, Transporters Evidence at protein level HPA052673, HPA056077 Approved Supported Vesicles
Plasma membrane
Cytosol Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 90.5;testis: 84.4 bone marrow: 66.3 SLC7A6 KIAA0245, LAT-2, LAT3, y+LAT-2 ENSG00000103064 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 16 68264516-68301823 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050713 Uncertain Approved Vesicles
Plasma membrane Urothelial cancer:1.84e-4 (unfavourable) Expressed in all Mixed adipose tissue: 35.1 SLC8A1 NCX1 ENSG00000183023 Solute carrier family 8 (sodium/calcium exchanger), member 1 2 40097270-40611053 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022694, HPA070007 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced heart muscle: 79.5 seminal vesicle: 38.2 SLC9A1 APNH, NHE1, PPP1R143 ENSG00000090020 Solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 1 27098815-27166981 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022371, HPA048532, HPA052891 Supported Supported Plasma membrane Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all stomach: 66.4 SLC9A3 NHE3 ENSG00000066230 Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 5 473310-524332 Predicted membrane proteins, Transporters Evidence at protein level HPA036493, HPA036669 Supported Supported Plasma membrane Melanoma:8.49e-4 (unfavourable) Mixed Tissue enhanced colon: 82.6;small intestine: 74.1 gallbladder: 66.3 SLC9A3R1 EBP50, NHERF ENSG00000109062 Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1 17 74748652-74769353 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB001962, HPA009672, HPA027247 Supported Approved Vesicles
Plasma membrane
Microtubule organizing center Liver cancer:9.83e-5 (unfavourable) Expressed in all Expressed in all small intestine: 308.5 SLC9A3R2 E3KARP, NHERF-2, SIP-1, TKA-1 ENSG00000065054 Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 2 16 2025356-2039026 Predicted intracellular proteins, Transporters Evidence at protein level HPA001672 Approved Supported Plasma membrane Endometrial cancer:1.03e-4 (favourable) Expressed in all Mixed lung: 161.9 SLC9A4 NHE4 ENSG00000180251 Solute carrier family 9, subfamily A (NHE4, cation proton antiporter 4), member 4 2 102473303-102533972 Predicted membrane proteins, Transporters Evidence at protein level HPA036096 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 5 stomach: 51.1 kidney: 9.5 SLCO1A2 OATP, OATP-A, OATP1A2, SLC21A3 ENSG00000084453 Solute carrier organic anion transporter family, member 1A2 12 21264600-21419594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA071152 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 28.8 salivary gland: 6.6 SLCO1B3 OATP1B3, OATP8, SLC21A8 ENSG00000111700 Solute carrier organic anion transporter family, member 1B3 12 20810702-20916911 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA004943, HPA050892 Supported Supported Plasma membrane Tissue enhanced Tissue enriched 7 liver: 138.5 cervix, uterine: 19.4 SLITRK6 FLJ22774 ENSG00000184564 SLIT and NTRK-like family, member 6 13 85792790-85799488 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014491, HPA014513 Uncertain Supported Plasma membrane Head and neck cancer:8.52e-4 (unfavourable) Tissue enhanced Tissue enhanced urinary bladder: 20.4 salivary gland: 11.8 SLK KIAA0204, se20-9, STK2 ENSG00000065613 STE20-like kinase 10 103967201-104029233 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015757 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all esophagus: 61.2 SMAD1 JV4-1, MADH1, MADR1 ENSG00000170365 SMAD family member 1 4 145481194-145558079 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005389 Approved Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 69.4 SMAGP hSMAGP, MGC149453, MGC149454 ENSG00000170545 Small cell adhesion glycoprotein 12 51244558-51270890 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039711 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 144.1 esophagus: 83.7 SMAP1 FLJ13159, SMAP-1 ENSG00000112305 Small ArfGAP 1 6 70667776-70862015 Predicted intracellular proteins Evidence at protein level HPA030574 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 51.1 SMOC1 ENSG00000198732 SPARC related modular calcium binding 1 14 69854131-70032366 Disease related genes, Predicted secreted proteins Evidence at protein level HPA004153, CAB034427 Approved Approved Plasma membrane Mixed Tissue enhanced cerebral cortex: 136.1 testis: 64.9 SMPD2 ISC1, nSMase ENSG00000135587 Sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) 6 109440763-109443919 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018110, HPA018125 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable) Expressed in all Mixed testis: 55.6 SNAP23 HsT17016, SNAP23A, SNAP23B ENSG00000092531 Synaptosomal-associated protein, 23kDa 15 42491233-42545356 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001214, CAB037083, CAB037317 Approved Supported Plasma membrane Expressed in all Expressed in all spleen: 88.1 SNCG BCSG1, persyn, SR ENSG00000173267 Synuclein, gamma (breast cancer-specific protein 1) 10 86958618-86963260 Predicted intracellular proteins Evidence at protein level CAB001452, HPA014404, CAB040581 Supported Approved Approved Golgi apparatus
Plasma membrane Renal cancer:2.29e-8 (unfavourable), Stomach cancer:7.15e-4 (unfavourable) Group enriched Tissue enhanced adipose tissue: 174.4;adrenal gland: 199.0;urinary bladder: 190.7 seminal vesicle: 113.6 SNRK FLJ20224, HSNFRK, KIAA0096 ENSG00000163788 SNF related kinase 3 43286512-43424764 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042163 Uncertain Approved Nucleus
Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable) Expressed in all Expressed in all placenta: 47.5 SNX9 SDP1, SH3PX1, SH3PXD3A ENSG00000130340 Sorting nexin 9 6 157700387-157945077 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031410, HPA057203 Approved Validated Plasma membrane
Cytosol Lung cancer:3.77e-4 (unfavourable), Cervical cancer:5.95e-4 (unfavourable), Renal cancer:9.95e-4 (favourable) Expressed in all Expressed in all gallbladder: 71.1 SOCS5 CIS6, Cish5, CISH6, KIAA0671, SOCS-5 ENSG00000171150 Suppressor of cytokine signaling 5 2 46698952-46763129 Predicted intracellular proteins Evidence at protein level HPA020884, CAB025510 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:7.28e-4 (unfavourable), Ovarian cancer:7.53e-4 (unfavourable) Expressed in all Expressed in all ovary: 31.0 SOD1 ALS, ALS1, IPOA ENSG00000142168 Superoxide dismutase 1, soluble 21 31659622-31668931 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001401, CAB008670 Supported Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all liver: 767.7 SORBS1 CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12 ENSG00000095637 Sorbin and SH3 domain containing 1 10 95311771-95561414 Predicted intracellular proteins Evidence at protein level HPA027559, HPA043084 Approved Supported Plasma membrane
Focal adhesion sites
Centrosome Breast cancer:2.84e-4 (favourable) Expressed in all Expressed in all adipose tissue: 318.9 SORCS1 sorCS1 ENSG00000108018 Sortilin-related VPS10 domain containing receptor 1 10 106573663-107164534 Predicted membrane proteins Evidence at protein level HPA011948 Approved Approved Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 12.2;thyroid gland: 18.0 kidney: 4.8 SORT1 Gp95, NT3 ENSG00000134243 Sortilin 1 1 109309568-109397951 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006889, CAB011498 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable) Expressed in all Expressed in all epididymis: 166.9 SPAG16 DKFZp666P1710, FLJ22724, PF20, WDR29 ENSG00000144451 Sperm associated antigen 16 2 213284379-214410501 Predicted intracellular proteins Evidence at protein level HPA037542 Uncertain Approved Plasma membrane
Cytosol Renal cancer:3.82e-4 (favourable), Prostate cancer:4.90e-4 (unfavourable) Expressed in all Expressed in all testis: 83.8 SPATA12 ENSG00000186451 Spermatogenesis associated 12 3 57060441-57075432 Predicted intracellular proteins Evidence at transcript level HPA043323 Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enriched 54 testis: 22.9 fallopian tube,lung: 0.4 SPATC1L C21orf56 ENSG00000160284 Spermatogenesis and centriole associated 1-like 21 46161148-46184476 Predicted intracellular proteins Evidence at protein level HPA018979, HPA019165, HPA029394 Uncertain Approved Vesicles
Plasma membrane
Cytosol Pancreatic cancer:2.16e-4 (favourable) Expressed in all Tissue enhanced testis: 11.7 prostate: 6.4 SPERT CBY2, NURIT ENSG00000174015 Spermatid associated 13 45702311-45714559 Predicted intracellular proteins Evidence at protein level HPA039359, HPA040046 Supported Approved Plasma membrane
Cell Junctions Mixed Tissue enriched 175 testis: 49.2 fallopian tube,urinary bladder: 0.2 SPG11 FLJ21439, KIAA1840 ENSG00000104133 Spastic paraplegia 11 (autosomal recessive) 15 44562696-44663678 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040412, HPA040947 Approved Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:6.28e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.0 SPG20 KIAA0610, TAHCCP1 ENSG00000133104 Spastic paraplegia 20 (Troyer syndrome) 13 36301638-36370180 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039053, HPA039054, HPA061519 Approved Validated Plasma membrane
Cytosol Expressed in all Expressed in all epididymis: 80.0 SPHK1 SPHK ENSG00000176170 Sphingosine kinase 1 17 76376584-76387860 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022829, HPA028761 Uncertain Supported Plasma membrane
Cytosol Renal cancer:5.14e-6 (unfavourable) Expressed in all Mixed gallbladder: 19.0 SPINK13 HBVDNAPTP1, HESPINTOR, LiESP6, MGC149260, SPINK5L3 ENSG00000214510 Serine peptidase inhibitor, Kazal type 13 (putative) 5 148268180-148286254 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA036456 Uncertain Approved Nucleus
Plasma membrane Renal cancer:4.03e-10 (unfavourable) Group enriched Tissue enriched 8 epididymis: 304.8 seminal vesicle: 36.9 SPINT1 HAI, MANSC2 ENSG00000166145 Serine peptidase inhibitor, Kunitz type 1 15 40844018-40858207 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006903 Uncertain Uncertain Plasma membrane
Cytosol Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 219.8 SPINT2 HAI-2, Kop ENSG00000167642 Serine peptidase inhibitor, Kunitz type, 2 19 38244035-38292614 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011101, CAB018969 Approved Uncertain Plasma membrane
Intermediate filaments
Cytosol Renal cancer:3.41e-4 (favourable) Expressed in all Mixed thyroid gland: 536.5 SPN CD43, GPL115, LSN ENSG00000197471 Sialophorin 16 29662979-29670876 CD markers, Predicted membrane proteins Evidence at protein level CAB002666, HPA055244 Supported Uncertain Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 38.7;lung: 33.4 lymph node: 25.8 SPPL2B IMP4, KIAA1532, PSL1 ENSG00000005206 Signal peptide peptidase like 2B 19 2328615-2354806 Enzymes, Predicted membrane proteins Evidence at protein level HPA039292 Approved Nucleoplasm
Plasma membrane
Centrosome Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable) Expressed in all Expressed in all testis: 49.2 SPPL3 DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4 ENSG00000157837 Signal peptide peptidase like 3 12 120762510-120904371 Enzymes, Predicted membrane proteins Evidence at protein level HPA004194, HPA059958 Uncertain Supported Vesicles
Plasma membrane Liver cancer:1.29e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 SPRED3 ENSG00000188766 Sprouty-related, EVH1 domain containing 3 19 38388421-38399587 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA071521 Uncertain Nucleoplasm
Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 6.6 parathyroid gland: 2.6 SPSB4 SSB-4 ENSG00000175093 SplA/ryanodine receptor domain and SOCS box containing 4 3 141051402-141148611 Predicted intracellular proteins Evidence at protein level HPA073015 Approved Nucleoplasm
Plasma membrane Glioma:2.57e-4 (favourable) Group enriched Tissue enhanced cerebral cortex: 1.3;spleen: 1.5;testis: 2.4 pancreas: 1.2 SRC ASV, c-src, SRC1 ENSG00000197122 SRC proto-oncogene, non-receptor tyrosine kinase 20 37344685-37406050 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004023, HPA030875 Approved Validated Plasma membrane
Cytosol Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable) Expressed in all Mixed gallbladder,small intestine: 43.7 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 SRPK1 SFRSK1 ENSG00000096063 SRSF protein kinase 1 6 35832966-35921342 Enzymes, Predicted intracellular proteins Evidence at protein level HPA016431, HPA056486 Approved Supported Nucleus
Plasma membrane
Cytosol Liver cancer:7.90e-6 (unfavourable), Pancreatic cancer:6.53e-5 (unfavourable) Expressed in all Expressed in all testis: 81.8 SRPRB APMCF1 ENSG00000144867 Signal recognition particle receptor, B subunit 3 133784033-133825772 Predicted membrane proteins Evidence at protein level HPA011173 Approved Approved Plasma membrane Liver cancer:3.12e-5 (unfavourable) Expressed in all Expressed in all epididymis: 51.1 SRRM3 FLJ37078 ENSG00000177679 Serine/arginine repetitive matrix 3 7 76201900-76287288 Predicted intracellular proteins Evidence at protein level HPA019337 Uncertain Approved Plasma membrane
Intermediate filaments
Microtubules Mixed Group enriched 10 adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8 stomach: 0.4 SSFA2 CS-1, KIAA1927, KRAP, SPAG13 ENSG00000138434 Sperm specific antigen 2 2 181891833-181930738 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034665, HPA039989 Uncertain Supported Nucleus
Plasma membrane
Cytosol Renal cancer:2.91e-5 (favourable), Urothelial cancer:5.79e-5 (unfavourable), Pancreatic cancer:8.19e-4 (unfavourable) Expressed in all Expressed in all skin: 137.4 SSH1 KIAA1298 ENSG00000084112 Slingshot protein phosphatase 1 12 108778192-108857590 Enzymes, Predicted intracellular proteins Evidence at protein level HPA019845 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Liver cancer:5.80e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 9.5 SSH3 FLJ10928, FLJ20515 ENSG00000172830 Slingshot protein phosphatase 3 11 67303448-67312607 Enzymes, Predicted intracellular proteins Evidence at protein level HPA019949, HPA019957 Approved Approved Nuclear speckles
Plasma membrane
Actin filaments
Cytosol Pancreatic cancer:2.89e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 37.1 SSTR5 ENSG00000162009 Somatostatin receptor 5 16 1078781-1080142 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA066503 Supported Plasma membrane Mixed Tissue enhanced adrenal gland: 1.2 heart muscle: 0.8 ST8SIA5 SIAT8E ENSG00000101638 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 18 46667821-46759257 Predicted membrane proteins Evidence at protein level HPA043813, HPA046771 Approved Approved Plasma membrane
Midbody Tissue enriched Tissue enhanced adrenal gland: 5.5;cerebral cortex: 11.5 parathyroid gland: 3.4 STAC STAC1 ENSG00000144681 SH3 and cysteine rich domain 3 36380344-36548007 Predicted intracellular proteins, Transporters Evidence at protein level HPA035143 Uncertain Uncertain Nucleoplasm
Plasma membrane Mixed Tissue enhanced parathyroid gland: 23.0;prostate: 20.0 lung: 15.8 STAMBP AMSH ENSG00000124356 STAM binding protein 2 73828916-73873659 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035800 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.2 STAMBPL1 ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373 ENSG00000138134 STAM binding protein-like 1 10 88879734-88975153 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040202 Uncertain Approved Plasma membrane Renal cancer:1.08e-5 (unfavourable) Mixed Mixed adrenal gland,testis: 29.8 STARD4 ENSG00000164211 StAR-related lipid transfer (START) domain containing 4 5 111496033-111512590 Predicted intracellular proteins Evidence at protein level HPA046177, HPA048081 Approved Approved Plasma membrane Liver cancer:4.80e-5 (unfavourable), Renal cancer:5.89e-5 (unfavourable), Urothelial cancer:2.84e-4 (unfavourable) Expressed in all Mixed duodenum: 42.6 STAT2 STAT113 ENSG00000170581 Signal transducer and activator of transcription 2, 113kDa 12 56341597-56360155 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003858, HPA018888 Approved Supported Plasma membrane
Cytosol Renal cancer:4.78e-13 (unfavourable), Endometrial cancer:4.75e-4 (unfavourable) Expressed in all Expressed in all spleen: 48.7 STIL MCPH7, SIL ENSG00000123473 SCL/TAL1 interrupting locus 1 47250139-47314147 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046543 Approved Plasma membrane
Cytosol Pancreatic cancer:1.33e-4 (unfavourable) Mixed Mixed testis: 12.5 STIP1 HOP, STI1 ENSG00000168439 Stress-induced phosphoprotein 1 11 64185272-64204543 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017448, HPA039291, HPA044062 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:6.18e-8 (unfavourable), Head and neck cancer:1.23e-4 (unfavourable) Expressed in all Expressed in all testis: 219.7 STK17A DRAK1 ENSG00000164543 Serine/threonine kinase 17a 7 43582758-43626786 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA018138, HPA037979 Uncertain Approved Nuclear speckles
Plasma membrane Expressed in all Expressed in all lymph node: 49.9 STK17B DRAK2 ENSG00000081320 Serine/threonine kinase 17b 2 196133566-196176503 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034858 Approved Uncertain Plasma membrane
Cytosol Renal cancer:5.72e-8 (unfavourable) Expressed in all Tissue enhanced bone marrow: 248.9 lymph node: 135.0 STOML2 HSPC108, SLP-2 ENSG00000165283 Stomatin (EPB72)-like 2 9 35099776-35103195 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB015944, HPA062016 Approved Supported Plasma membrane
Cytosol Renal cancer:3.00e-5 (favourable), Liver cancer:4.77e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 97.5 STX18 Ufe1 ENSG00000168818 Syntaxin 18 4 4415742-4542346 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003019 Approved Approved Plasma membrane Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 181.9 STX4 p35-2, STX4A ENSG00000103496 Syntaxin 4 16 31032889-31042975 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001330 Approved Validated Plasma membrane Renal cancer:2.88e-9 (unfavourable), Cervical cancer:3.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 63.4 STXBP4 MGC50337, Synip ENSG00000166263 Syntaxin binding protein 4 17 54968727-55173632 Predicted intracellular proteins Evidence at protein level CAB007760, HPA022138, HPA022888, HPA024227 Approved Approved Plasma membrane
Cytosol Mixed Mixed parathyroid gland: 12.2 STYK1 DKFZp761P1010, NOK, SuRTK106 ENSG00000060140 Serine/threonine/tyrosine kinase 1 12 10618939-10674318 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040468, HPA048569 Uncertain Approved Nucleus
Plasma membrane Mixed Mixed rectum: 17.8 SUCLG1 ENSG00000163541 Succinate-CoA ligase, alpha subunit 2 84423523-84460045 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA036683, HPA036684 Supported Supported Plasma membrane
Mitochondria Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable) Expressed in all Expressed in all kidney: 467.4 SUCLG2 ENSG00000172340 Succinate-CoA ligase, GDP-forming, beta subunit 3 67360460-67654614 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046705, HPA051998 Supported Supported Plasma membrane
Mitochondria Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable) Expressed in all Expressed in all colon: 171.4 SUGT1 SGT1 ENSG00000165416 SGT1 homolog, MIS12 kinetochore complex assembly cochaperone 13 52652709-52700909 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015942, HPA043949 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:8.69e-4 (unfavourable) Expressed in all Expressed in all testis: 63.2 SUMF2 DKFZp566I1024 ENSG00000129103 Sulfatase modifying factor 2 7 56064002-56080670 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024040, CAB025743, HPA074892 Supported Uncertain Vesicles
Plasma membrane Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 159.3 SUPT6H KIAA0162, SPT6H ENSG00000109111 SPT6 homolog, histone chaperone 17 28662091-28702684 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012416, HPA036382 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:3.68e-5 (unfavourable), Renal cancer:4.36e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 61.1 SUSD2 BK65A6.2, FLJ22778 ENSG00000099994 Sushi domain containing 2 22 24181259-24189110 Predicted membrane proteins Evidence at protein level HPA004117 Approved Approved Plasma membrane Renal cancer:3.29e-5 (unfavourable) Expressed in all Tissue enhanced lung: 139.6 small intestine: 35.8 SVIL ENSG00000197321 Supervillin 10 29457338-29736781 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010878, HPA020095, HPA020138 Approved Supported Plasma membrane
Actin filaments
Cytosol Urothelial cancer:5.70e-5 (unfavourable) Expressed in all Expressed in all skeletal muscle: 279.8 SYCP2 SCP2 ENSG00000196074 Synaptonemal complex protein 2 20 59863563-59933655 Predicted intracellular proteins Evidence at protein level HPA062401, HPA065613 Supported Nucleoplasm
Plasma membrane
Cytosol Group enriched Group enriched 8 breast: 17.5;testis: 76.3 prostate,stomach: 5.8 SYK ENSG00000165025 Spleen tyrosine kinase 9 90801787-90898549 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA001384, CAB007773 Supported Approved Vesicles
Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 94.2 SYMPK SPK, SYM ENSG00000125755 Symplekin 19 45815410-45863290 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041756, HPA042449 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all testis: 74.6 SYNC SYNC1, SYNCOILIN ENSG00000162520 Syncoilin, intermediate filament protein 1 32680360-32703596 Predicted intracellular proteins Evidence at protein level HPA028311 Approved Approved Golgi apparatus
Vesicles
Plasma membrane Mixed Tissue enhanced smooth muscle: 70.4 skeletal muscle: 36.1 SYNGR3 ENSG00000127561 Synaptogyrin 3 16 1989660-1994275 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB034278, HPA042842 Supported Approved Plasma membrane Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable) Mixed Tissue enriched 7 cerebral cortex: 82.8 adrenal gland: 12.5 SYT4 HsT1192, KIAA1342 ENSG00000132872 Synaptotagmin IV 18 43267878-43277650 Predicted intracellular proteins Evidence at protein level HPA010574 Approved Supported Vesicles
Plasma membrane Tissue enhanced Tissue enhanced adrenal gland: 20.5;cerebral cortex: 82.7 seminal vesicle: 11.1 SYTL2 CHR11SYT, exophilin-4, FLJ20163, FLJ21219, KIAA1597, MGC102768, PPP1R151, SGA72M, SLP2 ENSG00000137501 Synaptotagmin-like 2 11 85694224-85811159 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039651 Approved Nucleus
Golgi apparatus
Plasma membrane Colorectal cancer:2.67e-4 (favourable), Urothelial cancer:9.07e-4 (favourable) Mixed Tissue enhanced stomach: 120.8 rectum: 82.7 SYVN1 DER3, HRD1 ENSG00000162298 Synovial apoptosis inhibitor 1, synoviolin 11 65121780-65134533 Predicted membrane proteins Evidence at protein level HPA005480, HPA024300, CAB037030 Supported Supported Nucleoplasm
Endoplasmic reticulum
Plasma membrane Head and neck cancer:6.88e-4 (favourable) Expressed in all Expressed in all tonsil: 76.7 TACC2 AZU-1 ENSG00000138162 Transforming, acidic coiled-coil containing protein 2 10 121989174-122254545 Predicted intracellular proteins Evidence at protein level HPA031020, HPA031021, HPA061394 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.50e-10 (favourable), Thyroid cancer:8.45e-4 (unfavourable) Expressed in all Mixed skeletal muscle: 112.7 TACSTD2 EGP-1, GA733-1, M1S1, TROP2 ENSG00000184292 Tumor-associated calcium signal transducer 2 1 58575423-58577773 Disease related genes, Predicted membrane proteins Evidence at protein level HPA043104, HPA055067, CAB072852 Supported Supported Nucleoli
Vesicles
Plasma membrane Renal cancer:3.99e-4 (favourable) Mixed Tissue enhanced esophagus: 315.1 skin: 210.1 TASP1 C20orf13, dJ585I14.2, FLJ20212 ENSG00000089123 Taspase, threonine aspartase, 1 20 13389392-13638940 Predicted intracellular proteins Evidence at protein level HPA030824, HPA030825 Uncertain Approved Plasma membrane Thyroid cancer:6.78e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 13.5 TAZ BTHS, CMD3A, EFE, EFE2, G4.5, XAP-2 ENSG00000102125 Tafazzin X 154411518-154421726 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039557 Approved Approved Plasma membrane Renal cancer:1.22e-7 (unfavourable), Cervical cancer:5.70e-4 (favourable) Expressed in all Expressed in all spleen: 21.2 TBC1D10A AC004997.C22.2, EPI64, TBC1D10 ENSG00000099992 TBC1 domain family, member 10A 22 30291990-30327046 Predicted intracellular proteins Evidence at protein level HPA007725, HPA008142, HPA076041 Approved Supported Nucleoplasm
Plasma membrane Expressed in all Mixed esophagus: 31.3 TBC1D24 DFNA65, DFNB86, KIAA1171, TLDC6 ENSG00000162065 TBC1 domain family, member 24 16 2475118-2505734 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA044712, HPA068080 Uncertain Supported Plasma membrane
Cell Junctions Breast cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 23.4 TBC1D30 KIAA0984 ENSG00000111490 TBC1 domain family, member 30 12 64781193-64881032 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039772, HPA040043 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable) Mixed Mixed parathyroid gland: 12.3 TBC1D9B KIAA0676 ENSG00000197226 TBC1 domain family, member 9B (with GRAM domain) 5 179862066-179907859 Predicted intracellular proteins Evidence at protein level HPA038350 Approved Approved Nucleus
Nucleoli fibrillar center
Plasma membrane Thyroid cancer:3.99e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 60.9 TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles
Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.3 TCAF2 FAM115C, FAM139A, FLJ40722 ENSG00000170379 TRPM8 channel-associated factor 2 7 143620950-143730409 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038756, HPA038758 Uncertain Supported Endoplasmic reticulum
Plasma membrane
Cell Junctions Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable) Mixed Mixed placenta: 8.4 TCHP MGC10854, TpMs ENSG00000139437 Trichoplein, keratin filament binding 12 109900264-109983841 Predicted intracellular proteins Evidence at protein level HPA038638, HPA061543 Supported Supported Plasma membrane
Centrosome
Cytosol Stomach cancer:5.52e-4 (favourable) Expressed in all Expressed in all skin: 32.7 TDO2 TDO, TPH2 ENSG00000151790 Tryptophan 2,3-dioxygenase 4 155854738-155920406 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039611 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enriched 17 liver: 277.5 appendix: 16.2 TDP1 FLJ11090, SCAN1 ENSG00000042088 Tyrosyl-DNA phosphodiesterase 1 14 89954939-90044768 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA071317 Supported Nucleus
Plasma membrane Liver cancer:8.99e-5 (unfavourable) Expressed in all Mixed testis: 41.7 TEC PSCTK4 ENSG00000135605 Tec protein tyrosine kinase 4 48135783-48269864 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005733, HPA024657 Approved Supported Plasma membrane Ovarian cancer:7.12e-4 (favourable) Mixed Mixed epididymis: 4.9 TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK tyrosine kinase, endothelial 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane
Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.3 lung: 42.7 TES DKFZP586B2022, TESS-2, TESTIN ENSG00000135269 Testin LIM domain protein 7 116210493-116258783 Predicted intracellular proteins Evidence at protein level HPA015269, HPA018123 Approved Supported Plasma membrane
Cell Junctions
Focal adhesion sites
Cytosol Pancreatic cancer:1.20e-5 (unfavourable), Renal cancer:8.71e-5 (favourable) Expressed in all Expressed in all seminal vesicle: 269.2 TEX14 CT113 ENSG00000121101 Testis expressed 14 17 58556678-58692055 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030620 Approved Vesicles
Plasma membrane
Cell Junctions
Cytosol Mixed Tissue enriched 43 testis: 49.0 bone marrow: 1.1 TEX9 ENSG00000151575 Testis expressed 9 15 56244009-56445997 Predicted intracellular proteins Evidence at protein level HPA039415 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed fallopian tube: 44.1 TGFBR1 ACVRLK4, ALK-5, ESS1, MSSE ENSG00000106799 Transforming growth factor, beta receptor 1 9 99104038-99154192 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002441, CAB031481, HPA056473 Uncertain Supported Vesicles
Plasma membrane Expressed in all Expressed in all placenta: 69.3 TGFBR2 MFS2 ENSG00000163513 Transforming growth factor, beta receptor II (70/80kDa) 3 30606502-30694142 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB073537 Supported Plasma membrane Expressed in all Expressed in all adipose tissue: 290.3 TGM2 TGC ENSG00000198959 Transglutaminase 2 20 38127387-38166578 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002598, HPA021019, HPA029518 Approved Approved Plasma membrane
Cytosol Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 456.8 placenta: 317.8 THBS1 THBS, THBS-1, TSP, TSP-1, TSP1 ENSG00000137801 Thrombospondin 1 15 39581079-39599466 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB033678, HPA059756 Approved Approved Plasma membrane Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable) Expressed in all Expressed in all appendix: 585.7 THBS2 TSP2 ENSG00000186340 Thrombospondin 2 6 169215780-169254044 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB017716, HPA044304 Approved Approved Nuclear speckles
Plasma membrane
Cytosol Renal cancer:3.77e-6 (unfavourable) Expressed in all Tissue enhanced gallbladder: 113.8 endometrium: 71.0 THY1 CD90 ENSG00000154096 Thy-1 cell surface antigen 11 119417378-119424985 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003733, CAB068243, CAB068244 Supported Approved Nucleus
Plasma membrane Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 422.9;smooth muscle: 428.6 gallbladder: 161.7 TICAM1 MGC35334, PRVTIRB, TICAM-1, TRIF ENSG00000127666 Toll-like receptor adaptor molecule 1 19 4815932-4831704 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042460 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Lung cancer:3.48e-4 (unfavourable), Endometrial cancer:4.81e-4 (favourable) Expressed in all Expressed in all esophagus: 22.1 TIGD7 Sancho ENSG00000140993 Tigger transposable element derived 7 16 3298832-3305729 Predicted intracellular proteins Evidence at protein level HPA041357, HPA041474 Uncertain Supported Plasma membrane
Cytosol Mixed Mixed testis: 13.6 TIMD4 ENSG00000145850 T-cell immunoglobulin and mucin domain containing 4 5 156919282-156963255 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015625, CAB026027 Approved Approved Plasma membrane
Cytosol Renal cancer:3.37e-4 (favourable) Tissue enriched Group enriched 6 lymph node: 64.4;testis: 161.6 adipose tissue: 17.7 TJP2 DFNA51, X104, ZO-2, ZO2 ENSG00000119139 Tight junction protein 2 9 69121264-69255208 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001813, CAB009228 Supported Validated Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.78e-14 (favourable) Expressed in all Expressed in all parathyroid gland: 136.2 TLN1 ILWEQ, TLN ENSG00000137076 Talin 1 9 35696948-35732395 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002006, HPA004748 Supported Supported Plasma membrane
Focal adhesion sites
Microtubule organizing center
Cytosol Colorectal cancer:5.56e-4 (unfavourable), Renal cancer:7.21e-4 (favourable) Expressed in all Expressed in all smooth muscle: 202.0 TM2D2 BLP1 ENSG00000169490 TM2 domain containing 2 8 38988808-38996824 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047152, HPA050547 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all testis: 51.1 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 TM4SF4 il-TMP ENSG00000169903 Transmembrane 4 L six family member 4 3 149473974-149503281 Predicted membrane proteins, Transporters Evidence at protein level HPA046430 Supported Approved Plasma membrane
Cytosol Group enriched Group enriched 34 duodenum: 595.8;gallbladder: 1326.5;liver: 343.7;small intestine: 515.2 stomach: 20.3 TM4SF5 ENSG00000142484 Transmembrane 4 L six family member 5 17 4771884-4783213 Predicted membrane proteins Evidence at protein level HPA055674 Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Tissue enriched Group enriched 5 duodenum: 181.8;small intestine: 172.8 liver: 33.2 TMC5 FLJ13593 ENSG00000103534 Transmembrane channel-like 5 16 19410496-19499113 Predicted membrane proteins Evidence at protein level HPA040810, HPA042037 Approved Approved Nucleus
Plasma membrane Liver cancer:7.96e-4 (unfavourable) Mixed Tissue enhanced small intestine: 60.2 duodenum: 46.6 TMEM101 FLJ23987, MGC4251 ENSG00000091947 Transmembrane protein 101 17 44011188-44023946 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039739 Approved Nucleoplasm
Plasma membrane Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 156.9 TMEM139 FLJ90586 ENSG00000178826 Transmembrane protein 139 7 143279957-143288048 Predicted membrane proteins, Transporters Evidence at protein level HPA036982, HPA036983 Approved Approved Plasma membrane
Focal adhesion sites Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable) Mixed Tissue enhanced duodenum: 34.9;kidney: 34.4 small intestine: 21.2 TMEM176B LR8, MS4B2 ENSG00000106565 Transmembrane protein 176B 7 150791285-150801360 Predicted membrane proteins Evidence at protein level HPA047509 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Expressed in all Expressed in all liver: 842.9 TMEM183A C1orf37 ENSG00000163444 Transmembrane protein 183A 1 203007386-203024848 Predicted membrane proteins Evidence at protein level HPA072607 Approved Nucleus
Plasma membrane
Cell Junctions Liver cancer:2.62e-4 (unfavourable) Expressed in all Expressed in all testis: 58.5 TMEM218 ENSG00000150433 Transmembrane protein 218 11 125096545-125111763 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038489 Uncertain Approved Plasma membrane
Cytosol Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.7 TMEM222 C1orf160, DKFZP564D0478 ENSG00000186501 Transmembrane protein 222 1 27322145-27336400 Predicted membrane proteins Evidence at protein level HPA016579, HPA059374 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 47.4 TMEM229A ENSG00000234224 Transmembrane protein 229A 7 124030916-124033023 Predicted membrane proteins Evidence at protein level HPA056391 Uncertain Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 7.1;duodenum: 8.9;testis: 10.4 small intestine: 4.4 TMEM245 C9orf5, CG-2 ENSG00000106771 Transmembrane protein 245 9 109015152-109119945 Predicted membrane proteins Evidence at protein level HPA023892 Approved Approved Plasma membrane
Cytosol Renal cancer:4.46e-9 (favourable) Expressed in all Expressed in all thyroid gland: 123.5 TMEM254 bA369J21.6, C10orf57, FLJ13263 ENSG00000133678 Transmembrane protein 254 10 80078646-80092557 Predicted membrane proteins Evidence at protein level HPA029105 Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 85.9 TMEM258 C11orf10 ENSG00000134825 Transmembrane protein 258 11 61768501-61792802 Predicted membrane proteins Evidence at protein level HPA044602 Approved Approved Plasma membrane
Cytosol Ovarian cancer:4.37e-4 (favourable) Expressed in all Expressed in all epididymis: 429.6 TMEM266 C15orf27, FLJ38190 ENSG00000169758 Transmembrane protein 266 15 76059837-76229121 Predicted membrane proteins Evidence at protein level HPA041921 Uncertain Supported Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 1.9;skeletal muscle: 1.5 placenta: 1.1 TMEM50A SMP1 ENSG00000183726 Transmembrane protein 50A 1 25337917-25362361 Predicted membrane proteins Evidence at protein level HPA065192 Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable) Expressed in all Expressed in all prostate: 71.1 TMEM63B C6orf110, dJ421H19.2, DKFZp434P0531 ENSG00000137216 Transmembrane protein 63B 6 44126914-44155519 Predicted membrane proteins, Transporters Evidence at protein level HPA029249, HPA029250, HPA029251 Uncertain Validated Plasma membrane
Actin filaments Expressed in all Expressed in all lung: 59.2 TMEM97 MAC30 ENSG00000109084 Transmembrane protein 97 17 28319095-28328685 Predicted membrane proteins Evidence at protein level HPA044795 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Renal cancer:1.24e-4 (unfavourable) Expressed in all Expressed in all testis: 109.7 TNFRSF10D CD264, DcR2, TRAILR4, TRUNDD ENSG00000173530 Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 8 23135588-23164030 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA070971 Approved Plasma membrane
Actin filaments Cervical cancer:1.70e-4 (unfavourable) Expressed in all Mixed gallbladder: 12.7 TNFRSF11A CD265, FEO, LOH18CR1, PDB2, RANK ENSG00000141655 Tumor necrosis factor receptor superfamily, member 11a, NFKB activator 18 62325287-62391292 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010391, HPA027728, HPA047976 Uncertain Supported Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 31.2 small intestine: 20.9 TNFRSF12A CD266, FN14, TweakR ENSG00000006327 Tumor necrosis factor receptor superfamily, member 12A 16 3018445-3022383 Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007853 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.6 TNFRSF9 4-1BB, CD137, ILA ENSG00000049249 Tumor necrosis factor receptor superfamily, member 9 1 7915894-7943165 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA071425 Approved Nucleoli
Plasma membrane Renal cancer:2.69e-8 (unfavourable) Mixed Tissue enhanced lymph node: 11.2;tonsil: 7.4 appendix: 5.3 TOLLIP IL-1RAcPIP ENSG00000078902 Toll interacting protein 11 1274371-1309654 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038621, HPA038622 Supported Approved Plasma membrane
Cytosol Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 132.7 TOM1 ENSG00000100284 Target of myb1 membrane trafficking protein 22 35299275-35347994 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000818, HPA001749 Approved Approved Plasma membrane
Microtubule organizing center
Cytosol Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable) Expressed in all Expressed in all esophagus: 54.8 TPD52L1 D53, hD53 ENSG00000111907 Tumor protein D52-like 1 6 125119049-125264407 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027915, HPA027916 Approved Approved Plasma membrane
Cell Junctions
Cytosol Renal cancer:3.26e-4 (favourable), Thyroid cancer:3.97e-4 (favourable), Urothelial cancer:5.34e-4 (unfavourable) Expressed in all Tissue enhanced adrenal gland: 321.3 salivary gland: 126.8 TPRN C9orf75, DFNB79, FLJ90254 ENSG00000176058 Taperin 9 137191617-137204193 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA020899 Uncertain Approved Plasma membrane Renal cancer:5.16e-9 (favourable), Cervical cancer:2.13e-4 (favourable) Expressed in all Expressed in all small intestine: 28.9 TRAF7 DKFZp586I021, MGC7807, RFWD1, RNF119 ENSG00000131653 TNF receptor-associated factor 7, E3 ubiquitin protein ligase 16 2155698-2178129 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041229 Approved Supported Vesicles
Plasma membrane Expressed in all Expressed in all duodenum: 41.1 TRAIP RNF206, TRIP ENSG00000183763 TRAF interacting protein 3 49828599-49856574 Predicted intracellular proteins Evidence at protein level HPA036261, HPA036262 Approved Supported Plasma membrane
Cytosol Liver cancer:8.77e-5 (unfavourable) Expressed in all Mixed testis: 11.3 TRAPPC13 C5orf44, FLJ13611, FLJ26957, MGC48585 ENSG00000113597 Trafficking protein particle complex 13 5 65624716-65666233 Predicted intracellular proteins Evidence at protein level HPA037777 Approved Approved Nucleus
Plasma membrane Renal cancer:8.66e-4 (favourable) Expressed in all Expressed in all prostate: 30.0 TRDN ENSG00000186439 Triadin 6 123216339-123637093 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038226, HPA058226 Supported Approved Plasma membrane
Cytosol Tissue enhanced Group enriched 25 heart muscle: 254.8;skeletal muscle: 650.4 prostate: 18.2 TRIB1 C8FW, GIG2, TRB1 ENSG00000173334 Tribbles pseudokinase 1 8 125430321-125438405 Enzymes, Predicted intracellular proteins Evidence at protein level HPA063982 Approved Plasma membrane Expressed in all Expressed in all bone marrow: 244.0 TRIM16 EBBP ENSG00000221926 Tripartite motif containing 16 17 15627960-15684311 Predicted intracellular proteins Evidence at protein level HPA023623, HPA066431 Uncertain Supported Plasma membrane
Cytosol Liver cancer:3.94e-4 (unfavourable), Urothelial cancer:6.71e-4 (unfavourable) Expressed in all Expressed in all esophagus: 118.3 TRIM16L TRIM70 ENSG00000108448 Tripartite motif containing 16-like 17 18697998-18736118 Predicted intracellular proteins Evidence at protein level HPA066431 Approved Plasma membrane
Cytosol Thyroid cancer:2.29e-5 (unfavourable), Liver cancer:2.87e-4 (unfavourable) Expressed in all Mixed gallbladder: 22.7 TRIM38 RNF15, RORET ENSG00000112343 Tripartite motif containing 38 6 25962802-25991226 Predicted intracellular proteins Evidence at protein level HPA031685 Approved Approved Plasma membrane
Cell Junctions
Centrosome Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable) Expressed in all Mixed spleen: 20.1 TRIM4 RNF87 ENSG00000146833 Tripartite motif containing 4 7 99876958-99919600 Predicted intracellular proteins Evidence at protein level HPA019356, HPA029461 Approved Supported Plasma membrane
Cytosol Renal cancer:7.36e-6 (favourable) Expressed in all Expressed in all ovary: 50.7 TRIM44 DIPB, MC7 ENSG00000166326 Tripartite motif containing 44 11 35662805-35818007 Predicted intracellular proteins Evidence at protein level HPA049053, HPA057633 Approved Approved Vesicles
Plasma membrane Liver cancer:5.24e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 30.8 TRIM71 LIN-41, LIN41 ENSG00000206557 Tripartite motif containing 71, E3 ubiquitin protein ligase 3 32818018-32897826 Predicted intracellular proteins Evidence at protein level HPA038141, HPA038142 Uncertain Approved Plasma membrane
Actin filaments
Focal adhesion sites Tissue enriched Tissue enriched 8 testis: 9.1 lung: 1.1 TRIML2 FLJ25801, SPRYD6 ENSG00000179046 Tripartite motif family-like 2 4 188091273-188109603 Predicted intracellular proteins Evidence at protein level HPA043838 Uncertain Approved Plasma membrane
Cytosol Tissue enriched Group enriched 25 placenta: 5.9;testis: 3.4 cerebral cortex,lung: 0.1 TRIP6 MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1 ENSG00000087077 Thyroid hormone receptor interactor 6 7 100867138-100873454 Predicted intracellular proteins Evidence at protein level CAB046454, CAB046460, HPA052813 Approved Supported Plasma membrane
Focal adhesion sites
Cytosol Expressed in all Expressed in all parathyroid gland: 84.3 TRMT1 FLJ20244, TRM1 ENSG00000104907 TRNA methyltransferase 1 19 13104902-13117567 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041130, HPA041380 Approved Approved Nucleus
Plasma membrane
Cytosol Renal cancer:9.87e-7 (unfavourable) Expressed in all Expressed in all lymph node: 27.0 TRMT10B bA3J10.9, FLJ31455, RG9MTD3 ENSG00000165275 TRNA methyltransferase 10B 9 37753803-37778972 Predicted intracellular proteins Evidence at transcript level HPA021800 Uncertain Approved Nucleoplasm
Plasma membrane Lung cancer:3.91e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable) Expressed in all Mixed skin: 13.0 TRMT13 CCDC76, FLJ10287, FLJ11219 ENSG00000122435 TRNA methyltransferase 13 homolog (S. cerevisiae) 1 100133150-100150497 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028494 Approved Approved Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Renal cancer:6.89e-6 (unfavourable), Liver cancer:5.81e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 28.8 TRPM4 FLJ20041 ENSG00000130529 Transient receptor potential cation channel, subfamily M, member 4 19 49157741-49211836 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA041169 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable) Expressed in all Mixed colon: 27.5 TRPV2 VRL, VRL-1, VRL1 ENSG00000187688 Transient receptor potential cation channel, subfamily V, member 2 17 16415542-16437003 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044993 Uncertain Supported Plasma membrane Renal cancer:1.19e-6 (unfavourable), Testis cancer:5.53e-4 (unfavourable) Tissue enriched Mixed lung: 44.1 TRPV3 VRL3 ENSG00000167723 Transient receptor potential cation channel, subfamily V, member 3 17 3510502-3557995 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA069550 Approved Plasma membrane
Centrosome
Cytosol Mixed Tissue enhanced skin: 5.2;small intestine: 4.6 duodenum: 1.7 TSG101 TSG10, VPS23 ENSG00000074319 Tumor susceptibility 101 11 18468336-18527232 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004283, HPA006161 Approved Supported Nucleoli
Plasma membrane
Cytosol Liver cancer:3.74e-6 (unfavourable), Renal cancer:5.52e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 80.4 TTC17 FLJ10890 ENSG00000052841 Tetratricopeptide repeat domain 17 11 43358932-43494933 Predicted intracellular proteins Evidence at protein level HPA038508 Approved Supported Plasma membrane
Cytosol Renal cancer:4.75e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 61.6 TTC23 FLJ12572, HCC-8 ENSG00000103852 Tetratricopeptide repeat domain 23 15 99136323-99251223 Predicted intracellular proteins Evidence at protein level HPA039806, HPA040369 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable) Expressed in all Mixed testis: 24.2 TTC7B TTC7L1 ENSG00000165914 Tetratricopeptide repeat domain 7B 14 90524564-90816479 Predicted intracellular proteins Evidence at protein level HPA058363, HPA059577 Supported Supported Plasma membrane Renal cancer:3.20e-6 (favourable) Mixed Expressed in all cerebral cortex: 72.8 TTLL12 KIAA0153 ENSG00000100304 Tubulin tyrosine ligase-like family member 12 22 43166622-43187133 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003054, CAB046029 Approved Approved Plasma membrane
Cytosol Liver cancer:2.84e-4 (unfavourable) Expressed in all Expressed in all esophagus: 74.6 TTLL5 KIAA0998 ENSG00000119685 Tubulin tyrosine ligase-like family member 5 14 75633625-75955078 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA032128 Uncertain Approved Plasma membrane
Cytosol Expressed in all Tissue enriched 5 testis: 103.3 parathyroid gland: 20.2 TULP3 TUBL3 ENSG00000078246 Tubby like protein 3 12 2877223-2941140 Predicted intracellular proteins Evidence at protein level HPA015285, HPA018496 Uncertain Supported Nucleus
Nucleoli
Plasma membrane Liver cancer:7.97e-5 (unfavourable), Endometrial cancer:2.99e-4 (favourable), Renal cancer:7.18e-4 (unfavourable) Expressed in all Expressed in all ovary: 46.4 TWF2 A6r, A6RP, PTK9L ENSG00000247596 Twinfilin actin binding protein 2 3 52228610-52239260 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA053874 Uncertain Supported Plasma membrane Expressed in all Expressed in all lymph node: 62.1 TXNDC11 EFP1 ENSG00000153066 Thioredoxin domain containing 11 16 11679080-11742878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041174, HPA041390 Supported Supported Plasma membrane
Cytosol Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 83.0 TXNIP EST01027, HHCPA78, THIF, VDUP1 ENSG00000265972 Thioredoxin interacting protein 1 145992435-145996600 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA031085, HPA053694 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all adipose tissue: 1573.3 TYW3 C1orf171, FLJ40918 ENSG00000162623 TRNA-yW synthesizing protein 3 homolog (S. cerevisiae) 1 74733152-74766678 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029641 Approved Approved Plasma membrane
Cytosol Liver cancer:1.49e-7 (unfavourable) Expressed in all Expressed in all ovary: 32.6 UAP1 AgX, AGX1, SPAG2 ENSG00000117143 UDP-N-acetylglucosamine pyrophosphorylase 1 1 162561506-162599842 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA014659 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:5.12e-5 (unfavourable) Expressed in all Expressed in all testis: 165.3 UBA3 hUba3, NAE2, UBE1C ENSG00000144744 Ubiquitin-like modifier activating enzyme 3 3 69054730-69080408 Predicted intracellular proteins Evidence at protein level HPA034873, HPA034874, HPA065335 Supported Approved Nucleoplasm
Plasma membrane
Centrosome
Cytosol Liver cancer:8.57e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 68.1 UBA52 CEP52, HUBCEP52, L40, MGC126879, MGC126881, MGC57125, RPL40 ENSG00000221983 Ubiquitin A-52 residue ribosomal protein fusion product 1 19 18571730-18577550 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA041344, HPA049132, HPA056624 Supported Approved Nucleoplasm
Endoplasmic reticulum
Plasma membrane
Cytosol Expressed in all Expressed in all ovary: 1909.1 UBAC1 GBDR1, UBADC1 ENSG00000130560 UBA domain containing 1 9 135932969-135961380 Predicted intracellular proteins Evidence at protein level HPA005651 Approved Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.58e-7 (favourable), Cervical cancer:4.34e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 88.7 UBAP1 UBAP ENSG00000165006 Ubiquitin associated protein 1 9 34179005-34252523 Predicted intracellular proteins Evidence at protein level HPA019804, HPA041590 Approved Validated Plasma membrane
Cytosol Renal cancer:7.49e-6 (favourable) Expressed in all Expressed in all testis: 88.4 UBASH3B KIAA1959, STS-1, TULA2 ENSG00000154127 Ubiquitin associated and SH3 domain containing B 11 122655675-122814473 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038605, HPA038607 Approved Approved Plasma membrane Mixed Tissue enhanced placenta: 19.4;spleen: 21.6 lung: 6.8 UBE2A HHR6A, RAD6A, UBC2 ENSG00000077721 Ubiquitin-conjugating enzyme E2A X 119574467-119591083 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA003875, HPA051765, HPA065898 Supported Nucleoplasm
Vesicles
Plasma membrane
Cytosol Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable) Expressed in all Expressed in all placenta: 75.9 UBE2B HHR6B, RAD6B, UBC2 ENSG00000119048 Ubiquitin-conjugating enzyme E2B 5 134371179-134391992 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003875, HPA051765, HPA065898 Supported Nucleoplasm
Vesicles
Plasma membrane
Cytosol Expressed in all Expressed in all adrenal gland: 99.5 UBE2C UBCH10 ENSG00000175063 Ubiquitin-conjugating enzyme E2C 20 45812576-45816957 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB011464, HPA034569, CAB035990, HPA054975 Approved Validated Plasma membrane
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable) Expressed in all Mixed tonsil: 59.1 UBE2D1 E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A ENSG00000072401 Ubiquitin-conjugating enzyme E2D 1 10 58334975-58370753 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 47.8 UBE2D2 UBC4, UbcH5B ENSG00000131508 Ubiquitin-conjugating enzyme E2D 2 5 139526431-139628433 Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable) Expressed in all Expressed in all testis: 237.4 UBE2D3 UbcH5C ENSG00000109332 Ubiquitin-conjugating enzyme E2D 3 4 102794383-102868896 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.51e-4 (favourable) Expressed in all Expressed in all bone marrow: 301.5 UBE2D4 HBUCE1 ENSG00000078967 Ubiquitin-conjugating enzyme E2D 4 (putative) 7 43926438-43956136 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 12.6 UBE2QL1 FLJ25076 ENSG00000215218 Ubiquitin-conjugating enzyme E2Q family-like 1 5 6448623-6494909 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA057414 Supported Nucleus
Plasma membrane Renal cancer:6.81e-8 (favourable) Mixed Tissue enhanced cerebral cortex: 42.0 seminal vesicle: 10.3 UBE2S E2-EPF ENSG00000108106 Ubiquitin-conjugating enzyme E2S 19 55399745-55407777 Enzymes, Predicted intracellular proteins Evidence at protein level CAB015228, HPA057150 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable) Expressed in all Expressed in all testis: 120.1 UBE3C KIAA0010, KIAA10 ENSG00000009335 Ubiquitin protein ligase E3C 7 157138913-157269372 Predicted intracellular proteins Evidence at protein level HPA039915 Approved Approved Nucleoplasm
Plasma membrane
Mitochondria Renal cancer:9.18e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 50.2 UBQLN2 Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157 ENSG00000188021 Ubiquilin 2 X 56563639-56567868 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006431, CAB013481 Supported Validated Plasma membrane
Cytosol Liver cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 53.9 UBR2 bA49A4.1, C6orf133, dJ392M17.3, KIAA0349 ENSG00000024048 Ubiquitin protein ligase E3 component n-recognin 2 6 42564062-42693504 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027869, HPA027880 Approved Approved Nucleoplasm
Plasma membrane Ovarian cancer:1.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.0 UBTD1 FLJ11807 ENSG00000165886 Ubiquitin domain containing 1 10 97498868-97571209 Predicted intracellular proteins Evidence at protein level HPA034825 Uncertain Approved Vesicles
Plasma membrane
Cytosol Colorectal cancer:5.54e-4 (unfavourable) Expressed in all Mixed testis: 34.1 UBXN10 FLJ25429, UBXD3 ENSG00000162543 UBX domain protein 10 1 20186085-20196048 Predicted intracellular proteins Evidence at protein level HPA028555, HPA028564 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable) Mixed Tissue enhanced fallopian tube: 78.2 testis: 25.4 UCP3 SLC25A9 ENSG00000175564 Uncoupling protein 3 (mitochondrial, proton carrier) 11 74000281-74009435 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB010771, HPA072225 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enriched 19 skeletal muscle: 71.2 testis: 3.8 UHRF1BP1L KIAA0701 ENSG00000111647 UHRF1 binding protein 1-like 12 100028455-100142848 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039671, HPA040399 Uncertain Approved Plasma membrane Expressed in all Mixed cerebral cortex: 33.0 ULBP1 RAET1I ENSG00000111981 UL16 binding protein 1 6 149964007-149973710 Predicted membrane proteins Evidence at protein level HPA007547, HPA071005 Supported Approved Plasma membrane
Actin filaments
Cytosol Mixed Tissue enhanced testis: 11.0 thyroid gland: 3.5 ULBP2 RAET1H ENSG00000131015 UL16 binding protein 2 6 149942000-149949235 Predicted membrane proteins Evidence at protein level CAB018974 Approved Supported Vesicles
Plasma membrane Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable) Expressed in all Mixed cerebral cortex,esophagus: 3.0 UNC5A KIAA1976, UNC5H1 ENSG00000113763 Unc-5 netrin receptor A 5 176810477-176880895 Predicted membrane proteins Evidence at protein level HPA071450 Approved Plasma membrane
Cytosol Endometrial cancer:2.23e-4 (unfavourable) Tissue enhanced Group enriched 22 adrenal gland: 10.4;cerebral cortex: 35.5 lymph node: 1.0 UQCC1 BFZB, C20orf44, CBP3, FLJ10850, UQCC ENSG00000101019 Ubiquinol-cytochrome c reductase complex assembly factor 1 20 35302566-35412141 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034875 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments Expressed in all Expressed in all parathyroid gland: 42.6 USP2 UBP41 ENSG00000036672 Ubiquitin specific peptidase 2 11 119355215-119381726 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006777, HPA007222 Approved Supported Plasma membrane
Cytosol Renal cancer:3.09e-11 (favourable) Expressed in all Tissue enhanced testis: 119.2 skeletal muscle: 59.3 USP20 KIAA1003 ENSG00000136878 Ubiquitin specific peptidase 20 9 129834698-129881838 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006287, HPA007008 Uncertain Approved Approved Nucleus
Plasma membrane
Cytosol Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable) Expressed in all Expressed in all thyroid gland: 22.1 USP21 USP16, USP23 ENSG00000143258 Ubiquitin specific peptidase 21 1 161159450-161165723 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028397 Uncertain Supported Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:9.50e-6 (unfavourable), Urothelial cancer:3.35e-5 (favourable), Liver cancer:1.68e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 45.2 USP4 UNP, Unph ENSG00000114316 Ubiquitin specific peptidase 4 (proto-oncogene) 3 49277831-49340712 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018499 Approved Supported Plasma membrane
Cytosol Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable) Expressed in all Expressed in all testis: 56.7 UTP20 1A6/DRIM, DRIM ENSG00000120800 UTP20 small subunit (SSU) processome component 12 101280109-101386616 Predicted intracellular proteins Evidence at protein level HPA049341 Supported Nucleoli
Plasma membrane Liver cancer:1.15e-5 (unfavourable), Renal cancer:8.87e-4 (favourable) Expressed in all Mixed parathyroid gland: 12.2 UTRN DMDL, DRP, DRP1 ENSG00000152818 Utrophin 6 144285701-144853034 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016348, HPA018894 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:7.61e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 171.0 VAMP5 ENSG00000168899 Vesicle-associated membrane protein 5 2 85584408-85593412 Predicted membrane proteins Evidence at protein level HPA035082 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:1.28e-5 (unfavourable) Expressed in all Expressed in all lung: 120.0 VANGL1 STB2 ENSG00000173218 VANGL planar cell polarity protein 1 1 115641953-115698224 Disease related genes, Predicted membrane proteins Evidence at protein level HPA025235, CAB076375 Approved Approved Plasma membrane Colorectal cancer:7.53e-4 (favourable), Pancreatic cancer:7.89e-4 (unfavourable) Expressed in all Mixed fallopian tube: 19.2 VASP ENSG00000125753 Vasodilator-stimulated phosphoprotein 19 45506579-45526983 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004612, HPA005724 Supported Supported Plasma membrane
Cell Junctions
Focal adhesion sites Renal cancer:5.91e-7 (unfavourable), Liver cancer:3.49e-5 (unfavourable) Expressed in all Expressed in all appendix: 93.1 VCPIP1 DUBA3, FLJ23132, KIAA1850, VCIP135 ENSG00000175073 Valosin containing protein (p97)/p47 complex interacting protein 1 8 66628487-66667217 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023932 Uncertain Approved Plasma membrane Expressed in all Mixed bone marrow: 13.2 VIL1 D2S1471, VIL ENSG00000127831 Villin 1 2 218419092-218453295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002452, HPA006884, HPA006885 Supported Supported Plasma membrane Tissue enhanced Group enriched 7 colon: 175.1;duodenum: 409.9;rectum: 199.9;small intestine: 489.9 gallbladder: 44.9 VPS36 C13orf9, CGI-145, Eap45 ENSG00000136100 Vacuolar protein sorting 36 homolog (S. cerevisiae) 13 52412602-52450628 Predicted intracellular proteins Evidence at protein level HPA039734, HPA043947 Approved Supported Vesicles
Lysosomes
Plasma membrane
Cell Junctions Renal cancer:9.91e-6 (favourable) Expressed in all Expressed in all skin: 62.6 VPS50 CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L ENSG00000004766 VPS50 EARP/GARPII complex subunit 7 93232340-93361121 Predicted intracellular proteins Evidence at protein level HPA026679 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 25.5 VPS8 FLJ32099, KIAA0804 ENSG00000156931 Vacuolar protein sorting 8 homolog (S. cerevisiae) 3 184812143-185052614 Predicted intracellular proteins Evidence at protein level HPA036871 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 31.0 VSIG4 Z39IG ENSG00000155659 V-set and immunoglobulin domain containing 4 X 66021738-66040125 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003903, CAB026000 Approved Uncertain Nucleoli
Plasma membrane
Cytosol Renal cancer:1.95e-6 (unfavourable), Colorectal cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all lung: 243.3 VTCN1 B7-H4, B7H4, B7S1, B7X, FLJ22418 ENSG00000134258 V-set domain containing T cell activation inhibitor 1 1 117143587-117210960 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054200 Approved Approved Plasma membrane
Cell Junctions
Focal adhesion sites Group enriched Tissue enhanced breast: 127.6;fallopian tube: 50.8 cervix, uterine: 21.9 VWA5B1 FLJ32784 ENSG00000158816 Von Willebrand factor A domain containing 5B1 1 20290919-20354894 Predicted intracellular proteins Evidence at protein level HPA027496, HPA028405, HPA064829 Supported Approved Plasma membrane
Mitochondria
Cytosol Mixed Group enriched 5 epididymis: 7.9;testis: 5.0 parathyroid gland: 1.2 VWA7 C6orf27, G7c, NG37 ENSG00000204396 Von Willebrand factor A domain containing 7 6 31765590-31777294 Predicted secreted proteins Evidence at transcript level HPA046954, HPA054262, HPA055033 Approved Approved Plasma membrane
Cytosol Renal cancer:4.35e-8 (favourable) Mixed Tissue enhanced fallopian tube: 9.0 parathyroid gland: 1.9 WARS2 TrpRS ENSG00000116874 Tryptophanyl tRNA synthetase 2, mitochondrial 1 119031216-119140671 Enzymes, Predicted intracellular proteins Evidence at protein level HPA069692 Supported Supported Plasma membrane
Mitochondria Renal cancer:1.45e-4 (favourable) Expressed in all Expressed in all fallopian tube: 15.2 WASF2 SCAR2, WAVE2 ENSG00000158195 WAS protein family, member 2 1 27404226-27490158 Predicted intracellular proteins Evidence at protein level CAB022632, HPA045288 Supported Approved Plasma membrane
Cytosol Liver cancer:5.29e-8 (unfavourable), Ovarian cancer:8.48e-4 (unfavourable) Expressed in all Expressed in all esophagus: 88.5 WBP4 FBP21, MGC117310 ENSG00000120688 WW domain binding protein 4 13 41061274-41084006 Predicted intracellular proteins Evidence at protein level HPA038965, HPA058738 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Thyroid cancer:2.89e-4 (favourable) Expressed in all Expressed in all endometrium: 27.5 WDFY3 ALFY, KIAA0993, ZFYVE25 ENSG00000163625 WD repeat and FYVE domain containing 3 4 84669610-84966391 Predicted intracellular proteins Evidence at protein level HPA042734, HPA048572 Approved Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.6 WDR12 FLJ10881, YTM1 ENSG00000138442 WD repeat domain 12 2 202874782-203014798 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036389 Uncertain Approved Nucleoli
Plasma membrane
Cytosol Liver cancer:2.57e-6 (unfavourable) Expressed in all Mixed testis: 7.3 WDR13 ENSG00000101940 WD repeat domain 13 X 48590042-48608867 Predicted intracellular proteins Evidence at protein level HPA000913 Supported Supported Nucleoplasm
Plasma membrane
Microtubule organizing center Expressed in all Expressed in all fallopian tube: 90.6 WDR53 MGC12928, MGC64882 ENSG00000185798 WD repeat domain 53 3 196554177-196568674 Predicted intracellular proteins Evidence at protein level HPA016420, HPA019332 Approved Approved Plasma membrane
Cytosol Liver cancer:1.57e-6 (unfavourable), Melanoma:3.09e-4 (unfavourable) Expressed in all Tissue enriched 6 testis: 112.1 parathyroid gland: 19.5 WDR6 ENSG00000178252 WD repeat domain 6 3 49007062-49015953 Predicted intracellular proteins Evidence at protein level HPA042622 Approved Supported Plasma membrane
Cytosol Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 199.7 WDR66 CaM-IP4, MGC33630 ENSG00000158023 WD repeat domain 66 12 121917862-122003927 Predicted intracellular proteins Evidence at protein level HPA039902, HPA040005 Supported Uncertain Plasma membrane
Cytosol Endometrial cancer:3.11e-4 (favourable) Mixed Tissue enhanced fallopian tube: 32.2;testis: 30.6 thyroid gland: 7.4 WIPF1 WASPIP, WIP ENSG00000115935 WAS/WASL interacting protein family, member 1 2 174559572-174682916 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003739, CAB009737, HPA070706 Supported Approved Plasma membrane
Cytosol Renal cancer:1.14e-4 (unfavourable) Expressed in all Expressed in all lymph node: 159.5 WNT8A WNT8D ENSG00000061492 Wingless-type MMTV integration site family, member 8A 5 138083892-138092365 Predicted secreted proteins Evidence at transcript level HPA038539 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Not detected testis: 0.7 WWP1 AIP5, DKFZP434D2111 ENSG00000123124 WW domain containing E3 ubiquitin protein ligase 1 8 86342738-86478420 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023180 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:5.45e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 185.9 XIAP API3, BIRC4, hILP ENSG00000101966 X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase X 123859724-123913979 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009203, HPA042428 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Breast cancer:9.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.0 XPC RAD4, XPCC ENSG00000154767 Xeroderma pigmentosum, complementation group C 3 14145147-14178783 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009932, HPA035707, HPA069673 Supported Validated Nucleus
Plasma membrane Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.3 XPO6 FLJ22519, KIAA0370, RANBP20 ENSG00000169180 Exportin 6 16 28097979-28211920 Predicted intracellular proteins Evidence at protein level HPA038246 Uncertain Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable) Expressed in all Expressed in all testis: 94.0 XRCC6BP1 KUB3 ENSG00000166896 XRCC6 binding protein 1 12 57941541-57957269 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035804, HPA043204 Uncertain Validated Vesicles
Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.44e-5 (unfavourable) Expressed in all Tissue enhanced testis: 26.6 rectum: 5.6 XRN1 SEP1 ENSG00000114127 5'-3' exoribonuclease 1 3 142306607-142448062 Predicted intracellular proteins Evidence at protein level HPA035005, HPA035006 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:9.43e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 21.9 YES1 c-yes, HsT441, Yes ENSG00000176105 YES proto-oncogene 1, Src family tyrosine kinase 18 721588-812546 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004370, HPA026480 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 61.6 YIPF4 FinGER4, MGC11061 ENSG00000119820 Yip1 domain family, member 4 2 32277910-32316594 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017884 Supported Supported Golgi apparatus
Vesicles
Plasma membrane Expressed in all Expressed in all cerebral cortex: 19.0 YOD1 DKFZp451J1719, DUBA8, OTUD2 ENSG00000180667 YOD1 deubiquitinase 1 207043849-207052980 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028400, HPA028439 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Tissue enhanced bone marrow: 37.2 esophagus: 27.9 YTHDC1 KIAA1966, YT521, YT521-B ENSG00000083896 YTH domain containing 1 4 68310387-68350089 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036462 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:7.29e-5 (favourable) Expressed in all Expressed in all bone marrow: 75.2 ZBED3 MGC15435 ENSG00000132846 Zinc finger, BED-type containing 3 5 77072072-77087323 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055995 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:1.68e-4 (favourable) Expressed in all Mixed thyroid gland: 18.7 ZBTB33 kaiso, WUGSC:H_DJ525N14.1, ZNF-kaiso, ZNF348 ENSG00000177485 Zinc finger and BTB domain containing 33 X 120250752-120258398 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000755, CAB001980, HPA005732 Approved Validated Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 23.0 ZBTB8OS ARCH ENSG00000176261 Zinc finger and BTB domain containing 8 opposite strand 1 32600172-32650903 Predicted intracellular proteins Evidence at protein level HPA046315 Approved Approved Plasma membrane Renal cancer:7.11e-8 (unfavourable), Liver cancer:4.25e-4 (unfavourable), Melanoma:8.56e-4 (unfavourable) Expressed in all Expressed in all lymph node: 42.9 ZCCHC16 FLJ46608, Mar4, Mart4 ENSG00000187823 Zinc finger, CCHC domain containing 16 X 112454500-112457112 Predicted intracellular proteins Evidence at transcript level HPA003272 Uncertain Approved Nucleus
Plasma membrane
Cytosol Group enriched Not detected kidney: 0.8 ZCCHC5 FLJ38865, Mar3, Mart3, ZHC5 ENSG00000179300 Zinc finger, CCHC domain containing 5 X 78656069-78659328 Predicted intracellular proteins Evidence at transcript level HPA051991, HPA053174, HPA075136 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Not detected Not detected endometrium,smooth muscle: 0.7 ZDHHC20 FLJ25952 ENSG00000180776 Zinc finger, DHHC-type containing 20 13 21372573-21459370 Enzymes, Predicted membrane proteins Evidence at protein level HPA014483, HPA014702 Approved Uncertain Vesicles
Plasma membrane
Mitochondria Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable) Expressed in all Expressed in all testis: 60.4 ZDHHC22 C14orf59 ENSG00000177108 Zinc finger, DHHC-type containing 22 14 77131270-77142734 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072213 Approved Plasma membrane Tissue enriched Tissue enriched 57 cerebral cortex: 64.4 epididymis: 1.1 ZDHHC5 KIAA1748, ZNF375 ENSG00000156599 Zinc finger, DHHC-type containing 5 11 57667747-57701187 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014670 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions
Cytosol Pancreatic cancer:6.74e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 86.1 ZFP41 FLJ00028, FLJ38705, ZNF753 ENSG00000181638 ZFP41 zinc finger protein 8 143246821-143262705 Predicted intracellular proteins Evidence at transcript level HPA047232, HPA056268 Uncertain Uncertain Nucleus
Nucleoli
Plasma membrane Liver cancer:3.46e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 7.5 ZFP90 KIAA1954, NK10, ZNF756 ENSG00000184939 ZFP90 zinc finger protein 16 68530090-68576072 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029017 Uncertain Supported Vesicles
Plasma membrane
Centrosome Renal cancer:1.78e-4 (favourable) Expressed in all Mixed parathyroid gland: 31.1 ZFYVE28 KIAA1643 ENSG00000159733 Zinc finger, FYVE domain containing 28 4 2269582-2418663 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038175, HPA057587 Approved Approved Nucleus
Plasma membrane
Cytosol Renal cancer:1.35e-6 (favourable) Mixed Mixed cerebral cortex: 9.9 ZGPAT dJ583P15.3, FLJ14972, GPATC6, GPATCH6, KIAA1847, MGC44880, ZC3H9, ZC3HDC9, ZIP ENSG00000197114 Zinc finger, CCCH-type with G patch domain 20 63707465-63736142 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056705 Supported Nucleus
Plasma membrane Head and neck cancer:6.17e-5 (favourable) Expressed in all Expressed in all liver: 26.9 ZMYND10 BLU, CILD22 ENSG00000004838 Zinc finger, MYND-type containing 10 3 50341110-50346852 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035255 Uncertain Approved Plasma membrane
Cytosol Renal cancer:6.75e-5 (favourable) Tissue enhanced Group enriched 16 fallopian tube: 228.5;testis: 284.3 lung: 15.8 ZNF10 KOX1 ENSG00000256223 Zinc finger protein 10 12 133130575-133159465 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003204 Uncertain Approved Nucleus
Vesicles
Plasma membrane Expressed in all Expressed in all parathyroid gland: 40.2 ZNF18 HDSG1, KOX11, Zfp535, ZKSCAN6, ZNF535, ZSCAN38 ENSG00000154957 Zinc finger protein 18 17 11977439-11997510 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006144 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:5.12e-6 (favourable), Cervical cancer:6.32e-4 (favourable) Expressed in all Expressed in all testis: 22.2 ZNF185 ENSG00000147394 Zinc finger protein 185 (LIM domain) X 152914442-152973480 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000400, HPA016438 Supported Supported Plasma membrane
Actin filaments
Focal adhesion sites
Cytosol Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 393.3;esophagus: 279.4;seminal vesicle: 200.0 cervix, uterine: 104.7 ZNF2 A1-5, Zfp661, ZNF661 ENSG00000275111 Zinc finger protein 2 2 95165432-95184317 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA041358 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Lung cancer:4.69e-5 (favourable) Expressed in all Mixed parathyroid gland: 6.3 ZNF20 KOX13 ENSG00000132010 Zinc finger protein 20 19 12092843-12140407 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA020887 Uncertain Approved Nucleoplasm
Plasma membrane Not detected Mixed testis: 9.3 ZNF227 ENSG00000131115 Zinc finger protein 227 19 44207547-44237268 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030573 Uncertain Approved Plasma membrane Urothelial cancer:2.64e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 18.4 ZNF229 ENSG00000278318 Zinc finger protein 229 19 44417519-44448578 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA001494 Uncertain Approved Vesicles
Plasma membrane Renal cancer:8.43e-5 (favourable) Mixed Tissue enhanced parathyroid gland: 6.5 fallopian tube,thyroid gland: 3.1 ZNF276 CENP-Z, CENPZ, MGC45417, ZADT, ZFP276, ZNF477 ENSG00000158805 Zinc finger protein 276 16 89720400-89740903 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA021309, HPA022255 Uncertain Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Renal cancer:3.37e-4 (unfavourable) Expressed in all Expressed in all spleen: 23.2 ZNF277 NRIF4, ZNF277P ENSG00000198839 Zinc finger protein 277 7 112206588-112343096 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA027307 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:9.47e-4 (favourable) Expressed in all Expressed in all thyroid gland: 33.4 ZNF337 dJ694B14.1 ENSG00000130684 Zinc finger protein 337 20 25674215-25696841 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044303, HPA064219 Uncertain Approved Nuclear speckles
Plasma membrane Renal cancer:2.87e-6 (unfavourable) Mixed Expressed in all parathyroid gland: 28.7 ZNF397 MGC13250, ZNF47, ZSCAN15 ENSG00000186812 Zinc finger protein 397 18 35241030-35267133 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA026087 Uncertain Approved Nucleoli
Plasma membrane
Microtubules
Cytosol Pancreatic cancer:9.44e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 32.8 ZNF407 FLJ13839, FLJ20307, KIAA1703 ENSG00000215421 Zinc finger protein 407 18 74597870-75065671 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028255, HPA041673 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:9.79e-5 (favourable) Expressed in all Mixed parathyroid gland: 8.8 ZNF503 FLJ45745, MGC2555, Nlz2 ENSG00000165655 Zinc finger protein 503 10 75397830-75401906 Predicted intracellular proteins Evidence at protein level HPA026848 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.97e-4 (favourable), Prostate cancer:3.50e-4 (unfavourable) Expressed in all Mixed adrenal gland: 25.9 ZNF510 KIAA0972 ENSG00000081386 Zinc finger protein 510 9 96755865-96778129 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049139 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:5.94e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 12.2 ZNF571 HSPC059 ENSG00000180479 Zinc finger protein 571 19 37554782-37594790 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA054762 Approved Nucleus
Nucleoli
Plasma membrane Mixed Tissue enriched 5 thyroid gland: 130.2 testis: 25.9 ZNF598 FLJ00086 ENSG00000167962 Zinc finger protein 598 16 1997654-2009823 Predicted intracellular proteins Evidence at protein level HPA041760, HPA041896 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed spleen: 12.4 ZNF599 FLJ30663 ENSG00000153896 Zinc finger protein 599 19 34758076-34773229 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA014701 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Mixed epididymis: 14.4 ZNF620 MGC50836 ENSG00000177842 Zinc finger protein 620 3 40505992-40518736 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA031452 Uncertain Approved Plasma membrane Mixed Mixed thyroid gland: 6.0 ZNF646 KIAA0296 ENSG00000167395 Zinc finger protein 646 16 31074422-31084196 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA042364 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.28e-6 (unfavourable) Expressed in all Tissue enhanced testis: 34.4 spleen: 11.0 ZNF655 VIK, VIK-1 ENSG00000197343 Zinc finger protein 655 7 99558406-99576453 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029534, HPA050750 Uncertain Supported Nucleoplasm
Plasma membrane Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable) Expressed in all Expressed in all lymph node: 21.5 ZNF688 ENSG00000229809 Zinc finger protein 688 16 30569346-30572734 Predicted intracellular proteins Evidence at transcript level HPA048922 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable) Expressed in all Expressed in all testis: 23.9 ZNF706 HSPC038 ENSG00000120963 Zinc finger protein 706 8 101177878-101206193 Predicted intracellular proteins Evidence at protein level HPA042793 Approved Plasma membrane Renal cancer:5.90e-11 (unfavourable), Endometrial cancer:3.12e-5 (unfavourable) Expressed in all Expressed in all skin: 159.7 ZNF717 X17, ZNF838 ENSG00000227124 Zinc finger protein 717 3 75709643-75785583 Predicted intracellular proteins Evidence at transcript level HPA044549 Uncertain Approved Nucleoplasm
Nuclear bodies
Plasma membrane Mixed Expressed in all epididymis: 29.1 ZNF783 DKFZp667J212 ENSG00000204946 Zinc finger family member 783 7 149262171-149297302 Predicted intracellular proteins Evidence at protein level HPA020375 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.24e-7 (unfavourable), Urothelial cancer:4.11e-4 (favourable) Expressed in all Mixed spleen: 9.4 ZNF785 FLJ32130 ENSG00000197162 Zinc finger protein 785 16 30573740-30585771 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030510 Approved Nucleoplasm
Plasma membrane Pancreatic cancer:2.03e-5 (favourable), Lung cancer:8.99e-4 (favourable) Expressed in all Expressed in all endometrium: 11.8 ZNF79 pT7 ENSG00000196152 Zinc finger protein 79 9 127424374-127445372 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028977 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:6.04e-7 (favourable), Pancreatic cancer:5.42e-5 (favourable), Endometrial cancer:6.83e-5 (favourable), Lung cancer:5.96e-4 (favourable) Expressed in all Mixed testis: 11.4 ZNF839 C14orf131 ENSG00000022976 Zinc finger protein 839 14 102317377-102342702 Predicted intracellular proteins Evidence at protein level HPA020434 Uncertain Approved Nucleoplasm
Plasma membrane Pancreatic cancer:4.57e-4 (favourable), Renal cancer:5.00e-4 (favourable) Expressed in all Expressed in all testis: 36.9 ZSCAN22 HKR2, ZNF50 ENSG00000182318 Zinc finger and SCAN domain containing 22 19 58327019-58342332 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006471 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Expressed in all Mixed parathyroid gland: 3.6 ZSCAN29 FLJ35867, Zfp690, ZNF690 ENSG00000140265 Zinc finger and SCAN domain containing 29 15 43358172-43371025 Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA007241, HPA011109 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments Expressed in all Expressed in all testis: 27.5 ZSWIM1 C20orf162, dJ337O18.5 ENSG00000168612 Zinc finger, SWIM-type containing 1 20 45881227-45885266 Predicted intracellular proteins Evidence at protein level HPA041147, HPA046751 Uncertain Approved Plasma membrane
Cytosol Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 10.6 ZSWIM8 4832404P21Rik, KIAA0913 ENSG00000214655 Zinc finger, SWIM-type containing 8 10 73785582-73801797 Predicted intracellular proteins Evidence at protein level HPA041244 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.61e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 62.8